CELEX: 32021M10247
Language: en
Date: 2021-10-22 00:00:00
Title: Commission Decision of 22/10/2021 declaring a concentration to be compatible with the common market (Case No COMP/M.10247 - CVC / COOPER) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                Brussels, 22.10.2021
                                                                C(2021) 7708 final
                                                                                  PUBLIC VERSION
                                                                 In the published version of this decision,
                                                                 some information has been omitted
                                                                 pursuant to Article 17(2) of Council
                                                                 Regulation (EC) No 139/2004 concerning
                                                                 non-disclosure of business secrets and other
                                                                 confidential information. The omissions are
                                                                 shown thus […]. Where possible the
                                                                 information omitted has been replaced by
                                                                 ranges of figures or a general description.
                                                                CVC Capital Partners SICAV-FIS S.A.
                                                                20 Avenue Monterey
                                                                L-2163 Luxembourg
                                                                Luxembourg
Subject:            Case M. 10247 – CVC/Cooper
                    Commission decision pursuant to Article 6(1)(b) of Council Regulation
                    No 139/20041 and Article 57 of the Agreement on the European Economic
                    Area2
Dear Sir or Madam,
(1)       On 17 September 2021, the Commission received notification of a proposed
          concentration pursuant to Article 4 of the Merger Regulation , by which CVC
          Capital Partners SICAV-FIS S.A. (“CVC”, Luxembourg or the “Notifying Party”)
          acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control
          of the whole of Cooper Consumer Health S.A.S. and its subsidiaries (“Cooper”,
          France or the “Target”) (the “Transaction”)3, by way of purchase of securities.
          Together, CVC and Cooper are referred to as the “Parties”.
1    OJ L 24, 29.1.2004, p. 1 (the ’Merger Regulation’). With effect from 1 December 2009, the Treaty on the
     Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the replacement of
     ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology of the TFEU will
     be used throughout this decision.
2    OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3    Publication in the Official Journal of the European Union No C 392, 28.09.2021, p. 5.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak--- 1.      THE PARTIES
(2)     CVC and/or its subsidiaries manage investment funds and platforms. CVC controls a
        number of companies, including companies in the pharmaceutical sector, e.g.,
        Recordati; Genetic; and Theramex, as well as in the private hospital and clinics
        (Hellenic health Care Group and Mehiläinen), nursing homes (Vitalia), provision of
        specialised medical equipment (Sebia), flexible packaging (AR Packaging) and
        packaging machinery (Syntegon) sectors.
(3)     Cooper and its subsidiaries develop, produce, and market pharmaceuticals, which are
        typically sold over the counter (“OTC”).
2.      THE OPERATION AND THE CONCENTRATION
(4)     Pursuant to a Put Option Agreement, dated 10 March 2021, and a Securities
        Purchase Agreement, dated 5 May 2021, CVC plans to acquire control over Cooper
        through a special purpose vehicle. Post-Transaction, CVC will hold [60-70]% of the
        Target’s share capital. As a result, CVC will acquire sole control over Cooper. The
        Transaction constitutes a concentration under Article 3(1)(b) EUMR.
3.      UNION DIMENSION
(5)     The undertakings concerned have a combined aggregate world-wide turnover of
        more than EUR 5 000 million4. Each of them has a Union-wide turnover in excess of
        EUR 250 million, but they do not achieve more than two-thirds of their aggregate
        Union-wide turnover within one and the same Member State. The notified operation
        therefore has a Union dimension.
4.      ASSESSMENT
4.1.    Horizontal overlaps
(6)     Both Parties are active in the development, manufacture, and commercialisation of
        finished dose pharmaceuticals (“FDPs”). FDPs are pharmaceutical products that
        have undergone all stages of production, including packaging in the final container
        and labelling.
4.1.1. Market Definitions
4.1.1.1. Product market definitions
(7)     To define relevant product markets regarding FDPs, the Commission typically takes
        into account the Anatomical Therapeutic Classification (“ATC”) of the European
        Pharmaceutical Marketing Research Association. In the context of this classification,
        at the ATC3 level,5 FDPs are grouped by therapeutic indications. The Commission
4   Turnover calculated in accordance with Article 5 of the Merger Regulation.
5   ATC3 level classification is narrower than ATC1 and ATC2 level classifications. At ATC1, drugs are
    divided into 16 anatomical main groups. At ATC2, drugs are divided at pharmacological or therapeutic
    groups.
                                                          2
 ---pagebreak---         uses ATC3 as the starting point for relevant product market definition, since all
        products in the same ATC3 class generally have the same therapeutic indication and
        cannot be substituted by products from other ATC3 classes. 6 However, the
        Commission also recognised7 that it may be appropriate to carry out analyses at the
        narrower classification level ATC4,8 or possibly at the level of molecule. ATC
        classification concerns prescription-bound (Rx) and OTC-sold drugs. For OTC-sold
        drugs, IQVIA9 also administers the Consumer Health Classification (“CHC”). With
        respect to OTC-sold drugs, the Commission typically uses CHC3 level10 (the
        equivalent of ATC3) as a starting point for relevant product market definition but
        narrower delineations are also considered (e.g., at CHC4 level (the equivalent of
        ATC4) or by molecule).11
(8)     For the purposes of the present Decision, it is not necessary to depart from the above
        approach, that is to define the markets for FDPs either at ATC3/CHC3, ATC4/CHC4
        or molecule levels. The market investigation did not provide any indications that
        would require the Commission to depart from its previous decisional practice with
        respect to the product market definition for FDPs concerning the FDP categories in
        which the Parties overlap.
               (A)        Methodology for the identification and the assessment of affected
                          markets
(9)     To identify the affected markets that the Transaction gives rise to in relation to
        FDPs, the Notifying Party used IQVIA data (previously known as IMS). These are
        data on sales in value and volume of FDPs compiled by IQVIA, a third-party
        intelligence provider focusing on the healthcare sector.
(10)    As will be further discussed further below in the present Decision (paragraphs (41)
        to (43), the Commission consistently defines relevant markets at national level.
(11)    In line with Commission precedents in pharmaceutical mergers with a large number
        of affected markets (involving numerous product and geographic markets), the
        Commission has applied a system of filters aimed at determining the group of
        markets where concerns are most likely and on which it focuses its analysis. Based
        on the Commission’s decisional practice in the pharmaceutical sector,12 horizontally
        affected markets regarding FDPs can be grouped in the categories summarized in
6   Case M.9995 – Permira/Neuraxpharm, para. 7.
7   Case M.9995 – Permira/Neuraxpharm, para. 7.
8   ATC4 level classification is typically based on mode of action or mode of administration of the drugs.
9   IQVIA is an American multinational company serving the combined industries of health information
    technology and clinical research, formerly Quintiles and IMS Health, Inc.
10 Case COMP/M.8889 – Teva/PGT OTC Assets, para. 21
11 Case COMP/M.8889 – Teva/PGT OTC Assets, para. 21
12 Case M.9554 – Elanco Animal Health/Bayer Animal Health Division, para. 89; M.8889 - Teva/PGT OTC
    Assets, para. 35; M.7746 – Teva/Allergan Generics, para. 58; and M.9044 - CVC/Recordati, para. 25;
    M.7645 - Mylan/ Perrigo, para. 33; M.8974 – Procter & Gamble / Merck Consumer Health Business, para.
    24.
                                                          3
 ---pagebreak---  ---pagebreak---  ---pagebreak---         etc. for the treatment of haemorrhoids and anal fissures.14 Preparations used for
        treatment of perineal trauma are also classified here.
(16)    The Commission has in the past left open the questions of either whether ATC3 class
        was the appropriate level to define the relevant product market for antihaemorrhoids
        (as opposed to the ATC4 class)15, or whether prescription and non prescription-
        products should be seen as belonging to the same market. 16 The Commission has not
        assessed antihaemorrhoids in the past based on their CHC3 or CHC4 classification.
(17)    As explained above,17 the Commission consistently defines the market for FDPs
        looking at both the ATC3/CHC3 level and at ATC4/CHC4 level. Also in this case,
        both ATC3 class C5A, CHC3 code 10A1 and CHC4 code 10A1O constitute
        plausible relevant product markets.
(18)    In the present case, the Notifying Party considers that the precise product market
        definition can be left open because the Transaction does not give rise to competition
        concerns under any plausible product market definition (including under the
        narrowest plausible market definition where the Parties’ activities overlap, namely at
        CHC4 level – Antihaemorrhoids – Ointments / Creams).
(19)    The Commission’s market investigation did not provide conclusive evidence
        regarding the question whether the relevant product market should be defined at
        ATC3/CHC3 level (including all types of antihaemorrhoids) or at ATC4/CHC4 level
        (including only antihaemorrhoidal ointments and creams).18 For the purposes of this
        decision, the product market definition for antihaemorrhoids can be left open, as the
        Transaction does not give rise to serious doubts as to its compatibility with the
        internal market or the functioning of the EEA agreement even in the narrowest
        plausible market where the Parties’ activities overlap (i.e., antihaemorrhoidal
        ointments and creams at CHC4 level).
                                                (C.ii)      Sore throat remedies
(20)    In the past, 19 the Commission considered a relevant market for sore throat remedies
        at ATC3 level (R2A) but eventually left open the issue of product market definition.
        The Commission has not assessed sore throat remedies in the past based on their
        CHC3 or CHC4 classification.
(21)    In the present case, the Notifying Party considers that the precise product market
        definition could be left open because the Transaction does not give rise to
        competition concerns under any plausible product market definition (including under
        the narrowest plausible market definition where the Parties’ activities overlap,
        namely at CHC4 level – sore throat remedies in the form of aerosols and sprays).
14 Although the ATC3 class C5A (topical antihaemorrhoidals) is not fully identical to the CHC3 class 10A1
   (antihaemorrhoids) since the ATC3 class only covers the topical drugs against haemorrhoids, both classes
   have essentially the same therapeutic indication: the treatment of haemorrhoids. Consequently, ATC3
   class C5A includes some, but not all, products of the Parties falling under the CHC3 class 10A1 in Italy.
15 See M.4198 – Bayer / Schering, paragraph 12.
16 Commission decision, Case M.4314 – Johnson & Johnson / Pfizer Consumer Healthcare, paragraph 22.
17 See paragraph (7).
18 Replies to Questionnaire Q3 and to Questionnaire Q4.
19 M.7276 GSK / Novartis, paragraph 249.
                                                          6
 ---pagebreak--- (22)   The Commission’s market investigation did not provide conclusive evidence
       regarding the question whether the relevant product market should be defined at
       ATC3/CHC3 level (including all types of sore throat remedies) or at ATC4/CHC4
       level (including only aerosols and sprays).20 For the purposes of this decision, the
       product market definition for sore throat remedies can be left open, as the
       Transaction does not give rise to serious doubts as to its compatibility with the
       internal market or the functioning of the EEA agreement even in the narrowest
       plausible market where the Parties’ activities overlap (i.e., sore throat remedies in
       form of aerosols or sprays at CHC4 level).
                                              (C.iii)   Mouth pain relief products
(23)   In the past, 21 the Commission considered that the there are two separate product
       markets for mouth pain relief products. Namely (i) a market for adult mouth pain
       relief products that covers products classified under ATC4 class A1A2 excluding
       mouthwashes (i.e. antiseptics and anti-infectives) and products classified under
       ATC4 class A1A3 (i.e. anti-inflammatories and analgesics), and (ii) a market for
       paediatric mouth pain relief products that covers products classified under ATC4
       class A1A2 excluding mouthwashes (i.e. antiseptics and anti-infectives) and
       products classified under ATC4 class A1A3 (i.e. anti-inflammatories and
       analgesics).
(24)   The Commission has not assessed mouth pain relief products in the past based on
       their CHC3 or CHC4 classification.
(25)   The Notifying Party does not contest the Commission’s general approach to the
       product market definition for FDPs. However, it submits that in markets where the
       Parties’ activities overlap, the competition takes place at ATC3 level.22
(26)   The Commission’s market investigation did not provide any indication on whether
       the relevant product market should be defined at ATC3/CHC3 level (including all
       types of mouth pain relief products) or at ATC4/CHC4 level (including only
       liquids). For the purposes of this decision, the product market definition for mouth
       pain relief products can be left open, as the Transaction does not give rise to serious
       doubts as to its compatibility with the internal market or the functioning of the EEA
       agreement even in the narrowest plausible market where the Parties’ activities
       overlap (i.e., mouth pain relief in the form of liquids at CHC4 level).
                                              (C.iv)    Ear care products
(27)   The Parties’ ear care products that give rise to affected markets belong to the CHC3
       code 08A1 – Ear Care and CHC4 code 08A1Z – Ear Care in other forms. The
       Commission has not previously considered the markets for ear care products
       belonging to these categories. As explained above,23 the Commission consistently
       defines market for FDPs based on both the CHC3 level and at CHC4 level, and
       therefore both CHC3 code 08A1 and CHC4 code 08A1Z constitute plausible
       relevant product markets.
20 Replies to Questionnaire Q1, question 11.
21 Case M.5953 – Reckitt Benckiser/SSL, paragraph 27.
22 Form CO, paragraph 99.
23 See paragraph (7).
                                                      7
 ---pagebreak--- (28)   The CHC4 code 08A1Z, however, is a catch-all category that includes any products
       that cannot be included in other CHC4 codes within the CHC3 code 08A1, instead of
       combining products with similar properties. With respect to other catch-all
       pharmaceutical classes, the Commission has previously considered that these do not
       form an appropriate basis for defining the relevant product markets.24
(29)   The Notifying Party does not contest the Commission’s general approach to the
       product market definition for FDPs. However, it submits that in markets where the
       Parties’ activities overlap, the competition takes place at ATC3 level.25 With respect
       to CHC4 code 08A1Z specifically, the Notifying Party notes that the category does
       not represent the actual market conditions given its catch-all nature.26
(30)   The investigation did not provide any indication on whether CHC4 code 08A1Z –
       Ear Care in other forms could constitute a separate relevant product market.
(31)   For the purposes of this decision, the exact product market definition for ear care
       products can be left open since the Transaction does not give rise to serious doubts
       as to its compatibility with the internal market or the functioning of the EEA
       agreement even under the narrowest plausible market defined at the CHC4 code
       08A1Z –Ear Care products in other forms.
                                              (C.v)    Antitussives (in combination)
(32)   ATC4 class R5D2 includes antitussives (which relieve coughs by blocking the cough
       reflex, and are most effective at relieving dry coughs, also known as cough
       suppressants) in combinations with expectorants, antihistamines, ephedrine, herbal
       tinctures, etc. 27 ATC3 class R5D includes all antitussives.
(33)   The Commission has not previously considered the markets for antitussives
       belonging to these categories. As explained above,28 the Commission consistently
       defines market for FDPs based on both the ATC3 level and at ATC4 level, and
       therefore both ATC3 code R5D and ATC4 code R5D2 constitute plausible relevant
       product markets.
(34)   The investigation did not provide any indication on whether the relevant product
       market could be defined either at ATC3 class R5D or ATC4 class R5D2.
(35)   In the present case, the Notifying Party considers that the precise product market
       definition for antitussives could be left open because the Transaction does not give
       rise to competition concerns under any plausible product market definition (namely
       the narrowest plausible market definition where the Parties’ activities overlap, ATC4
       class R5D2).
24 Case M.5476 – Pfizer/Wyeth, paragraph 43.
25 Form CO, paragraph 99.
26 Form CO, paragraph 386.
27 Combinations with analgesics and antipyretics (ATC3 class R5A) and combinations with anti-infectives
   (ATC3 class R5B) are excluded.
28 See paragraph (7).
                                                     8
 ---pagebreak---                                                 (C.vi)     Intestinal anti-infective anti-diarrhoeals
(36)    Intestinal anti-infective anti-diarrhoeals are used for disinfection and stabilisation of
        the intestinal microflora and for treatment of acute diarrhoeal diseases. They can be
        based on different molecules, including nifuroxazide, colistin, fidacomicin, and
        rifaximin.
(37)    In Sanofi-Aventis/Zentiva, the Commission considered a relevant market for
        intestinal anti-infective anti-diarrhoeals at ATC3 level (A7A) but eventually left
        open the issue of relevant market definition.29 The Commission has not assessed
        intestinal anti-infective anti-diarrhoeals at molecule level in the past.
(38)    In the present case, the Notifying Party considers that the precise product market
        definition could be left open because the Transaction does not give rise to
        competition concerns under any plausible product market definition (including under
        the narrowest plausible market definition where the Parties’ activities overlap,
        namely at molecule level – nifuroxazide-based intestinal anti-infective anti-
        diarrhoeals).
(39)    The investigation did not provide any indication on whether the ATC3 class A7A
        could be considered a distinct product market.
(40)    For the purposes of this decision, the product market definition for intestinal anti-
        infective anti-diarrhoeals can be left open, as the Transaction does not give rise to
        serious doubts as to its compatibility with the internal market or the functioning of
        the EEA agreement even in the narrowest plausible market where the Parties’
        activities overlap (i.e., at molecule level for nifuroxazide-based products).
4.1.1.2. Geographic market definitions
(41)    For FDPs, the Commission consistently defines relevant markets at national level.30
(42)    The market investigation did not provide any indications that would require the
        Commission to depart from its previous decisional practice on the geographic scope
        of the different plausible markets for FDPs. 31
(43)    Therefore, for the purposes of this decision, the Commission considers the
        geographic scope of the different plausible markets for FDPs, including all of the
        Group1/1+ markets, Group 2 and Group 3 to be national in scope.
4.1.2. Legal framework
(44)    Article 2 of the Merger Regulation requires the Commission to examine whether
        notified concentrations are compatible with the internal market, by assessing whether
        they would significantly impede effective competition in the internal market or in a
        substantial part of it, in particular as a result of the creation or strengthening of a
        dominant position.
29  Case M.5253 – Sanofi-Aventis/Zentiva, recitals 55ff.
30  Case M.9995 – Permira/Neuraxpharm, para. 11.
31 Replies to Questionnaires Q1 to Questionnaire Q6.
                                                         9
 ---pagebreak--- (45)    A merger giving rise to a significant impediment of effective competition may do so
        as a result of the creation or strengthening of a dominant position in the relevant
        market(s). Moreover, mergers in oligopolistic markets involving the elimination of
        the important competitive constraints that the parties previously exerted on each
        other, together with a reduction of competitive pressure on the remaining
        competitors, may also result in a significant impediment to effective competition,
        even in the absence of dominance.
(46)    The Commission Guidelines on the assessment of horizontal mergers under the
        Merger Regulation (the “Horizontal Merger Guidelines”)32 describe horizontal non-
        coordinated effects as follows: “A merger may significantly impede effective
        competition in a market by removing important competitive constraints on one or
        more sellers who consequently have increased market power. The most direct effect
        of the merger will be the loss of competition between the merging firms. For
        example, if prior to the merger one of the merging firms had raised its price, it
        would have lost some sales to the other merging firm. The merger removes this
        particular constraint. Non-merging firms in the same market can also benefit from
        the reduction of competitive pressure that results from the merger, since the merging
        firms’ price increase may switch some demand to the rival firms, which, in turn, may
        find it profitable to increase their prices. The reduction in these competitive
        constraints could lead to significant price increases in the relevant market.”33
(47)    The Horizontal Merger Guidelines list a number of factors which may influence
        whether or not significant non-coordinated effects are likely to result from a merger,
        such as large market shares of the merging firms, the fact that the merging firms are
        close competitors, the limited possibilities for customers to switch suppliers, or the
        fact that the merger would eliminate an important competitive force. 34 That list of
        factors applies equally regardless of whether a merger would create or strengthen a
        dominant position, or would otherwise significantly impede effective competition
        due to non-coordinated effects. Furthermore, not all of these factors need to be
        present for significant non-coordinated effects to be likely. The list of factors, each
        of which is not necessarily decisive in its own right, is also not an exhaustive list.35
(48)    Finally, the Horizontal Merger Guidelines describe a number of factors, which could
        counteract the harmful effects of the merger on competition, including the likelihood
        of buyer power, the entry of new competitors on the market, and efficiencies.
4.1.3. Competitive assessment of group 2 and 3 markets
(49)    For all of the Group 2 and Group 3 markets, the market shares of the Parties are
        limited, and significant competitors that will likely sufficiently constrain the merged
        entity remain on the market post-Transaction and/or the Transaction brings about
        only a limited increment. In addition, the market investigation did not reveal any
        concerns in relation to any of the Group 2 and 3 markets.36
32  OJ C 31, 5.2.2004, p. 5.
33  Horizontal Merger Guidelines, paragraph 24.
34 Horizontal Merger Guidelines, paragraphs 27 and following.
35 Horizontal Merger Guidelines, paragraphs 24-38.
36 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                         10
 ---pagebreak--- (50)    The Commission assessed the competitive situation on these markets analysing the
        nature and the number of existing competitors and considered that the Transaction
        does not raise serious doubts as to its compatibility with the internal market or the
        functioning of the EEA agreement as a result of a horizontal effects in any of those
        markets. Consequently, in line with previous decisions37 Group 2 and Group 3
        overlaps will not be assessed any further in the present Decision.
4.1.4. Competitive assessment of group 1 and 1+ markets
4.1.4.1. Antihaemorrhoids in Italy and in Romania
(51)    At each of the ATC3 class C5A (topical antihaemorrhoidals) and CHC3 code 10A1
        (antihaemorrhoids), the Parties activities result in a Group 1/1+ affected market in
        Italy, while in the CHC4 code 10A1O (antihaemorrhoids - ointments and creams)
        the Parties activities result in a Group 1/1+ affected market in Italy and Romania.
               (A)      ATC3 level C5A (topical antihaemorrhoidals) in Italy
(52)    Recordati sells Proctolyn (based on fluocinolone acetonide and ketocaine), while
        Cooper sells Ruscoroid (based on ruscogenins and tetracaine) in Italy.
(53)    The Notifying Party submits that the Transaction does not give rise to competition
        concerns in topical antihaemorrhoidals in Italy, because the Parties’ products do not
        compete closely, given their different active ingredients and the combined entity
        would face vigorous competition in this market.
(54)    Tables 4 below show the market shares of the Parties and their main rivals in the
        market for topical antihaemorrhoidals in Italy in the last three years, in value and in
        volume.
37  See M.8974 – Procter & Gamble / Merck Consumer Health Business, para. 25.
                                                    11
 ---pagebreak---  ---pagebreak--- (55)     In 2020, the combined share of the Parties in the market for topical
         antihaemorrhoidals in Italy was [40-50]% in value and [40-50]% in volume (with an
         increment of [5-10]% in value and [5-10]% in volume contributed by Cooper). There
         are four competitors with market shares in value and volume higher than the
         increment brought by the Transaction.
(56)     In this market, the Transaction is unlikely to give rise to serious doubts as to its
         compatibility with the internal market or the functioning of the EEA agreement for
         the following reasons:
         (a) Post-Transaction, in the market for topical antihaemorrhoidals in Italy, the
             combined entity would face competitive constraints from several rivals.
             According to IQVIA, in 2020, there were around 12 competitors active in this
             market.38 These rivals include Bayer, Neopharmed Gentili, Glaxosmithkline and
             Alfasigma, each holding shares at, or above 10% (both in value and in volume)
             in 2020. The results of the market investigation confirm this. All respondents
             (competitors and customers) replied that post-Transaction a sufficient number of
             suppliers will continue offering topical antihaemorrhoidals in Italy.39
         (b) There is no evidence that the products of the Parties in this market compete
             closely with each other, since they are not close substitutes. Proctolyn and
             Ruscoroid are based on different active ingredients and Proctolyn contains
             corticosteroids, while Ruscoroid does not. Products with corticosteroids may lead
             to severe side effects, consequently, anti-haemorrhoidals with corticosteroids are
             preferably used to treat acute and severe haemorroids due to a strong anti-
             inflammatory action for a short period of no longer than seven days, while anti-
             haemorroidals without corticosteroids can be used for milder symptoms and
             possibly for a longer period as a maintenance therapy since they have a weaker
             anti-inflammatory action.40 The results of the market investigation confirmed to a
             certain extent that Proctolyn and Ruscoroid are not each others’ closest
             competitor. 41
         (c) Finally, the market investigation did not reveal any concerns in relation to
              topical antihaemorrhoidals in Italy.42
(57)     In light of the above considerations, the Commission concludes that the Transaction
         does not raise serious doubts as to its compatibility with the internal market or the
         functioning of the EEA agreement as a result of a horizontal effects in the market for
         topical antihaemorrhoidals in Italy.
38   See Form CO Annex 7.4-1.
39   Replies to Questionnaire Q3, question 12 - 14 and Questionnaire Q4, question 9 - 11.
40   Replies to Questionnaire Q3, question 10 and Questionnaire Q4, question7.
41   Replies to Questionnaire Q3, question 8 and Questionnaire Q4, question 6.
42   Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised
     competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only
     one competitor of the Parties considered that the Transaction could have a negative impact because of the
     increased capacity of the merged entity to invest. However, this customer does not foresee any impact on
     the price and availability of topical antihaemorrhoidals in Italy.
                                                           13
 ---pagebreak---               (B)       CHC3 code 10A1 (antihaemorrhoids) and CHC4 code 10A1O
                        (antihaemorrhoids - ointments and creams) in Italy
(58)   Recordati sells Proctolyn in the forms of cream and suppositories, and Proctolyn
       Integra Plus, a food supplement sold in the form of sachets. Cooper sells Ruscoroid
       in the form of cream, Ruscoroid Forte, a food supplement in sachet form, Vasostar,
       which comes in the form of a cream and used to treat internal and external
       haemorrhoids and Micro H in the form of a gel or wipes, producing a calming effect
       that reduces haemorrhoidal problems.43
(59)   While the products contain some of the same active substances, each product also
       contain further substances with different mechanisms of action to achieve the desired
       effect.44
(60)   The Notifying Party submits that the Transaction does not give rise to competition
       concerns either in antihaemorrhoids, or in antihaemorrhoidal ointments and creams
       in Italy, because the Parties’ products do not compete closely, given their different
       active ingredients and the combined entity would face vigorous competition in this
       market.
(61)   Tables 6 and 7 below show the market shares of the Parties and their main rivals in
       the market for antihaemorrhoids in Italy in the last three years in value and in
       volume.
43 Micro H is exiting the market as a result of commercial decisions by Cooper. See Form CO, paragraph
   281.
44 See Form CO, paragraph 289.
                                                     14
 ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---               exist in different forms, cream (Proctolyn, Vasostar and Ruscoroid), food
              supplements in the form of a sachet (Proctolyn Integra Plus and Ruscoroid Fort)
              and single-dose gel and a single-dose wipe (Micro H). The results of the market
              investigation confirmed to a certain extent that the Parties’ products are not each
              others’ closest competitor. 51
         (c) Finally, the market investigation did not reveal any concerns in relation to
              antihaemorrhoids and antihaemorrhoidal creams and ointments in Italy.52
(66)     In light of the above considerations, the Commission concludes that the Transaction
         does not raise serious doubts as to its compatibility with the internal market or the
         functioning of the EEA agreement as a result of a horizontal effects in the markets
         for antihaemorrhoids and in the market for antihaemorrhoidal creams and ointments
         in Italy.
                (C)        CHC4 level 10A1O (antihaemorrhoids - ointments and creams) in
                           Romania53
(67)     Recordati sells Procto Glyvenol in the form of an ointment. Cooper has sold its
         Micro H (in form of a gel) in an one-off sale.54
(68)     The Notifying Party submits that the Transaction does not give rise to competition
         concerns in antihaemorrhoidal ointments and creams in Romania, because the
         Parties’ products do not compete closely, given their different active ingredients and
         the combined entity would face vigorous competition in this market.
(69)     Tables 10 and 11 below show the market shares of the Parties and their main rivals
         in the market for antihaemorrhoids - ointments and creams in Romania in the last
         three years, in value and in volume.
51   Replies to Questionnaire Q3, question 8 and Questionnaire Q4, question 6.
52   Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised
     competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only
     one competitor of the Parties considered that the Transaction could have a negative impact because of the
     increased capacity of the merged entity to invest. However this customer does not foresee any impact on
     the price and availability of topical antihaemorrhoidals in Italy.
53 At ATC3/CHC3 level (10A1), the Parties’ market shares result in a Group 3 affected market in Romania.
54 The Notifying Party submits that this was truly marginal in absolute terms ([…]). See Form CO,
   paragraph 318. Moreover, the Notifying Party recalls that Micro H is exiting the market, see footnote 43.
                                                           19
 ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---       (with an increment of [10-20]% contributed by Cooper).63 In this market, the
      Transaction is unlikely to give rise to serious doubts as to its compatibility with the
      internal market or the functioning of the EEA agreement for the following reasons:
      (a) Post-Transaction, in the market for sore throat remedies in the form of
           aerosols/sprays in France, the combined entity would face competitive
           constraints from several rivals. According to IQVIA, in 2020, there were more
           than 60 competitors active in this market. These rivals include Procter &
           Gamble; Urgo; and Pfizer, each holding shares above 5% in 2020. The results of
           the market investigation confirm this. All respondents (competitors and
           customers) replied that post-Transaction a sufficient number of suppliers will
           continue offering sore throat remedies in the form of aerosols and sprays in
           France.64
      (b) There is no evidence that the products of the Parties in this market compete
           closely with each other. Colludol and Hexaspray have different therapeutic
           effects.65 Hexaspray has antibacterial and antiseptic action. Colludol has
           antiseptic action but also includes lidocaine and thus works as an anaesthetic for
           the sore throat. Colludol competes more closely with Procter & Gamble’s and
           Urgo’s products (which contain lidocaine and have anaesthetic action) than with
           Hexaspray.
            The results of the market investigation confirm this. None of the respondents
            (competitors and customers) identified Hexaspray as the closest competing
            product for Colludol.66 The vast majority of the respondents did not identify
            Hexaspray among the three closest competitors to Colludol nor Colludol among
            the three closest competitors to Hexaspray.67
            […].68 […].69 […].70
      (c)      Sore throat remedies are also available in forms other than aerosols/sprays,
               e.g., as lozenges or syrups. While lozenges and syrups are not part of the
               relevant market which is affected by the concentration (01C1A – Sore throat
               Remedies – Aerosols/Sprays), they could still exert competitive constraints
               over the combined entity post-Transaction.
               The results of the market investigation confirm this. The majority of
               competitors stated that consumers consider substitutable (at least to some
63 By volume, Cooper held a share of [0-5]% and CVC held a share of [0-5]%. This discrepancy between
   value- and volume-based market shares exists because IQVIA does not properly convert “actual units” of
   competitor products to “standard units” (which it does for the Parties’ products).
64 Replies to Questionnaire Q1, question 12 and Questionnaire Q2, question 10.
65 Clariver and Hexaspray also do not compete closely. Clariver is based on natural ingredients while
   Hexaspray includes active pharmaceutical ingredients. In the market investigation, none of the
   respondents identified Clariver as a product competing closely with Hexaspray (Replies to Questionnaire
   Q1, question 8 and Replies to Questionnaire Q2, question 6).
66 Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.
67 Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.
68 Form CO, Annex 7.4-XI – Target’s Document (Part 1) on Colludol_Hexaspray, page 30.
69 Form CO, Annex 7.4-XI – Target’s Document (Part 1) on Colludol_Hexaspray, page 30.
70 Form CO, footnote 161.
                                                        23
 ---pagebreak---                   extent) sore throat remedies in aerosols/sprays and sore throat remedies in
                  other forms.71
                  In its internal documents, Recordati […]”.72
         (d)      The market investigation did not reveal any substantiated concerns in relation
                  to sore throat remedies in the form of aerosols/sprays in France.73
(77)     In light of the above considerations, the Commission concludes that the Transaction
         does not raise serious doubts as to its compatibility with the internal market or the
         functioning of the EEA agreement as a result of a horizontal effects in the market for
         sore throat remedies in the form of aerosols/sprays in France.
4.1.4.3.          Mouth pain relief liquids in France
(78)     The Parties’ activities in this product category in France give rise to a Group 1/1+
         horizontally affected market only at CHC4 level (02D1L – Mouth Pain Relief –
         Liquids (Topical)).74
(79)     Cooper markets products under the brand names Hyalugel and Dentobaume.
         Hyalugel is a mouthwash based on hyaluronic acid used to treat irritant conditions of
         the gums (e.g. inflammation of the gums, bleeding, receding gums) or traumatic
         conditions of the gums (e.g. due to cleaning, abrasion, extraction of teeth). As such,
         Hyalugel is recommended by dentists and practitioners as part of healing treatments.
         Dentobaume is a local anaesthetic indicated for the treatment of acute gingivodental
         pain. The product is liquid is and applied by a soaked pad directly on the painful
         gum or tooth. In 2020, Dentobaume represented [60-70]% of Cooper’s sales in this
         market.
(80)     Recordati markets Aphtavea, a mouthwash based on hyaluronic acid and aloe vera to
         treat mouth ulcers and mouth injury. Aphtavea provides a protective mechanical
         barrier over aphthous ulcers or oral lesions, isolating it from potential external
         influences, such as food particles or hot liquids.
(81)     The Notifying Party submits that the Transaction does not give rise to competition
         concerns in mouth pain relief products in the form of liquids because the Parties’
         products are not close competitors, the Parties will continually consider their
         competitors and there is vibrant competition with recent entrants.75
71   Replies to Questionnaire Q1, question 11.
72   Form CO, Annex 7.4-XV-1 – Recordati’s additional ordinary course documents prepared in 2019 and
     2020, page 2.
73   Replies to Questionnaire Q1, question 13 and Questionnaire Q2, question 11. No customer raised
     competition concerns regarding the impact of the Transaction in sore throat remedies in the form of
     aerosols/sprays in France. Only one competitor of the Parties considered that the Transaction could have
     a negative impact on the market (leading to higher prices). However, this competitor did not substantiate
     its concerns. Instead, this same competitor identified “16 other sore throat sprays brands” that would
     compete with the combined entity and admitted that the Parties’ products do not compete closely with
     each other (see Replies to Questionnaire Q1, questions 8, 12.1, and 13).
74   At ATC3/CHC3 level (02D1 – Mouth Pain Relief), the Parties’ market shares result in a Group 3 affected
     market. The Parties’ products do not overlap at molecule level.
75 Form CO, paragraphs 379 ff.
                                                          24
 ---pagebreak---  ---pagebreak---                  The fact that Aphtavea is not a close competitor to Hyalugel (which
                represents more than [60-70]% of Coopers’ sales by value),78 is reflected in a
                response of a competitor to the market investigation, which indicates that the
                closest substitutes to Hyalugel are Bioxaphte (a product marketed by Bausch
                Health), and Urgo Dentilia and Mercurochrome (marketed by Urgo) and not
                Aphtavea 79 since “The two brands selected are we believe as strong as
                Hyalugel. A pharmacist could easily recommend one or another.”
                Consequently, the bulk of the Cooper’s sales are for a product which is not
                seen as a close competitor of CVC Recordati.
                 The share increment contributed by CVC Recordati is limited to [0-5]% in
                value, so the Transaction will not significantly affect the competitive
                landscape in this market. The Parties would continue facing competitive
                constraints from several competitors with shares higher or equal to that of
                CVC Recordati. These include Bausch Health ([20-30]% value share in
                2020), Urgo ([5-10]%), Groupe Batteur ([5-10]%), and Aboca ([0-5]%).
                The results of the market investigation confirm that post-Transaction a
                sufficient number of suppliers will offer mouth pain relief liquids in France.80
                The same competitor states: “Mouth pain relief products exist in different
                formats. The liquid form is popular but gels are also very common. Plus
                some mouthwashes can also be used to treat mouth pain relief (eg. Eludril).
                Therefore plenty of products exist on the market.”81
        (b)     There is some evidence of new entrants into this market, suggesting that
                barriers to entry are not high. Urgo and Aboca entered the market only in
                2020 and already have market shares comparable or higher to that of Cooper.
        (c)     The market investigation did not reveal any concerns in relation to mouth
                pain relief products in the form of liquids in France.82
(85)    In light of the above considerations, the Commission concludes that the Transaction
        does not raise serious doubts as to its compatibility with the internal market or the
        functioning of the EEA agreement as a result of horizontal effects in the market for
        mouth pain relief products in the form of liquids in France.
4.1.4.4.         Ear care products in Spain
(86)    The Parties’ activities in this product category in Spain give rise to a Group 1/1+
        horizontally affected market only at CHC4 level (08A1Z – Ear Care – Other
        Forms).83
78  Form CO Table 11
79  Reply to Questionnaire Q5, question 7. “The two brands selected [ are we believe as strong as Hyalugel. A
    pharmacist could easily recommend one or another.”
80 Reply to Questionnaire Q5, question 9.
81 Reply to Questionnaire Q5, question 9.
82 Replies to Questionnaire Q5, questions 12-13, as well as replies to Questionnaire Q1, questions 15-16 ; to
    Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions
    13-14.
                                                        26
 ---pagebreak---  ---pagebreak---  ---pagebreak---         (c) Again, even if the Parties were to compete in this market, Post-Transaction, the
             combined entity would continue facing competitive constraints from several
             competitors with shares higher than that of CVC Recordati. These include Faes
             Farma ([20-30]% in value and [10-20]% in volume in 2020), Perrigo ([10-20]%
             in value and [10-20]% in volume) and M4 Pharma ([10-20]% in value and [5-
             10]% in volume).
        (d)      The market investigation did not reveal any concerns in relation to ear care
                 products in other forms in Spain.89
(92)    In light of the above considerations, the Commission concludes that the Transaction
        does not raise serious doubts as to its compatibility with the internal market or the
        functioning of the EEA agreement as a result of a horizontal effects in the market for
        ear care products in other forms in Spain.
4.1.4.5. Antitussives (in combination) in Luxembourg
(93)    Antitussives90 (also known as cough suppressants), relieve coughs by blocking the
        cough reflex, and are most effective at relieving dry coughs. The ATC4 class R5D2,
        the only class where the Parties’ activities in antitussives give rise to an affected
        market, includes antitussives in combinations with expectorants, antihistamines,
        ephedrine, herbal tinctures, etc.91
(94)    Coopers' Pholco Mereprine is an OTC medicine used for antitussive effect. It is a
        syrup intended to suppress dry coughs and irritable coughs. Recordati's Neo-Codion
        is a cough suppressant, i.e. used as a treatment that stops the cough reflex. It is used
        to treat dry coughs for adults and children. It is sold both in Rx and OTC variants.
(95)    Tables 16 and 17 below show the market shares of the Parties and their main rivals
        in the market for antitussives in Luxembourg in the last three years, in value and in
        volume.
89  Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
90 ATC3 class R5D.
91 Combinations with analgesics and antipyretics (R5A) and combinations with anti-infectives (R5B) are
    excluded, see https://www.ephmra.org/media/4973/atc-guidelines-2021-final.pdf, page 133.
                                                         29
 ---pagebreak---  ---pagebreak--- (96)    In 2020, the combined share of the Parties in the market for antitussives in
        combination in Luxembourg was [90-100]% in value and [90-100]% in volume
        (with an increment of [0-5]% both in value and in volume contributed by Cooper).
(97)    The Notifying Party submits that these combined shares do not appear to reflect the
        current competitive dynamics within the market segment R5D2, because regulatory
        changes stemming from the Belgian legislation92 which are expected to be followed
        by Luxembourg, ban the combination syrups as of January 2020. As a result, during
        2020, Pholco-Mereprine has been withdrawn from the market and is no longer
        marketed in the EEA. Its replacement, Pholco Mereprine Mono is not part of the
        ATC4 class R5D2, but of R5D1. Thus, the overlap in the ATC4 class R5D2 is only
        historical and will not persist in the future.93 Additionally, one of the largest market
        participants, Klosterfrau, is no longer included in the IQVIA data set in the R5D2
        class for 2020, while it had market shares of more than approximately [20-30]% in
        the previous years. 94 Finally, the Notifying Party notes that the overall sales in this
        market decreased by around [70-80]%, further proof that other players also had
        fewer sales.
(98)    Moreover, the Notifying Party underlines that the two do not contain the same
        molecules95 and can also be distinguished based on the different forms in which they
        are marketed and used. Vemedia's Pholco Mereprine is sold in the form of a syrup,
        while Recordati's Neo-Codion is sold either in the form of a tablet or in the form of a
        syrup.96
(99)    The Commission takes note that the regulatory changes discussed above, make that
        the Parties no longer overlap in ATC4 class R5D2. Vermedia has replaced Pholco
        Mereprine by Pholco Mereprine Mono, based on the molecule pholcodine (which is
        not contained in Recordati's Neo-Codion). Therefore, there is no overlap at the
        molecule level.
(100) The Commission also notes that in ATC3 class R5D (including both Neo-Codion’s
        R5D2 and Pholco Mereprine’s Mono R5D1), combined market shares would be
        below [20-30]%.
(101) Finally, the market investigation did not reveal any concerns in relation to
        antitussives, in combination in Luxembourg.97
92 Decision of the Federal Agency for Medicines and Health Products ("FAMHP") of Belgium of January
   2020.
93 See Form CO paragraph 340 and Annex 7.4-VII
94 According to the Notifying Party, Klosterfrau was active on the Luxemburg market with a combined
   product named "Toplexil", but this product was withdrawn on 1 Jan 2020 and has not been replaced by an
   alternative, see Form CO, footnote 156.
95 Vemedia's Pholco Mereprine has been a combined syrup based (until May 2020), on the following
   ingredients benzoic acid, doxylamine, pholcodine and sulfogaiacol. On the other hand, Recordati's Neo-
   Codion, is based on ascorbic acid, bromoform, codeine, benzoic acid, bromine, adiantum capillus veneris,
   drosera rotundifolia, grindelia robusta, papaver rhoeas, polygala senega, senna, sulfogaiacol and thymus
   serpyllum. Therefore the Parties' products are considered antitussives in combinations (R5D2) rather than
   plain antitussives (R5D1) have only two molecules in common (sulfogaiacol, an expectorant, and benzoic
   acid, a preservative). See Form CO paragraph 339.
96 See Form CO paragraph 341 and footnote 148.
97 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
   Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                        31
 ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak--- (111) The market investigation did not provide any indications that would require the
        Commission to depart from its previous decisional practice with respect to the
        product market definition for FDPs that are vertically affected.
(112) The precise delineation of the FDP market(s) that are vertically affected by the
        Transaction can be left open because no competition concerns arise under any
        plausible relevant market definition.
               (B)       Geographic market definition
(113) As explained above,104 the Commission consistently defines the different plausible
        markets for FDPs as national in scope.
(114) The market investigation did not provide any indications that would require the
        Commission to depart from its previous decisional practice on the geographic scope
        of the different plausible markets for FDPs that are vertically affected.
(115) Therefore, for the purposes of this decision, the Commission considers the
        geographic scope of the different plausible markets for FDPs to be national in scope.
4.2.2.2. Flexible packaging for pharmaceuticals
               (A)       Product market definition
(116) Previously the Commission described the production of flexible packaging as the
        manufacture, supply and conversion of plastic and cellulose films, aluminium foils
        and papers into reels of packaging.105
(117) The Commission previously considered that flexible packaging could be segmented
        by distinguishing the end-use of the packaging. That is, distinct product markets
        exist for flexible packaging for: (i) food, (ii) medical supplies, (iii) pharmaceuticals,
        (iv) household products, and (v) other non-food.106
(118) With respect to flexible packaging for pharmaceuticals, the Commission has
        previously considered a narrower segmentation into (a) laminated sachets, (b)
        coldform blister bases, (c) plastic-based blister bases and (d) blister lidding, but
        ultimately left the product market definition open.107
(119) The Notifying Party submits that there is a high degree of supply-side substitutability
        within all types of flexible packaging,108 but does not contest the Commission’s
        decisional practice.
(120) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice to
        consider a distinct market for flexible packaging for pharmaceuticals.
103 See Section 4.1.2.
104 See Section 4.1.2.
105 Case M.9094 – Amcor/Bemis, paragraph 13.
106 Case M.9094 – Amcor/Bemis, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 15; Case M.3225 –
    Alcan/Pechiney, paragraphs 128 and 131.
107 Case M.8107 – CVC/AR Packaging, paragraph 12; Case M.5599 – Amcor/Alcan, paragraph 13.
108 Form CO, paragraph 94.
                                                   35
 ---pagebreak--- (121) In this case, the question of whether the market for flexible packaging for
        pharmaceuticals should be further segmented in line with the four segments listed at
        paragraph (118) above, can be left open since the Transaction does not give rise to
        serious doubts as to its compatibility with the internal market or the functioning of
        the EEA agreement under any of these narrower plausible market definitions.
              (B)       Geographic market definition
(122) The Commission has previously considered the geographic scope of markets for
        flexible packaging for pharmaceuticals as EEA-wide or wider.109
(123) The Notifying Party agrees with the previous Commission decisions that the
        geographic market for flexible packaging is EEA-wide or wider.110
(124) The Commission’s investigation did not provide any indications that would require
        the Commission to depart from its previous decisional practice that the geographic
        market for flexible packaging for pharmaceuticals is at least EEA-wide.
(125) Therefore, for the purposes of this decision, the Commission considers the
        geographic scope for flexible packaging for pharmaceuticals to be at least EEA-
        wide.
4.2.2.3. Packaging machinery for the pharmaceutical sector
              (A)       Product market definition
(126) The Commission has not considered the market for packaging machinery in its
        previous Decisions.
(127) The Notifying Party explains that there is typically competitive interaction between
        the different formats, types of machines and/or technologies, as customers would
        typically purchase a range of packaging machines and technologies that could be
        applied to different categories/sectors, as opposed to a single type of packaging
        machinery or technology for a specific type of product.111 However, the Notifying
        Party submits that, on the narrowest plausible basis, the market for packaging
        machinery could be defined by reference to end-use (e.g. packaging machinery for
        the pharmaceutical sector, medical sector etc.).112
(128) The Commission’s investigation did not provide any indications as to the appropriate
        level for defining the market for packaging machinery. The question of whether the
        relevant product market includes all packaging machinery, or packaging machinery
        for the pharmaceutical sector only, can be left open since the Transaction does not
        give rise to serious doubts as to its compatibility with the internal market or the
        functioning of the EEA agreement under any plausible product market definition.
109 Case M.8107 – CVC/AR Packaging, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 48.
110 Form CO, paragraph 121.
111 Form CO, paragraph 109.
112 Form CO, paragraph 109.
                                                   36
 ---pagebreak---               (B)       Geographic market definition
(129) The Commission has not previously considered the geographic scope of markets for
        packaging machinery.
(130) The Notifying Party submits that the geographic market for packaging machinery
        (including for packaging machinery for the pharmaceutical sector) is EEA-wide or
        wider.113
(131) The Commission’s investigation did not provide any indications as to the appropriate
        geographic scope of the market for packaging machinery (or packaging machinery
        for the pharmaceutical sector).
(132) Therefore, for the purposes of this decision, the Commission considers the
        geographic scope for packaging machinery for pharmaceuticals to be at least EEA-
        wide.
4.2.2.4. APIs
                        (A)      Product market definition
(133) Active pharmaceutical ingredients (“APIs”) are the molecules (under patent or
        expired) that are used to manufacture FDPs.114
(134) Per the Commission’s decisional practice, in principle, each API belongs to a
        separate product market but substitutability between APIs, either in general, or for
        certain applications must also be considered.115
(135) The Notifying Party agrees with the decisional practice of the Commission regarding
        the product market definition in APIs.116
(136) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        APIs.
(137) In this case, the exact product market definition for APIs can be left open since the
        Transaction does not give rise to serious doubts as to its compatibility with the
        internal market or the functioning of the EEA agreement under any plausible market
        definition.
                        (B)      Geographic market definition
(138) The Commission has previously considered the geographic scope for APIs is at least
        EEA-wide.117
(139) The Notifying Party did not depart from the decisional practice of the Commission
        regarding the geographic market definition in APIs. 118
113 Form CO, paragraph 122.
114 Case M.6278 – Takeda/Nycomed, para. 16.
115 Case M. 7746 – Teva/Allergan Generics, paras. 644, 645.
116 Form CO, paragraph 81.
117 Case M. 7746 – Teva/Allergan Generics, paras. 646, 647.
                                                       37
 ---pagebreak--- (140) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        APIs.
(141) In this case, the exact geographic market definition for APIs can be left open since
        the Transaction does not give rise to serious doubts as to its compatibility with the
        internal market or the functioning of the EEA agreement under any plausible market
        definition.
4.2.2.5. Excipients
              (A)       Product market definition
(142)    (Pharmaceutical) excipients are inert substances with which the API is combined to
        form an FDP.
(143) In Ashland/International Specialty Products, the Commission considered
        pharmaceutical excipients belong to separate relevant markets based on the
        substance from which each excipient was made (e.g., lactose, starch, cellulose) and
        considered plausible markets for binders, coatings and plausible narrower
        segments.119 In Friesland Foods/Campina, the Commission defined even narrower
        markets for lactose excipients, namely separate markets for (i) wet granulation
        lactose and (ii) direct compression lactose.120
(144) The Notifying Party did not depart from the decisional practice of the Commission
        regarding product market definition in pharmaceutical excipients.
(145) The Commission’s investigation did not provide any indications that would require
        the Commission to depart from its previous decisional practice to consider separate
        markets for excipients based on their substance ingredients and to sub-segment the
        market for lactose into (i) wet granulation lactose and (ii) direct compression lactose.
              (B)       Geographic market definition
(146)    In Ashland/International Specialty Products and in Friesland Foods/Campina, the
        Commission found that the scope of the relevant markets for excipients is at least
        EEA-wide.121
(147) The Notifying Party did not depart from the decisional practice of the Commission
        regarding geographic market definition in pharmaceutical excipients.
(148) The Commission’s investigation did not provide any indications that would require
        the Commission to depart from its previous decisional practice to consider at least
        EEA-wide markets for excipients based on their substance ingredients and to sub-
        segment the market for lactose into (i) wet granulation lactose and (ii) direct
        compression lactose.
118 Form CO, paragraph 113.
119 Case M.6313 – Ashland/International Speciality Products, para. 12.
120 Case M.5046 – Friesland Foods/Campina, paras. 1622 and 1652, 1656
121 Case M.6313 – Ashland/International Speciality Products, para. 26.
                                                       38
 ---pagebreak--- 4.2.2.6. CDMO services to pharmaceutical companies
               (A)       Product market definition
(149) Contract development and manufacturing organisations (“CDMOs”) provide
        manufacturing services for FDPs and APIs to third-party pharmaceutical companies.
(150) In the past, the Commission distinguished (i) a CDMO market for FDPs and (ii) a
        CDMO market for APIs.122 As regards the CDMO market for FDPs, further
        segmentation was considered based on (i) the pharmaceutical form manufactured
        (e.g., solids, semi-solids, injectables); (ii) the conditions of manufacture (e.g.,
        toxicity, sterile environment); (iii) the type of API used for its production and the
        delivery mechanism used (e.g., swallowing, intravenous, injection, etc.). 123 The
        Commission also examined whether there is a separate market for contract
        manufacturing organization (“CMO”) services but eventually left the question
        open.124
(151) The Notifying Party submits that irrespective of the precise market definition and
        even based on the narrowest plausible market segment, the Transaction would not
        lead to competitive concerns.125
(152) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        CDMOs.
(153) In this case, the exact product market definition for CDMOs can be left open since
        the Transaction does not give rise to serious doubts as to its compatibility with the
        internal market or the functioning of the EEA agreement under any plausible market
        definition.
               (B)       Geographic market definition
(154) The Commission added that the geographic scope of all plausible CDMO services
        markets is at least EEA-wide.126
(155) The Notifying Party did not depart from the decisional practice of the Commission
        regarding the geographic market definition for CDMOs. 127
(156) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        CDMOs.
(157) In this case, the exact geographic market definition for CDMOs can be left open
        since the Transaction does not give rise to serious doubts as to its compatibility with
        the internal market or the functioning of the EEA agreement under any plausible
        geographic market definition for CDMOs.
122 Case M.9315 – CHR. Hansen/Lonza/JV, para. 17.
123 Case M.9315 – CHR. Hansen/Lonza/JV, para. 22.
124 Case M.9315 – CHR. Hansen/Lonza/JV, para. 19.
125 Form C0, paragraph 105.
126 Case M.9315 – CHR. Hansen/Lonza/JV, para. 24.
127 Form C0, paragraph 116.
                                                   39
 ---pagebreak--- 4.2.2.7. Private hospital services
               (A)       Product market definition
(158) In CVC/Recordati, the Commission considered a relevant product market for private
        hospital services which would be separate from public hospital services, depending
        on the specificities of the case and the national market in question.128
(159) The Notifying Party acknowledges the past decisional practice of the Commission
        and submits that the issue can be left open, since the Transaction would not lead to
        competitive concerns even if a product market for private hospital services were to
        be considered.129
(160) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        private hospital services.
(161) In this case, the product market definition for hospital services can be left open since
        the Transaction does not give rise to serious doubts as to its compatibility with the
        internal market or the functioning of the EEA agreement even under the narrowest
        plausible product market definition of private hospital services.
               (B)       Geographic market definition
(162) The Commission found that the geographic scope of this market is national or
        narrower.130
(163) The Notifying Party did not depart from the decisional practice of the Commission
        regarding market definition in private hospital services.
(164) The Commission’s investigation did not provide any indications that it would be
        appropriate for the Commission to depart from its previous decisional practice for
        private hospital services.
(165) In this case, the exact geographic market definition for private hospital services can
        be left open since the Transaction does not give rise to serious doubts as to its
        compatibility with the internal market or the functioning of the EEA agreement
        under any plausible product market definition of private hospital services.
4.2.3. Legal framework
(166) A concentration can also entail vertical and/or conglomerate effects. The
        Commission Guidelines on the assessment of non-horizontal mergers under the
        Merger Regulation131 (the “Non-Horizontal Merger Guidelines”) distinguish
        between two main ways in which non-horizontal mergers may significantly impede
        effective competition: (a) when they give rise to input and/or customer foreclosure
        (non-coordinated effects); and (b) when the merger changes the nature of
128 Case M.9044 – CVC/Recordati, paras. 21 and 145.
129 See Form CO, paragraph 184 (c) (i)
130 Case M.9044 – CVC/Recordati, para. 22.
131 Commission Guidelines on the assessment of non-horizontal mergers under the Merger Regulation (OJ
     C 265, 18.10.2008, p. 6).
                                                    40
 ---pagebreak---         competition in such a way that firms that previously were not coordinating their
        behaviour, are now more likely to coordinate to raise prices or otherwise harm
        effective competition (coordinated effects).132 The Non-Horizontal Merger
        Guidelines distinguish two types of foreclosure: (a) where the merger is likely to
        raise the costs of downstream rivals by restricting their access to an important input
        (input foreclosure) and (b) where the merger is likely to foreclose upstream rivals by
        restricting their access to a sufficient customer base (customer foreclosure)133.
(167) In assessing the likelihood of an anticompetitive input foreclosure strategy, the
        Commission has to examine whether (i) the merged entity would have the ability to
        substantially foreclose access to inputs; (ii) whether it would have the incentive to do
        so; and (iii) whether a foreclosure strategy would have a significant detrimental
        effect on competition downstream.134 In assessing the likelihood of an
        anticompetitive customer foreclosure strategy, the Commission has to examine
        whether (i) the merged entity would have the ability to foreclose access to
        downstream markets by reducing its purchases from upstream rivals; (ii) whether it
        would have the incentive to do so; and (iii) whether a foreclosure strategy would
        have a significant detrimental effect on consumers in the downstream market.135
        According to the Non-Horizontal Merger Guidelines, the Commission is unlikely to
        find concern in non-horizontal mergers, where the market share post-merger of the
        new entity in each of the markets concerned is below 30%.136
(168) The Non-Horizontal Merger Guidelines define conglomerate mergers as mergers
        between firms that are in a relationship which is neither horizontal (as competitors in
        the same relevant market) nor vertical (as suppliers or customers).137
4.2.4. Competitive assessment
4.2.4.1. Flexible Packaging for Pharmaceuticals – CVC (Upstream) / FDPs – Target
        (Downstream)
(169) One of the CVC portfolio companies, Syntegon, is active in the upstream market for
        flexible packaging for pharmaceuticals in the EEA. Flexible packaging is an input
        for several FDPs of the Target (downstream). The vertically linked upstream and
        downstream markets and the Parties’ shares are identified in Appendix 1. As shown
        in this Appendix, CVC Syntegon’s share in all upstream markets (that is in flexible
        packaging for the pharmaceutical sector and narrower plausible segments for
        laminated sachets, coldform blister bases, plastic-based blister bases and blister
        lidding) is 10% or less while Cooper’s share is 30% or more in all the downstream
        markets.
(170) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in any of the upstream markets for flexible
        packaging for pharmaceuticals (under any plausible market delineation) in the EEA,
        where it is active. CVC Syntegon holds a share of 10% or less in the upstream
132 Non-horizontal Merger Guidelines, paragraphs 17-19.
133 Non-horizontal Merger Guidelines, paragraph 30.
134 Non-horizontal Merger Guidelines, paragraph 32.
135 Non-horizontal Merger Guidelines, paragraph 59.
136 Non-horizontal Merger Guidelines, paragraph 25.
137 Non-horizontal Merger Guidelines, paragraph 5.
                                                      41
 ---pagebreak---         markets for flexible packaging for pharmaceuticals (under any plausible market
        delineation) in the EEA and it would face competition from several players,
        including Amcor, Wipak, Constantia Flexibles and others. Post-Transaction, the
        Target’s downstream rivals could turn to any of CVC’s rivals (at least CVC’s rivals
        in the EEA or possibly to an even wider set of rivals if the geographic upstream
        market is defined as wider than the EEA) to source flexible packaging, even if the
        combined entity decided to discontinue supply of its upstream inputs.
(171) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for flexible packaging of
        pharmaceuticals (or any plausible market delineation) in the EEA. Rather, Cooper’s
        demand for any flexible packaging of pharmaceuticals in the upstream markets does
        not exceed 10% of the total EEA-wide demand.138 That is because flexible
        packaging used for individual FDPs of Cooper is used for a variety of other use
        cases, including for example other FDPs where Cooper’s market share is limited. In
        case the combined entity decided to source flexible packaging that CVC Syntegon
        offers today only in-house, CVC’s rivals (both its rivals in the EEA or in a wider
        market) would continue to have access to a significant customer base to sell their
        products.
(172) Given that the combined entity would not have the ability to foreclose its
        downstream rivals in FDPs or its upstream rivals in the provision of flexible
        packaging for pharmaceuticals in the EEA (or wider), it would also not have an
        incentive to attempt a foreclosure as it would not be able to gain anything from such
        a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the
        combined entity would have no impact on the national markets for FDP and the
        market for flexible packaging for pharmaceuticals in the EEA (or wider). In any
        event, no respondent to the market investigation raised concerns regarding the
        impact of the proposed Transaction on these vertically linked markets. 139
4.2.4.2. Packaging Machinery for Pharmaceuticals – CVC (Upstream) / FDPs – Target
          (Downstream)
(173) One of the CVC portfolio companies, AR Packaging, is active in the plausible
        upstream market for packaging machines (for pharmaceuticals) in the EEA. Such
        machines are used to manufacture several FDPs of the Target (downstream). The
        vertically linked upstream and downstream markets and the Parties’ shares are
        identified in Appendix 2. As shown in this Appendix, CVC AR Packaging’s share in
        all plausible upstream markets (that is in packaging machinery or packaging
        machinery for pharmaceuticals) is 10% or less while the Target’s share is 30% or
        more in all the downstream markets.
138 Cooper’s share of 30% or more are based on markets defined at ATC3/CHC3, ATC4/CHC4, or molecule
    level (or in case of anti-lice products on GERS data). Cooper’s high market shares in a few countries
    concerning a small number of FDPs (and often under narrow market delineations) do not give the
    combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 –
    Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi-
    Aventis/Zentiva, para. 533.)
139 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                         42
 ---pagebreak--- (174) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in any of the upstream markets (for
        packaging machinery or packaging machinery for pharmaceuticals) in the EEA,
        where it is active. CVC AR Packaging holds a share of 10% or less in the upstream
        markets for packaging machinery (under any plausible market delineation) in the
        EEA and it would face competition from several players, including IMA Group,
        Bausch & Ströbel, Optima and others. Post-Transaction, the Target’s downstream
        rivals could turn to any of CVC’s rivals (at least CVC’s rivals in the EEA or possibly
        to an even wider set of rivals if the geographic upstream market is defined as wider
        than the EEA) to source packaging machines, even if the combined entity decided to
        discontinue supply of its upstream inputs.
(175) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for packaging machines for
        pharmaceuticals (or any narrower plausible market) in the EEA. Rather, the Target’s
        demand for any packaging machines for pharmaceuticals in the upstream markets
        does not exceed 10% of the total EEA-wide demand.140 That is because the
        packaging machinery used for FDPs by Cooper is also used for a variety of other
        packaging purposes, and because, according to the Parties, Cooper only procures
        packaging machinery in case of an expansion or to replace obsolete packaging
        machinery.141 In case the combined entity decided to source packaging machine that
        CVC AR Packaging offers today only in-house, CVC’s rivals (both its rivals in the
        EEA or in a wider market) would continue to have access to a significant customer
        base to sell their products.
(176) Given that the combined entity would not have the ability to foreclose its
        downstream rivals in national markets for FDPs or its upstream rivals in the
        provision of packaging machines for pharmaceuticals in the EEA (or wider), it
        would also not have an incentive to attempt a foreclosure as it would not be able to
        gain anything from such a strategy. In the absence of the ability to foreclose, any
        foreclosure strategy by the combined entity would have no impact on the national
        markets for FDP and the market for packaging machines for pharmaceuticals in the
        EEA (or wider). In any event, no respondent to the market investigation raised
        concerns regarding the impact of the proposed Transaction on these vertically linked
        markets. 142
4.2.4.3. APIs – CVC’s Recordati (Upstream) / FDPs – Cooper (Downstream)
(177) CVC is active in the upstream API markets for (i) diphenhydramine hydrochloride in
        the EEA and (ii) dimenhydrinate in the EEA. These APIs are inputs to 15 FDPs
        marketed by Cooper downstream. The vertically linked upstream and downstream
        markets and the Parties’ shares are identified in Appendix 4.
140 Cooper’s share of 30% or more are based on markets defined at ATC3/CHC3, ATC4/CHC4, or molecule
    level (or in case of anti-lice products on GERS data). Cooper’s high market shares in a few countries
    concerning a small number of FDPs (and often under narrow market delineations) do not give the
    combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 –
    Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi-
    Aventis/Zentiva, para. 533.)
141 Form CO, paragraph 251.
142 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                         43
 ---pagebreak--- (178) In 2020, the Target sourced diphenhydramine hydrochloride from CVC worth
         approximately EUR […] (or [5-10]% of CVC’s total sales in the EEA for this API).
         143 The Target has not sourced dimenhydrinate since 2018 due to sufficient material
         in stock. 144
(179) The combined entity is unlikely to have the ability to engage in input foreclosure for
         either of these products. Firstly, for diphenhydramine hydrochloride, since it is a
         product which can be manufactured easily and which is sold by a number of
         companies globally and in Europe, e.g. by Caesar & Loretz GmbH, Tiefenbacher
         API + Ingredients, LGC Limited, Wanbury Limited and Kongo Chemical Co.
         Limited. All these suppliers would be able to supply Cooper’s downstream rivals.
         Given Cooper’s low market shares in the downstream markets (overall sales values
         of less than EUR 1m), Recordati would have to forego all or the vast majority of its
         sales for diphenhydramine hydrochloride in the EEA. Regarding dimenhydrinate the
         fact that for the last three years the Target has not sourced it demonstrates the low
         importance of the product and therefore the lack of any ability to foreclose.
(180) The combined entity is unlikely to have the ability to engage in customer foreclosure
         because it would not constitute an important customer for diphenhydramine
         hydrochloride or dimenhydrinate in the EEA or wider. In 2020 Cooper’s purchases
         of diphenhydramine hydrochloride amounted to approximately EUR […] ([5-10]%
         of the total of Recordati's total EEA sales for that year).145
(181) Given that the combined entity would not have the ability to foreclose its
         downstream rivals in the national markets for FDPs or its upstream rivals in APIs in
         the EEA or wider, it would also not have an incentive to attempt a foreclosure as it
         would not be able to gain anything from such a strategy. In the absence of the ability
         to foreclose, any foreclosure strategy by the combined entity would have no impact
         on the national markets for FDPs and the market for APIs in the EEA or wider. In
         any event, no respondent to the market investigation raised concerns regarding the
         impact of the proposed Transaction on these vertically linked markets. 146
4.2.4.4. APIs – Target (Upstream) / FDPs – CVC (Downstream)
(182) The Target is active in different upstream markets for APIs in the EEA. These APIs
         can be an input for a number of FDPs of CVC’s Recordati and Genetic
         (downstream). The vertically linked ((at the ATC3/CHC3, ATC4/CHC4 and
         molecule levels)) upstream and downstream markets and the Parties’ shares are
         identified in Appendix 6 (under all plausible market definitions). As shown in this
         Appendix, Cooper’s share in all upstream markets is 10% or less while CVC’s
         Recordati and Genetic’s share is 30% or more in all the downstream markets.
(183) The combined entity is unlikely to have the ability to engage in input foreclosure
         because it would not have market power in any of the upstream markets for APIs in
         the EEA, where it is active. Under all plausible market definitions, the Target holds a
143 Form CO, footnote 88.
144 Form CO, footnote 106
145 See Form CO, footnote 88.
146 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
     Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                          44
 ---pagebreak---         share of 10% or less in the upstream markets for APIs in the EEA147 and it would
        face competition from several players, Brenntag, Univar, Helm, IMCD and others.148
        Post-Transaction, Recordati’s and Genetic’s downstream rivals could turn to any of
        Cooper’s rivals (at least Cooper’s rivals in the EEA or possibly to an even wider set
        of rivals if the geographic upstream market is defined as wider than the EEA) to
        source APIs, even if the combined entity decided to discontinue supply of its
        upstream inputs.
(184) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for APIs in the EEA or wider
        market. Rather, Recordati’s and Genetic’s demand for any APIs in the upstream
        markets does not exceed 10% of the total EEA-wide demand. In case the combined
        entity decided post-Transaction to source the APIs that Cooper offers today only in-
        house, Cooper’s rivals would continue to have access to a significant customer base
        to sell their products.
(185) Given that the combined entity would not have the ability to foreclose its
        downstream rivals in the national markets for FDPs or its upstream rivals in APIs, it
        would also not have an incentive to attempt a foreclosure as it would not be able to
        gain anything from such a strategy. In the absence of the ability to foreclose, any
        foreclosure strategy by the combined entity would have no impact on the national
        markets for FDPs and the market for APIs. In any event, no respondent to the market
        investigation raised concerns regarding the impact of the proposed Transaction on
        these vertically linked markets. 149
4.2.4.5. Excipients – Cooper (Upstream) / FDPs – CVC’s Recordati and Genetic
        (Downstream)
(186) The Target is active in different upstream markets for pharmaceutical excipients in
        the EEA. These excipients can be an input for several FDPs of CVC’s Recordati and
        Genetic (downstream). The vertically linked upstream and downstream markets and
        the Parties’ shares are identified in Appendix 5. As shown in this Appendix,
        Cooper’s share in all upstream markets (even under the narrowest plausible markets
        defined at the level of individual excipients) is 10% or less while CVC’s Recordati
        and Genetic’s share is 30% or more in all the downstream markets.
(187) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in any of the upstream markets for
        excipients in the EEA, where it is active. Under all plausible market definitions,
        Cooper holds a share of 10% or less in the upstream markets for excipients in the
        EEA150 and it would face competition from several players, including Brenntag,
        Safic Alcan, Quimdis, and others. Post-Transaction, Recordati’s and Genetic’s
        downstream rivals could turn to any of Cooper’s rivals (at least Cooper’s rivals in
        the EEA or possibly to an even wider set of rivals if the geographic upstream market
        is defined as wider than the EEA) to source excipients, even if the combined entity
        decided to discontinue supply of its upstream inputs.
147 See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).
148 See Form CO, footnote 117.
149 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
150 See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).
                                                         45
 ---pagebreak--- (188) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for excipients in the EEA.
        Rather, Recordati’s and Genetic’s demand for any excipients in the upstream
        markets does not exceed 10% of the total EEA-wide demand.151 In case the
        combined entity decided to source the excipients that Cooper offers today only in-
        house, Cooper’s rivals (both its rivals in the EEA or in a wider market) would
        continue to have access to a significant customer base to sell their products.
(189) Given that the combined entity would not have the ability to foreclose its
        downstream rivals in the national markets for FDP and or its upstream rivals in
        excipients in the EEA (or wider), it would also not have an incentive to attempt a
        foreclosure as it would not be able to gain anything from such a strategy. In the
        absence of the ability to foreclose, any foreclosure strategy by the combined entity
        would have no impact on the national markets for FDPs and the market for
        excipients in the EEA (or wider). In any event, no respondent to the market
        investigation raised concerns regarding the impact of the proposed Transaction on
        these vertically linked markets.152
4.2.4.6. Excipients (Wet granulation lactose and direct compression lactose) – CVC’s DFE
        Pharma (Upstream) / FDPs and CDMO services – Cooper (Downstream)
(190) DFE Pharma (a portfolio company controlled by CVC) is active in the upstream
        markets for wet granulation lactose and direct compression lactose in the EEA.
        These excipients are used as inputs for FDPs of Cooper in 12 downstream markets
        and for CDMO services that Cooper offers to third parties. The vertically linked
        upstream and downstream markets and the Parties’ shares are identified in Appendix
        3. As shown in this Appendix, DFE Pharma’s share in the upstream markets is
        slightly above 30% while Cooper’s share is less than 30% in all the downstream
        markets.
(191) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in the upstream markets. In 2020, DFE
        Pharma held shares of [30-40]% in wet granulation lactose and [30-40]% in direct
        compression lactose in the EEA but it faced competition from major international
        rivals in the EEA153, e.g., Meggle ([10-20]% in wet granulation lactose and [30-
        40]% in direct compression lactose) and Kerry ([10-20]% in wet granulation lactose
        and [5-10]% in direct compression lactose). Post-Transaction, Cooper’s downstream
        rivals could turn to any of DFE Pharma’s competitors (at least rivals in the EEA or
        possibly to an even wider set of rivals if the geographic upstream market is defined
        as wider than the EEA) to source wet granulation lactose and direct compression
        lactose, even if the combined entity decided to discontinue supply of its upstream
        inputs. e.g., Meggle, Kerry, and Armor
(192) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for the upstream inputs in the
        EEA. In 2020, Cooper purchased wet granulation lactose worth EUR […] (which
        represents [0-5]% of the total demand for this product) and direct compression
151 See footnote 74 above.
152 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
153 See Form CO Tables 6 & 8.
                                                         46
 ---pagebreak---         lactose worth EUR […] (which represents [0-5]% of the total demand for this
        product). In case the combined entity decided to source wet granulation lactose and
        direct compression lactose only in-house, DFE Pharma’s rivals (both its rivals in the
        EEA or in a wider market) would continue to have access to a significant customer
        base to sell their products.
(193) Given that the combined entity would not have the ability to foreclose its
        downstream rivals in the national markets for FDPs and the market for CDMO
        services in the EEA (or wider), or its upstream rivals in the provision of in wet
        granulation and direct granulation lactose in the EEA (or wider), it would also not
        have an incentive to attempt a foreclosure as it would not be able to gain anything
        from such a strategy. In the absence of the ability to foreclose, any foreclosure
        strategy by the combined entity would have no impact on the national markets for
        FDPs, the market for CDMO services in the EEA (or wider) and the market for in
        wet granulation and direct granulation lactose in the EEA (or wider). In any event,
        no respondent to the market investigation raised concerns regarding the impact of the
        proposed Transaction on these vertically linked markets. 154
4.2.4.7. CDMO Services – Target (Upstream) / FDPs – CVC (Downstream)
(194) The Target is active in the upstream markets for CDMO services in the EEA. These
        CDMO services can be an input for several FDPs of CVC (downstream). For some
        of these FDPs, CVC has a share >30% at national level.
(195) The Target is active in different upstream markets for the provision of CDMO
        services in the EEA. These CDMO servicescan be an input for a number of FDPs of
        CVC’s Recordati and Theramex (downstream). The vertically linked ((at the
        ATC3/CHC3, ATC4/CHC4 and molecule levels)) upstream and downstream
        markets and the Parties’ shares are identified in Appendixes 7i and 7ii (under all
        plausible market definitions). As shown in this Appendix, Cooper’s share in all
        upstream markets is 10% or less while CVC’s Recordati and Theramex’s share is
        30% or more in all the downstream markets.
(196) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in any of the upstream markets for CDMO
        services in the EEA, where it is active. Under all plausible market definitions, The
        Target holds a share of 10% or less in the upstream markets for CDMO services in
        the EEA155 and it would face competition from several players, including Lonza,
        Catalent, Pantheon, Recipharm and others. Post-Transaction, Recordati’s and
        Theramex’s downstream rivals could turn to any of Cooper’s rivals (at least
        Cooper’s rivals in the EEA or possibly to an even wider set of rivals if the
        geographic upstream market is defined as wider than the EEA) to source CDMO
        services, even if the combined entity decided to discontinue supply of its upstream
        inputs.
(197) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for CDMO services in the
        EEA. Rather, Recordati’s and Genetic’s demand for any CDMO services in the
154 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
155 See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).
                                                         47
 ---pagebreak---         upstream markets does not exceed 10% of the total EEA-wide demand. In case the
        combined entity decided post-Transaction to source the CDMO services that Cooper
        offers today only in-house, Cooper’s rivals (both in the EEA or wider) would
        continue to have access to a significant customer base to sell their products.
(198) Given that the combined entity would not have the ability to foreclose its
        downstream rivals the national markets for FDPs, or its upstream rivals in CDMO
        services in the EEA (or wider), it would also not have an incentive to attempt a
        foreclosure as it would not be able to gain anything from such a strategy. In the
        absence of the ability to foreclose, any foreclosure strategy by the combined entity
        would have no impact on the national markets for FDPs and the market for CDMO
        services in the EEA (or wider). In any event, no respondent to the market
        investigation raised concerns regarding the impact of the proposed Transaction on
        these vertically linked markets. 156
4.2.4.8. FDPs – Target (Upstream) / Private Hospital Services – CVC (Downstream)
(199) CVC is active in the downstream market for private hospital services in Greece.157
        Cooper offers FDPs in Greece158 that could be an upstream input for the operation of
        private hospitals downstream. The vertically linked (at the ATC3/CHC3 level)
        upstream and downstream markets and the Parties’ shares are identified in Appendix
        8.
(200) The combined entity is unlikely to have the ability to engage in input foreclosure
        because it would not have market power in any of the upstream markets for FDPs in
        Greece. Cooper holds a share of 30% or less in all of the upstream markets for FDPs
        in Greece. Moreover, already now, Cooper does not supply any hospitals in Greece,
        which therefore do not rely on Cooper for the supply of FDPs. Post-Transaction,
        CVC’s downstream rivals could simply keep purchasing the FDPs from their current
        suppliers, even if the combined entity decided to not supply FDPs to its downstream
        rivals.
(201) The combined entity is unlikely to have the ability to engage in customer foreclosure
        because it would not constitute an important customer for the upstream FDP markets
        in Greece. In a plausible downstream market including all private hospitals in
        Greece, CVC’s hospitals held a share of [30-40]% in 2020. However, FDPs are used
        by a far wider set of customers other than hospitals, including for example
        wholesalers, drugstores and pharmacies. In case the combined entity decided to
        source FDPs that Cooper offers today only in-house, CVC’s rivals would continue to
        have access to a significant customer base to sell their products, including both
        private hospitals as well as other types of customers.
156 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire
    Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
157 Through the Hellenic Healthcare Group ("HHG"), which is the largest private hospital group in Greece,
    consisting of six hospitals: Metropolitan Hospital; Metropolitan General; Hygeia Hospital; Mitera; Leto;
    and Creta Interclinic. HHG provides all major procedures and treats approximately 100,000 inpatients and
    1 million outpatients annually.
158 These are FDPs in ATC3 class N5B – Hypnotics and Sedatives and in CHC3 class 13A2 – Calming
    Products.
                                                         48
 ---pagebreak--- (202) Given that the combined entity would not have the ability to foreclose its
         downstream rivals in the provision of hospital services in Greece its upstream rivals
         in FDPs in Greece, it would also not have an incentive to attempt a foreclosure as it
         would not be able to gain anything from such a strategy. In the absence of the ability
         to foreclose, any foreclosure strategy by the combined entity would have no impact
         on the market for hospital services in Greece and the market for FDPs in Greece. In
         any event, no respondent to the market investigation raised concerns regarding the
         impact of the proposed Transaction on these vertically linked markets. 159
4.2.4.9. Overall conclusion on vertical effects
(203) In light of the considerations discussed in paragraphs (169) to (202), the
         Commission concludes that the Transaction does not raise serious doubts as to its
         compatibility with the internal market or the functioning of the EEA agreement in
         terms of its competition impact on the vertical relationships identified in paragraph
         (109).
5.       CONCLUSION
(204) For the above reasons, the European Commission has decided not to oppose the
         notified operation and to declare it compatible with the internal market and with the
         EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the
         Merger Regulation and Article 57 of the EEA Agreement.
                                                               For the Commission
                                                               (Signed)
                                                               Margrethe VESTAGER
                                                               Executive Vice-President
159 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3,
    questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.
                                                         49
 ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---  ---pagebreak---                                                                                                                                                                                        Case M.10247 - CVC/Cooper
                                                                                          Appendix 6
                                        (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream)
                                   Upstream Market (Target)                                                                                          Downstream FDP Market (Recordati)
          Product Market (Target)    Geographic Market                                 Share (2020, EEA)                Geographic Market           Product Market (ATC3/CHC3)          Recordati share in 2020
                                                                                                                                              03D3 ANT DIARR ELECTROL                           [70-80]%
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
                                                                                                                                              A6B BOWEL CLEANSERS
ACIDE CITRIQUE ANH PDRE VR.K                                                                                            SPA N                                                                    volume
                                                                                                                                                                                     [80-90]% by value / [90-100]%
                                                                                                                                              A7G ORAL ELECTROL. REPLACER
                                                                                                                                                                                               by volume
                                                                                                                                                                                   [70-80]% by value / [30-40]% by
                                                                                                                        BELGIUM               03C4 SALINE LAXATIVES
                                                                                                                                                                                                 volume
ACIDE PHOSPHORIQUE 85%       VR.L
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
                                                                                                                        SPA N                 A6B BOWEL CLEANSERS
                                                                                                                                                                                                 volume
                                                                                                                                              03D3 ANT DIARR ELECTROL                           [70-80]%
GLUCOSE ANH VR.K                                                                                                        SPA N                                                        [80-90]% by value / [90-100]%
                                                                                                                                              A7G ORAL ELECTROL. REPLACER
                                                                                                                                                                                               by volume
                                                                                                                                                                                   [30-40]% by value / [40-50]% by
                                                                                                                        FRANCE                N7F DRUGS USED IN OPIOID DEP
                                                                                                                                                                                                 volume
GLYCERINE CONTAINER 1000 L
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
                                                                                                                        SPA N                 A6B BOWEL CLEANSERS
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [30-40]% by value / [50-60]% by
                                                                                                                                              06V1 OTHER SKIN PRODUCTS
                                                                                                                                                                                                 volume
ICHTHYOLAMMONIUM VR.K                                                                                                   CZECH REPUBLIC
                                                                                                                                                                                   [10-20]% by value / [80-90]% by
                                                                                                                                              D5A TOP ANTIPSORIASIS PRDS
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [70-80]% by value / [80-90]% by
                                                                                                                        CYPRUS                C5A TOPICAL ANTI-HAEMORRHO DALS
                                                                                                                                                                                                 volume
                                                                                                                                              10A1 ANTIHAEMORRHO DS                             [30-40]%
                                                                                                                        LATVIA                                                     [30-40]% by value / [20-30]% by
                                                                                                                                              C5A TOPICAL ANTIHAEMORRHO DL
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [30-40]% by value / [30-40]% by
                                                                                                                                              10A1 ANTIHAEMORRHO DS
                                                                                                                                                                                                 volume
                                                                                                                        POLAND
LIDOCAINE CHLTE VR.K                                                                                                                                                               [30-40]% by value / [30-40]% by
                                                                                                                                              C5A TOPICAL ANTIHAEMORRHO DL
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [20-30]% by value / [30-40]% by
                                                                                                                                              10A1 ANTIHAEMORRHO DS
                                                                                                                                                                                                 volume
                                                                                                                        ROMANIA
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
                                                                                                                                              C5A TOPICAL ANTIHAEMORRHO DL
                                      At least EEA-wide                                      <10%                                                                                                volume
                                                                                                                                                                                   [20-30]% by value / [30-40]% by
                                                                                                                        SLOVAKIA              C5A TOPICAL ANTIHAEMORRHO DL
                                                                                                                                                                                                 volume
                                                                                                                                              03D3 ANT DIARR ELECTROL                           [70-80]%
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
                                                                                                                                              A6B BOWEL CLEANSERS
POTASSIUM CHLORURE VR.K                                                                                                 SPA N                                                                    volume
                                                                                                                                                                                     [80-90]% by value / [90-100]%
                                                                                                                                              A7G ORAL ELECTROL. REPLACER
                                                                                                                                                                                               by volume
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
SODIUM BICARBONATE VR.K                                                                                                 SPA N                 A6B BOWEL CLEANSERS
                                                                                                                                                                                                 volume
                                                                                                                                              03C4 SALINE LAXATIVES                            [90-100]%
                                                                                                                                              03D3 ANT DIARR ELECTROL                           [70-80]%
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
SODIUM CHLORURE VR.K                                                                                                    SPA N                 A6B BOWEL CLEANSERS
                                                                                                                                                                                                 volume
                                                                                                                                                                                       [80-90]% by value / 90% by
                                                                                                                                              A7G ORAL ELECTROL. REPLACER
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [50-60]% by value / [40-50]% by
SODIUM PHOSPHATE MONO PUR CRIST VK                                                                                      SPA N                 A6B BOWEL CLEANSERS
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [70-80]% by value / [80-90]% by
                                                                                                                        CYPRUS                C5A TOPICAL ANTI-HAEMORRHO DALS
                                                                                                                                                                                                 volume
                                                                                                                                              10A1 ANTIHAEMORRHO DS                             [30-40]%
                                                                                                                        LATVIA                                                     [30-40]% by value / [20-30]% by
                                                                                                                                              C5A TOPICAL ANTIHAEMORRHO DL
                                                                                                                                                                                                 volume
                                                                                                                                                                                   [30-40]% by value / [30-40]% by
                                                                                                                                              10A1 ANTIHAEMORRHO DS
                                                                                                                                                                                                 volume
                                                                                                                        POLAND
SORBITOL VR.K                                                                                                                                                                      [30-40]% by value / [30-40]% by
                                                                                                                                              C5A TOPICAL ANTIHAEMORRHO DL
                                                                                                                                                                                                 volume
 ---pagebreak---                                       [20-30]% by value / [30-40]% by
         10A1 ANTIHAEMORRHO DS
                                                 volume
ROMANIA
                                      [50-60]% by value / [40-50]% by
         C5A TOPICAL ANTIHAEMORRHO DL
                                                 volume
                                      [20-30]% by value / [30-40]% by
SLOVAKIA C5A TOPICAL ANTIHAEMORRHO DL
                                                 volume
 ---pagebreak---                                                                                                                                                     Case M.10247 - CVC/Cooper
                                                                    Appendix 6
                                 (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream)
                            Upstream Market (Target)                                                              Downstream FDP Market (Recordati)
         Product Market (Target)             Geographic Marke     Share (2020, EEA)   Geographic Marke         Product Market (ATC4/CHC4)            Recordati share in 2020
                                                                                                                                                  [40-50]% by value / [5-10]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         FRANCE              A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [50-60]% by value / [10-20]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         GERMANY             03C5P POWDERS
                                                                                                                                                             volume
                                                                                                                                                 [30-40]% by value / [30-40]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         GERMANY             A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [90-100]% by value / [90-100]%
ACIDE CITRIQUE ANH PDRE VR.K                                                         IRELAND             03C4Q ENEMAS
                                                                                                                                                           by volume
                                                                                                                                                 [70-80]% by value / [70-80]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         ITALY               A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [70-80]% by value / [10-20]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         POLAND              A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [80-90]% by value / [80-90]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         PORTUGAL            A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [60-70]% by value / [40-50]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         SPAIN               03C1Z OTHER FORMS
                                                                                                                                                             volume
                                                                                                                                                 [80-90]% by value / [80-90]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         SPAIN               03D3P POWDER
                                                                                                                                                             volume
                                                                                                                                                 [90-100]% by value / [90-100]%
ACIDE CITRIQUE ANH PDRE VR.K                                                         SPAIN               A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                           by volume
                                                                                                                                                 [40-50]% by value / [20-30]% by
ACIDE CITRIQUE ANH PDRE VR.K                                                         SWEDEN              A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [40-50]% by value / [10-20]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          BELGIUM             03C4M MIXTURES (ORAL)
                                                                                                                                                             volume
                                                                                                                                                 [90-100]% by value / [90-100]%
ACIDE PHOSPHORIQUE 85% VR.L                                                          BELGIUM             03C4Q ENEMAS
                                                                                                                                                           by volume
                                                                                                                                                  [40-50]% by value / [5-10]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          FRANCE              A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [30-40]% by value / [30-40]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          GERMANY             A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [90-100]% by value / [90-100]%
ACIDE PHOSPHORIQUE 85% VR.L                                                          PORTUGAL            03C4Q ENEMAS
                                                                                                                                                           by volume
                                                                                                                                                 [70-80]% by value / [60-70]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          PORTUGAL            A6A4 LAXATIVE ENEMAS
                                                                                                                                                             volume
                                                                                                                                                 [80-90]% by value / [80-90]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          PORTUGAL            A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
                                                                                                                                                 [30-40]% by value / [10-20]% by
ACIDE PHOSPHORIQUE 85% VR.L                                                          SPAIN               A6A4 LAXATIVE ENEMAS
                                                                                                                                                             volume
                                                                                                                                                 [90-100]% by value / [90-100]%
ACIDE PHOSPHORIQUE 85% VR.L                                                          SPAIN               A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                           by volume
                                                                                                                                                 [80-90]% by value / [80-90]% by
GLUCOSE ANH VR.K                                                                     SPAIN               03D3P POWDER
                                                                                                                                                             volume
                                                                                                                                                 [20-30]% by value / [30-40]% by
GLYCERINE CONTAINER 1000 L                                                           CZECH REPUBLIC 06C4L LIQUIDS&LOTIONS (TOPICAL)
                                                                                                                                                             volume
                                                                                                                                                 [20-30]% by value / [30-40]% by
GLYCERINE CONTAINER 1000 L                                                           CZECH REPUBLIC 06F3O OINTMENTS/CREAMS
                                                                                                                                                             volume
                                                                                                                                                  [40-50]% by value / [5-10]% by
GLYCERINE CONTAINER 1000 L                                                           FRANCE              A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                                                                             volume
 ---pagebreak---                                                                                                [30-40]% by value / [30-40]% by
GLYCERINE CONTAINER 1000 L                        GERMANY        A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                           volume
                                                                                               [80-90]% by value / [80-90]% by
GLYCERINE CONTAINER 1000 L                        PORTUGAL       A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                           volume
                                                                                               [20-30]% by value / [40-50]% by
GLYCERINE CONTAINER 1000 L                        SLOVAKIA       06F3O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [30-40]% by value / [10-20]% by
GLYCERINE CONTAINER 1000 L                        SPAIN          A6A4 LAXATIVE ENEMAS
                                                                                                           volume
                           At least EEA-wide <10%
                                                                                               [90-100]% by value / [90-100]%
GLYCERINE CONTAINER 1000 L                        SPAIN          A6B1 OSMOTIC BOWEL CLEANSERS
                                                                                                         by volume
                                                                                               [40-50]% by value / [50-60]% by
ICHTHYOLAMMONIUM VR.K                             CZECH REPUBLIC 06V1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [40-50]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              LATVIA         10A1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [30-40]% by value / [20-30]% by
LIDOCAINE CHLTE VR.K                              LATVIA         10A1S SUPPOSITORIES
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              LATVIA         C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              LITHUANIA      C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              POLAND         10A1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [30-40]% by value / [20-30]% by
LIDOCAINE CHLTE VR.K                              POLAND         10A1S SUPPOSITORIES
                                                                                                           volume
                                                                                               [40-50]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              POLAND         C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              ROMANIA        10A1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [60-70]% by value / [50-60]% by
LIDOCAINE CHLTE VR.K                              ROMANIA        C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              SLOVAKIA       10A1S SUPPOSITORIES
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
LIDOCAINE CHLTE VR.K                              SLOVAKIA       C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [10-20]% by
MANNITOL VR.K                                     SLOVAKIA       G4C2 BPH ALPH-ADREN ANTAG PLN
                                                                                                           volume
                                                                                               [80-90]% by value / [80-90]% by
POTASSIUM CHLORURE VR.K                           SPAIN          03D3P POWDER
                                                                                                           volume
                                                                                               [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K                              SPAIN          03C4Q ENEMAS
                                                                                                         by volume
                                                                                               [80-90]% by value / [80-90]% by
SODIUM CHLORURE VR.K                              SPAIN          03D3P POWDER
                                                                                                           volume
                                                                                               [40-50]% by value / [30-40]% by
SORBITOL VR.K                                     LATVIA         10A1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [30-40]% by value / [20-30]% by
SORBITOL VR.K                                     LATVIA         10A1S SUPPOSITORIES
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
SORBITOL VR.K                                     LATVIA         C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
SORBITOL VR.K                                     LITHUANIA      C5A2 A-HAEMORRHOID W/O CORTIC
                                                                                                           volume
                                                                                               [30-40]% by value / [30-40]% by
SORBITOL VR.K                                     POLAND         10A1O OINTMENTS/CREAMS
                                                                                                           volume
                                                                                               [30-40]% by value / [20-30]% by
SORBITOL VR.K                                     POLAND         10A1S SUPPOSITORIES
                                                                                                           volume
 ---pagebreak---                                                      [40-50]% by value / [30-40]% by
SORBITOL VR.K POLAND   C5A2 A-HAEMORRHOID W/O CORTIC
                                                                 volume
                                                     [30-40]% by value / [30-40]% by
SORBITOL VR.K ROMANIA  10A1O OINTMENTS/CREAMS
                                                                 volume
                                                     [60-70]% by value / [50-60]% by
SORBITOL VR.K ROMANIA  C5A2 A-HAEMORRHOID W/O CORTIC
                                                                 volume
                                                     [30-40]% by value / [30-40]% by
SORBITOL VR.K SLOVAKIA 10A1S SUPPOSITORIES
                                                                 volume
                                                     [30-40]% by value / [30-40]% by
SORBITOL VR.K SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC
                                                                 volume
 ---pagebreak---                                                                                                                                                                                                                 Case M.10247 - CVC/Cooper
                                                             Appendix 6
                                                                     (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream)
                            Upstream Market (Target)                                                                                                   Downstream FDP Market (Recordati)
         Product Market (Target)         Geographic Market Share (2020, EEA)      Geographic Market                                                     Product Market (Molecule)                               Recordati share in 2020
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE ASCORBIQUE GRAN F N VR.K                                                 FRANCE                    R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE ASCORBIQUE GRAN F N VR.K                                                 FRANCE                    R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE ASCORBIQUE GRAN F N VR.K                                                 FRANCE                    R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL
                                                                                                                                                                                                                       by volume
                                                                                                         N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC                           [90-100]% by value / [90-100]%
AC DE ASCORBIQUE GRAN F N VR.K                                                 ITALY
                                                                                                         ACID PARACETAMOL!PROPYPHENAZONE                                                                               by volume
                                                                                                                                                                                                             [60-70]% by value / [60-70]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   FRANCE                    A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [30-40]% by value / [10-20]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   GERMANY                   03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [30-40]% by value / [20-30]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   GERMANY                   03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [50-60]% by value / [50-60]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   GERMANY                   03C5 CONTACT LAXATIVES --> 03C5P POWDERS --> CITRIC AC D MAGNESIUM PICOSULFURIC AC D
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [30-40]% by value / [20-30]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   GERMANY                   A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [40-50]% by value / [40-50]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   GERMANY                   A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   IRELAND                   03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   IRELAND                   A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [40-50]% by value / [30-40]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   ITALY                     A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [70-80]% by value / [70-80]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   ITALY                     A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [80-90]% by value / [80-90]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   ITALY                     N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [80-90]% by value / [80-90]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   POLAND                    A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [30-40]% by value / [30-40]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   PORTUGAL                  03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [70-80]% by value / [70-80]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   PORTUGAL                  A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   PORTUGAL                  A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                              [70-80]% by value / [0-5]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE F BRE
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHAR DES + MALTODEXTRIN
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                         A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN
                                                                                                         ACID!GLUCOSE POTASSIUM!SODIUM                                                                                 by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE CITRIQUE ANH PDRE VR.K                                                   SPAIN                     A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [40-50]% by value / [40-50]% by
AC DE CITRIQUE ANH PDRE VR.K                                                   SWEDEN                    A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID
                                                                                                                                                                                                                         volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]%      VR.L                                          BELGIUM                   03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]%      VR.L                                          BELGIUM                   03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                                                                                       by volume
                                                                                                                                                                                                             [70-80]% by value / [40-50]% by
AC DE PHOSPHORIQUE [80-90]%      VR.L                                          BELGIUM                   A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                                                                                         volume
 ---pagebreak---                                                                                                                                               [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L BELGIUM        A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> PHOSPHORIC AC D
                                                                                                                                                        by volume
                                                                                                                                              [50-60]% by value / [30-40]% by
AC DE PHOSPHORIQUE [80-90]% VR.L FRANCE         A12A CALCIUM --> A12A0 CALCIUM --> MAGNESIUM
                                                                                                                                                          volume
                                                                                                                                              [50-60]% by value / [30-40]% by
AC DE PHOSPHORIQUE [80-90]% VR.L FRANCE         A12A CALCIUM --> A12A0 CALCIUM --> PHOSPHORIC AC D
                                                                                                                                                          volume
                                                                                                                                              [50-60]% by value / [40-50]% by
AC DE PHOSPHORIQUE [80-90]% VR.L FRANCE         A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L GERMANY        03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L GERMANY        A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [30-40]% by value / [30-40]% by
AC DE PHOSPHORIQUE [80-90]% VR.L ITALY          03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2Q ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [40-50]% by value / [10-20]% by
AC DE PHOSPHORIQUE [80-90]% VR.L ITALY          A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L NORWAY         A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L PORTUGAL       03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
AC DE PHOSPHORIQUE [80-90]% VR.L PORTUGAL       A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [70-80]% by value / [70-80]% by
AC DE PHOSPHORIQUE [80-90]% VR.L PORTUGAL       A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [80-90]% by value / [80-90]% by
AC DE PHOSPHORIQUE [80-90]% VR.L SPAIN          A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [50-60]% by value / [50-60]% by
AC DE PHOSPHORIQUE [80-90]% VR.L SPAIN          A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE
                                                                                                                                                        by volume
                                                A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC                       [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN
                                                ACID!GLUCOSE POTASSIUM!SODIUM                                                                           by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN          A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM
                                                                                                                                                        by volume
                                                A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER -->                              [90-100]% by value / [90-100]%
GLUCOSE ANH VR.K                 SPAIN
                                                GLUCOSE!POTASSIUM!SODIUM!SUCROSE                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL MENTHOL!TALC!ZINC
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC
                                                                                                                                                        by volume
                                                                                                                                              [30-40]% by value / [30-40]% by
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PLANTAGO LANCEOLATA
                                                                                                                                                        by volume
                                                                                                                                              [30-40]% by value / [30-40]% by
GLYCERINE CONTA NER 1000 L       CZECH REPUBLIC 06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       FRANCE         01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL
                                                                                                                                                        by volume
                                                                                                                                              [50-60]% by value / [40-50]% by
GLYCERINE CONTA NER 1000 L       FRANCE         A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                          volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       FRANCE         N7F DRUGS USED N OPIOID DEP --> N7F0 DRUGS USED N OPIOID DEP --> METHADONE
                                                                                                                                                        by volume
                                                                                                                                               [90-100]% by value / [20-30]%
GLYCERINE CONTA NER 1000 L       FRANCE         R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       FRANCE         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       FRANCE         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       FRANCE         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       GERMANY        03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       GERMANY        A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
                                                                                                                                              [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L       NORWAY         A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                        by volume
 ---pagebreak---                                                                                                                                                                   [70-80]% by value / [70-80]% by
GLYCERINE CONTA NER 1000 L                        PORTUGAL       A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                                              volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L                        SLOVAKIA       02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL
                                                                                                                                                                            by volume
                                                                                                                                                                   [80-90]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L                        SLOVAKIA       02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> COMPOSITION UNKNOWN
                                                                                                                                                                            by volume
                                                                                                                                                                  [50-60]% by value / [50-60]% by
GLYCERINE CONTA NER 1000 L                        SLOVAKIA       06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID
                                                                                                                                                                              volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
GLYCERINE CONTA NER 1000 L                        SLOVAKIA       06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA
                                                                                                                                                                            by volume
                                                                                                                                                                  [50-60]% by value / [50-60]% by
GLYCERINE CONTA NER 1000 L                        SPAIN          A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID
                                                                                                                                                                              volume
                                                                 06V1 OTHER SK N PRODUCTS --> 06V1O O NTMENTS/CREAMS -->                                          [90-100]% by value / [90-100]%
ICHTHYOLAMMONIUM VR.K                             CZECH REPUBLIC
                                                                 ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI                                                             by volume
                                                                 D5A TOP ANT PSORIASIS PRDS --> D5A0 TOP ANTIPSORIASIS PRDS -->                                   [90-100]% by value / [90-100]%
ICHTHYOLAMMONIUM VR.K                             CZECH REPUBLIC
                                                                 ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI                                                             by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM
                                                                                                                                                                            by volume
                           At least EEA-wide <10%
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              CZECH REPUBLIC C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [40-50]% by value / [40-50]% by
LIDOCAINE CHLTE VR.K                              ITALY          02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN
                                                                                                                                                                              volume
                                                                                                                                                                  [50-60]% by value / [40-50]% by
LIDOCAINE CHLTE VR.K                              ITALY          M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN
                                                                                                                                                                              volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LATVIA         10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LATVIA         10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LATVIA         C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LITHUANIA      10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LITHUANIA      10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              LITHUANIA      C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [50-60]% by value / [60-70]% by
LIDOCAINE CHLTE VR.K                              POLAND         10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                                              volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              POLAND         10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [70-80]% by value / [60-70]% by
LIDOCAINE CHLTE VR.K                              POLAND         C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                              volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              PORTUGAL       10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              PORTUGAL       C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              ROMANIA        10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              ROMANIA        10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              ROMANIA        C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SLOVAKIA       10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SLOVAKIA       10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SLOVAKIA       10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SLOVAKIA       C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SPAIN          10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> ALLANTOIN!AMINOACR DINE HYDROCORTISONE LIDOCA NE
                                                                                                                                                                            by volume
                                                                 C5A TOPICAL ANT HAEMORRHOIDL --> C5A1 A-HAEMORRHO DL+CORTICOID -->                               [90-100]% by value / [90-100]%
LIDOCAINE CHLTE VR.K                              SPAIN
                                                                 ALLANTOIN!AMINOACR DINE!HYDROCORTISONE L DOCA NE                                                           by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
MANNITOL VR.K                                     AUSTRIA        G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                                            by volume
                                                                                                                                                                  [90-100]% by value / [90-100]%
MANNITOL VR.K                                     CZECH REPUBLIC G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                                            by volume
 ---pagebreak---                                                                                                                                             [30-40]% by value / [20-30]% by
MANNITOL VR.K                      FRANCE         G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                        volume
                                                                                                                                            [60-70]% by value / [60-70]% by
MANNITOL VR.K                      GERMANY        G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                        volume
                                                                                                                                            [90-100]% by value / [90-100]%
MANNITOL VR.K                      GREECE         G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
MANNITOL VR.K                      IRELAND        G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
MANNITOL VR.K                      ITALY          04C3 PLAIN VITAMIN B --> 04C3M MIXTURES (ORAL) --> COBAMAMIDE
                                                                                                                                                      by volume
                                                                                                                                            [60-70]% by value / [60-70]% by
MANNITOL VR.K                      ITALY          G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                        volume
                                                                                                                                            [90-100]% by value / [90-100]%
MANNITOL VR.K                      POLAND         G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                      by volume
                                                                                                                                            [50-60]% by value / [40-50]% by
MANNITOL VR.K                      PORTUGAL       G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                        volume
                                                                                                                                            [90-100]% by value / [90-100]%
MANNITOL VR.K                      ROMANIA        G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                      by volume
                                                                                                                                             [90-100]% by value / [80-90]%
MANNITOL VR.K                      SLOVAKIA       G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                      by volume
                                                                                                                                            [40-50]% by value / [40-50]% by
MANNITOL VR.K                      SPAIN          G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN
                                                                                                                                                        volume
                                                                                                                                            [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE
                                                                                                                                                      by volume
                                                  A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC          [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN
                                                  ACID POTASSIUM!SODIUM                                                                               by volume
                                                  A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC                   [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN
                                                  ACID!GLUCOSE POTASSIUM!SODIUM                                                                       by volume
                                                                                                                                            [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN          A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM
                                                                                                                                                      by volume
                                                  A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER -->                          [90-100]% by value / [90-100]%
POTASSIUM CHLORURE VR.K            SPAIN
                                                  GLUCOSE!POTASSIUM!SODIUM!SUCROSE                                                                    by volume
                                                  A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC          [90-100]% by value / [90-100]%
SODIUM BICARBONATE VR.K            SPAIN
                                                  ACID POTASSIUM!SODIUM                                                                               by volume
                                                                                                                                            [80-90]% by value / [80-90]% by
SODIUM CHLORURE VR.K               ITALY          N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC
                                                                                                                                                        volume
                                                                                                                                            [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               ITALY          R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUOCINOLONE ACETON DE
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN          03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> COMPOSITION UNKNOWN
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN          03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE
                                                                                                                                                      by volume
                                                  A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC          [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN
                                                  ACID POTASSIUM!SODIUM                                                                               by volume
                                                  A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC                   [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN
                                                  ACID!GLUCOSE POTASSIUM!SODIUM                                                                       by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN          A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM
                                                                                                                                                      by volume
                                                  A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER -->                          [90-100]% by value / [90-100]%
SODIUM CHLORURE VR.K               SPAIN
                                                  GLUCOSE!POTASSIUM!SODIUM!SUCROSE                                                                    by volume
                                                                                                                                            [80-90]% by value / [80-90]% by
SODIUM PHOSPHATE MONO PUR CRIST VK ITALY          N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC
                                                                                                                                                        volume
                                                  A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC          [90-100]% by value / [90-100]%
SODIUM PHOSPHATE MONO PUR CRIST VK SPAIN
                                                  ACID POTASSIUM!SODIUM                                                                               by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SORBITOL VR K                      CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SORBITOL VR K                      CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SORBITOL VR K                      CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM
                                                                                                                                                      by volume
                                                                                                                                            [90-100]% by value / [90-100]%
SORBITOL VR K                      CZECH REPUBLIC C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                                                      by volume
                                                                                                                                            [40-50]% by value / [40-50]% by
SORBITOL VR K                      ITALY          02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN
                                                                                                                                                        volume
                                                                                                                                            [50-60]% by value / [40-50]% by
SORBITOL VR K                      ITALY          M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN
                                                                                                                                                        volume
 ---pagebreak---                                                                                                                  [40-50]% by value / [60-70]% by
SORBITOL VR K ITALY     R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOL DE
                                                                                                                             volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LATVIA    10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LATVIA    10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LATVIA    C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K LITHUANIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [50-60]% by value / [60-70]% by
SORBITOL VR K POLAND    10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                             volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K POLAND    10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                           by volume
                                                                                                                 [70-80]% by value / [60-70]% by
SORBITOL VR K POLAND    C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                             volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K PORTUGAL  10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K PORTUGAL  C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K ROMANIA   10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K ROMANIA   10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K ROMANIA   C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K SLOVAKIA  10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K SLOVAKIA  10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K SLOVAKIA  10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM
                                                                                                                           by volume
                                                                                                                 [90-100]% by value / [90-100]%
SORBITOL VR K SLOVAKIA  C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE
                                                                                                                           by volume
 ---pagebreak---                                                                                                                                                                                            Case M.10247 - CVC/Cooper
                                                                            Appendix 7.1
                                              (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                               Upstream Market (Target)                                                                                   Downstream FDP Market (Recordati)
                                      Upstream
  Upstream Hypothetical Market      Hypothetical                                                Geographic
                                                    Geographic Market Share (2020, EEA)                                          Product Market (ATC3/CHC3)                                Share (2020)
        Segment (CDMO)               Market Sub-                                                 Market
                                  Segment (CDMO)
                                                                                                              A16A OTHER METABOLIC PRODUCTS                                    <[0-5]% by value / [40-50]% by volume
                                                                                            BELGIUM
                                                                                                              S1X OTHER OPHTHALMOLOGICALS                                     [80-90]% by value / [10-20]% by volume
                                                                                            DENMARK           S1X OTHER OPHTHALMOLOGICALS                                             Potentially up to [70-80]%
                                                                                            ESTONIA           H1C HYPOTHALAMIC HORMONES                                       [40-50]% by value / [40-50]% by volume
                                                                                            FRANCE            S1X OTHER OPHTHALMOLOGICALS                                   [90-100]% by value / [90-100]% by volume
                                                                                                              A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS [70-80]% by value / [70-80]% by volume
                                                                                            GREECE
                                                                                                              H1C HYPOTHALAMIC HORMONES                                       [30-40]% by value / [30-40]% by volume
                                                                                                              S1X OTHER OPHTHALMOLOGICALS                                     [50-60]% by value / [50-60]% by volume
CDMO services for FDPs           -
                                                                                            HUNGARY           B6X OTHER HAEMATOLOGICAL AGENTS                               [90-100]% by value / [90-100]% by volume
                                                                                            ITALY             S1X OTHER OPHTHALMOLOGICALS                                       [40-50]% by value / [0-5]% by volume
                                                                                            NETHERLANDS       S1X OTHER OPHTHALMOLOGICALS                                   [90-100]% by value / [90-100]% by volume
                                                                                                              B6X OTHER HAEMATOLOGICAL AGENTS                               [90-100]% by value / [90-100]% by volume
                                                                                            NORWAY
                                                                                                              S1X OTHER OPHTHALMOLOGICALS                                    [90-100]% by value / [30-40]% by volume
                                                                                            PORTUGAL          S1X OTHER OPHTHALMOLOGICALS                                    [90-100]% by value / [70-80]% by volume
                                                                                            SPAIN             B6X OTHER HAEMATOLOGICAL AGENTS                                  [40-50]% by value / <[0-5]% by volume
                                                                                                              B6X OTHER HAEMATOLOGICAL AGENTS                                [70-80]% by value / [90-100]% by volume
                                                                                            SWEDEN
                                                                                                              S1X OTHER OPHTHALMOLOGICALS                                   [90-100]% by value / [90-100]% by volume
                                                                                                              A16A OTHER METABOLIC PRODUCTS                                    <[0-5]% by value / [40-50]% by volume
                                                                                            BELGIUM
                                                                                                              C8B CALCIUM ANTAGONIST COMBS                                  [90-100]% by value / [90-100]% by volume
                                                                                            CYPRUS            C7A BETA-BLOCKING AGENTS, PLAIN                                 [30-40]% by value / [20-30]% by volume
                                                                                                              A13A TONICS                                                     [70-80]% by value / [70-80]% by volume
                                                                                            CZECH REPUBLIC
                                                                                                              S1K DRY EYE PRODUCTS                                            [30-40]% by value / [30-40]% by volume
 ---pagebreak---                                C7A B-BLOCKING AGENTS,PLAIN                          [40-50]% by value / [30-40]% by volume
                 ESTONIA
                               H1C HYPOTHALAMIC HORMONES                            [40-50]% by value / [40-50]% by volume
                 FINLAND       C8B CALCIUM ANTAGONIST COMBS                       [90-100]% by value / [90-100]% by volume
                               83E1 LEG CARE PRODUCTS                               [50-60]% by value / [50-60]% by volume
                 FRANCE
                               C8B CALCIUM ANTAGONIST COMBS                         [70-80]% by value / [50-60]% by volume
solid and powder GERMANY       M3B MUSCLE RELAXANTS,CENTRAL                        [40-50]% by value / [20-30]% by volume
pharmaceuticals
                               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS [70-80]% by value / [70-80]% by volume
                 GREECE
                               C8B CALCIUM ANTAGONIST COMBS                         [70-80]% by value / [70-80]% by volume
                               H1C HYPOTHALAMIC HORMONES                            [30-40]% by value / [30-40]% by volume
                 HUNGARY       C8B CALCIUM ANTAGONIST COMBS                         [40-50]% by value / [20-30]% by volume
                 ICELAND       C7A BETA-BLOCKING AGENTS, PLAIN                      [30-40]% by value / [20-30]% by volume
                 LITHUANIA     C7A B-BLOCKING AGENTS,PLAIN                          [30-40]% by value / [30-40]% by volume
                               05A1 TONICS                                                         [70-80]%
                 PORTUGAL
                               A5B HEPATIC PROCT LIPOTROPIC                         [70-80]% by value / [50-60]% by volume
                 SLOVAKIA      A13A TONICS                                        [90-100]% by value / [90-100]% by volume
                 SPAIN         C8B CALCIUM ANTAGONIST COMBS                       [90-100]% by value / [90-100]% by volume
                 SWEDEN        C8B CALCIUM ANTAGONISTS, COMBINATIONS                [40-50]% by value / [40-50]% by volume
                 CYPRUS        C5A TOPICAL ANTI-HAEMORRHOIDALS                      [70-80]% by value / [80-90]% by volume
                 CZECH REPUBLICS1K DRY EYE PRODUCTS                                 [30-40]% by value / [30-40]% by volume
                 FRANCE        83E1 LEG CARE PRODUCTS                              [50-60]% by value / [50-60]% by volume
                 GREECE        G1B GYNAECOLOG ANTIFUNGALS                           [60-70]% by value / [40-50]% by volume
                 HUNGARY       G1B GYNAECOLOG ANTIFUNGALS                           [20-30]% by value / [60-70]% by volume
                               02D1 MOUTH PAIN RELIEF                                              [30-40]%
                               09C1 MOUTH INFECTION TREATMENT                       [10-20]% by value / [40-50]% by volume
                               10A1 ANTIHAEMORRHOIDS                                [20-30]% by value / [30-40]% by volume
                 ITALY
                               C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [30-40]% by volume
 ---pagebreak--- CDMO services for FDPs segmented
by its pharmaceutical form, i e.                              G4X ALL OTH UROLOGICAL PRODS      [20-30]% by value / [40-50]% by volume
                                                              S2A ANTI-INFECTIVES - EAR         [40-50]% by value / [10-20]% by volume
                                 liquid and semi-
                                                              S2C STEROID/ANTI-INFECT-EAR       [20-30]% by value / [30-40]% by volume
                                 solid
                                 pharmaceuticals
                                                              10A1 ANTIHAEMORRHOIDS                             [30-40]%
                                                  LATVIA
                                                              C5A TOPICAL ANTIHAEMORRHOIDL      [30-40]% by value / [20-30]% by volume
                                                              10A1 ANTIHAEMORRHOIDS             [30-40]% by value / [30-40]% by volume
                                                              12D2 GYNAECOLOGICAL ANTIFUNGAL    [80-90]% by value / [30-40]% by volume
                                                  POLAND
                                                              C5A TOPICAL ANTIHAEMORRHOIDL      [30-40]% by value / [30-40]% by volume
                                                              G1B GYNAECOLOG ANTIFUNGALS        [50-60]% by value / [20-30]% by volume
                                                              10A1 ANTIHAEMORRHOIDS             [20-30]% by value / [30-40]% by volume
                                                  ROMANIA
                                                              C5A TOPICAL ANTIHAEMORRHOIDL      [50-60]% by value / [40-50]% by volume
                                                              G1B GYNAECOLOG ANTIFUNGALS        [10-20]% by value / [30-40]% by volume
                                                  SLOVAKIA    C5A TOPICAL ANTIHAEMORRHOIDL      [20-30]% by value / [30-40]% by volume
                                                              03D3 ANTIDIARR ELECTROL                           [70-80]%
                                                  SPAIN
                                                              A7G ORAL ELECTROL. REPLACER      [80-90]% by value / [90-100]% by volume
                                                  BELGIUM     S1X OTHER OPHTHALMOLOGICALS       [80-90]% by value / [10-20]% by volume
                                                  DENMARK     S1X OTHER OPHTHALMOLOGICALS               Potentially up to [70-80]%
                                                  ESTONIA     C7A B-BLOCKING AGENTS,PLAIN       [40-50]% by value / [30-40]% by volume
                                                  FRANCE      S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
                                                  GERMANY     M3B MUSCLE RELAXANTS,CENTRAL      [40-50]% by value / [20-30]% by volume
                                                  GREECE      S1X OTHER OPHTHALMOLOGICALS       [50-60]% by value / [50-60]% by volume
                                                  HUNGARY     B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
                                                  ICELAND     C7A BETA-BLOCKING AGENTS, PLAIN   [30-40]% by value / [20-30]% by volume
                                 sterile liquid
                                 pharmaceuticals  ITALY       S1X OTHER OPHTHALMOLOGICALS         [40-50]% by value / [0-5]% by volume
                                                  LITHUANIA   C7A B-BLOCKING AGENTS,PLAIN       [30-40]% by value / [30-40]% by volume
                                                  NETHERLANDS S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                                                        B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
                                                           NORWAY
                                                                       S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [30-40]% by volume
                                                           PORTUGAL    S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [70-80]% by volume
                                                           SPAIN       B6X OTHER HAEMATOLOGICAL AGENTS    [40-50]% by value / <[0-5]% by volume
                                                                       B6X OTHER HAEMATOLOGICAL AGENTS  [70-80]% by value / [90-100]% by volume
                                                           SWEDEN
                                                                       S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
                                                           BELGIUM     S1X OTHER OPHTHALMOLOGICALS       [80-90]% by value / [10-20]% by volume
                                                           DENMARK     S1X OTHER OPHTHALMOLOGICALS               Potentially up to [70-80]%
                                                           ESTONIA     C7A B-BLOCKING AGENTS,PLAIN       [40-50]% by value / [30-40]% by volume
                                                           FRANCE      S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
                                                           GERMANY     M3B MUSCLE RELAXANTS,CENTRAL      [40-50]% by value / [20-30]% by volume
                                                           GREECE      S1X OTHER OPHTHALMOLOGICALS       [50-60]% by value / [50-60]% by volume
                                                           HUNGARY     B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
                                                           ICELAND     C7A BETA-BLOCKING AGENTS, PLAIN   [30-40]% by value / [20-30]% by volume
                                       sterile environment
                                                           ITALY       S1X OTHER OPHTHALMOLOGICALS         [40-50]% by value / [0-5]% by volume
                                                           LITHUANIA   C7A B-BLOCKING AGENTS,PLAIN       [30-40]% by value / [30-40]% by volume
                                                           NETHERLANDS S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
                                                                       B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
                                                           NORWAY
                                                                       S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [30-40]% by volume
                                                           PORTUGAL    S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [70-80]% by volume
                                                           SPAIN       B6X OTHER HAEMATOLOGICAL AGENTS    [40-50]% by value / <[0-5]% by volume
                                                                       B6X OTHER HAEMATOLOGICAL AGENTS  [70-80]% by value / [90-100]% by volume
                                                           SWEDEN
CDMO services for FDPs segmented                                       S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
by the conditions of manufacture, i.e.
                                                           BELGIUM     C8B CALCIUM ANTAGONIST COMBS    [90-100]% by value / [90-100]% by volume
                                                           CYPRUS      C7A BETA-BLOCKING AGENTS, PLAIN   [30-40]% by value / [20-30]% by volume
                                                           ESTONIA     C7A B-BLOCKING AGENTS,PLAIN       [40-50]% by value / [30-40]% by volume
 ---pagebreak---                  FINLAND       C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                 FRANCE        C8B CALCIUM ANTAGONIST COMBS            [70-80]% by value / [50-60]% by volume
                               C8B CALCIUM ANTAGONIST COMBS            [70-80]% by value / [70-80]% by volume
                 GREECE
                               G1B GYNAECOLOG ANTIFUNGALS              [60-70]% by value / [40-50]% by volume
nature of the                  C8B CALCIUM ANTAGONIST COMBS            [40-50]% by value / [20-30]% by volume
                 HUNGARY
technology/know-
how needed to                  G1B GYNAECOLOG ANTIFUNGALS              [20-30]% by value / [60-70]% by volume
produce the FDP
                 ICELAND       C7A BETA-BLOCKING AGENTS, PLAIN         [30-40]% by value / [20-30]% by volume
                 ITALY         G4X ALL OTH UROLOGICAL PRODS            [20-30]% by value / [40-50]% by volume
                 LITHUANIA     C7A B-BLOCKING AGENTS,PLAIN             [30-40]% by value / [30-40]% by volume
                               12D2 GYNAECOLOGICAL ANTIFUNGAL          [80-90]% by value / [30-40]% by volume
                 POLAND
                               G1B GYNAECOLOG ANTIFUNGALS              [50-60]% by value / [20-30]% by volume
                 ROMANIA       G1B GYNAECOLOG ANTIFUNGALS              [10-20]% by value / [30-40]% by volume
                 SPAIN         C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                 SWEDEN        C8B CALCIUM ANTAGONISTS, COMBINATIONS   [40-50]% by value / [40-50]% by volume
                               A16A OTHER METABOLIC PRODUCTS            <[0-5]% by value / [40-50]% by volume
                 BELGIUM
                               C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                               S1X OTHER OPHTHALMOLOGICALS             [80-90]% by value / [10-20]% by volume
                               C5A TOPICAL ANTI-HAEMORRHOIDALS         [70-80]% by value / [80-90]% by volume
                 CYPRUS
                               C7A BETA-BLOCKING AGENTS, PLAIN         [30-40]% by value / [20-30]% by volume
                               A13A TONICS                             [70-80]% by value / [70-80]% by volume
                 CZECH REPUBLIC
                               S1K DRY EYE PRODUCTS                    [30-40]% by value / [30-40]% by volume
                 DENMARK       S1X OTHER OPHTHALMOLOGICALS                    Potentially up to [70-80]%
                               C7A B-BLOCKING AGENTS,PLAIN             [40-50]% by value / [30-40]% by volume
                 ESTONIA
                               H1C HYPOTHALAMIC HORMONES               [40-50]% by value / [40-50]% by volume
                 FINLAND       C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                               C8B CALCIUM ANTAGONIST COMBS            [70-80]% by value / [50-60]% by volume
                 FRANCE
 ---pagebreak---                                                                               FRANCE
                                                                                          S1X OTHER OPHTHALMOLOGICALS                        [90-100]% by value / [90-100]% by volume
                                                                              GERMANY     M3B MUSCLE RELAXANTS,CENTRAL                         [40-50]% by value / [20-30]% by volume
                                                                                          A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS [70-80]% by value / [70-80]% by volume
                                                                                          C8B CALCIUM ANTAGONIST COMBS                         [70-80]% by value / [70-80]% by volume
                                                  At least EEA-wide <[10-20]%
                                                                              GREECE
                                                                                          G1B GYNAECOLOG ANTIFUNGALS                           [60-70]% by value / [40-50]% by volume
                                                                                          H1C HYPOTHALAMIC HORMONES                            [30-40]% by value / [30-40]% by volume
                                                                                          S1X OTHER OPHTHALMOLOGICALS                          [50-60]% by value / [50-60]% by volume
                                                                                          C8B CALCIUM ANTAGONIST COMBS                         [40-50]% by value / [20-30]% by volume
                                                                              HUNGARY
                                                                                          G1B GYNAECOLOG ANTIFUNGALS                           [20-30]% by value / [60-70]% by volume
                                                                              ICELAND     C7A BETA-BLOCKING AGENTS, PLAIN                      [30-40]% by value / [20-30]% by volume
                                                                                          02D1 MOUTH PAIN RELIEF                                              [30-40]%
                                                                                          09C1 MOUTH INFECTION TREATMENT                       [10-20]% by value / [40-50]% by volume
                                 chemically-                                              10A1 ANTIHAEMORRHOIDS                                [20-30]% by value / [30-40]% by volume
                                 synthesized APIs
                                                                                          C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [30-40]% by volume
                                                                              ITALY
                                                                                          G4X ALL OTH UROLOGICAL PRODS                         [20-30]% by value / [40-50]% by volume
                                                                                          S1X OTHER OPHTHALMOLOGICALS                            [40-50]% by value / [0-5]% by volume
CDMO services for FDPs segmented
by the type of API used, i.e.                                                             S2A ANTI-INFECTIVES - EAR                            [40-50]% by value / [10-20]% by volume
                                                                                          S2C STEROID/ANTI-INFECT-EAR                          [20-30]% by value / [30-40]% by volume
                                                                                          10A1 ANTIHAEMORRHOIDS                                               [30-40]%
                                                                              LATVIA
                                                                                          C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [20-30]% by volume
                                                                              LITHUANIA   C7A B-BLOCKING AGENTS,PLAIN                          [30-40]% by value / [30-40]% by volume
                                                                              NETHERLANDS S1X OTHER OPHTHALMOLOGICALS                        [90-100]% by value / [90-100]% by volume
                                                                              NORWAY      S1X OTHER OPHTHALMOLOGICALS                         [90-100]% by value / [30-40]% by volume
                                                                                          10A1 ANTIHAEMORRHOIDS                                [30-40]% by value / [30-40]% by volume
                                                                                          12D2 GYNAECOLOGICAL ANTIFUNGAL                       [80-90]% by value / [30-40]% by volume
                                                                              POLAND
                                                                                          C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [30-40]% by volume
 ---pagebreak---                                 G1B GYNAECOLOG ANTIFUNGALS              [50-60]% by value / [20-30]% by volume
                                05A1 TONICS                                            [70-80]%
                  PORTUGAL
                                A5B HEPATIC PROCT LIPOTROPIC            [70-80]% by value / [50-60]% by volume
                                S1X OTHER OPHTHALMOLOGICALS            [90-100]% by value / [70-80]% by volume
                                10A1 ANTIHAEMORRHOIDS                   [20-30]% by value / [30-40]% by volume
                  ROMANIA
                                C5A TOPICAL ANTIHAEMORRHOIDL            [50-60]% by value / [40-50]% by volume
                                G1B GYNAECOLOG ANTIFUNGALS              [10-20]% by value / [30-40]% by volume
                                A13A TONICS                           [90-100]% by value / [90-100]% by volume
                  SLOVAKIA
                                C5A TOPICAL ANTIHAEMORRHOIDL            [20-30]% by value / [30-40]% by volume
                  SPAIN         C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                                C8B CALCIUM ANTAGONISTS, COMBINATIONS   [40-50]% by value / [40-50]% by volume
                  SWEDEN
                                S1X OTHER OPHTHALMOLOGICALS           [90-100]% by value / [90-100]% by volume
                  FRANCE        83E1 LEG CARE PRODUCTS                  [50-60]% by value / [50-60]% by volume
                  HUNGARY       B6X OTHER HAEMATOLOGICAL AGENTS       [90-100]% by value / [90-100]% by volume
                  NORWAY        B6X OTHER HAEMATOLOGICAL AGENTS       [90-100]% by value / [90-100]% by volume
biopharmaceutical
APIs                            03D3 ANTIDIARR ELECTROL                                [70-80]%
                  SPAIN
                                A7G ORAL ELECTROL. REPLACER            [80-90]% by value / [90-100]% by volume
                                B6X OTHER HAEMATOLOGICAL AGENTS          [40-50]% by value / <[0-5]% by volume
                  SWEDEN        B6X OTHER HAEMATOLOGICAL AGENTS        [70-80]% by value / [90-100]% by volume
                                A16A OTHER METABOLIC PRODUCTS            <[0-5]% by value / [40-50]% by volume
                  BELGIUM
                                C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
                  CYPRUS        C7A BETA-BLOCKING AGENTS, PLAIN         [30-40]% by value / [20-30]% by volume
                                A13A TONICS                             [70-80]% by value / [70-80]% by volume
                  CZECH REPUBLIC
                                S1K DRY EYE PRODUCTS                    [30-40]% by value / [30-40]% by volume
                  ESTONIA       C7A B-BLOCKING AGENTS,PLAIN             [40-50]% by value / [30-40]% by volume
                  FINLAND       C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                                                   83E1 LEG CARE PRODUCTS                               [50-60]% by value / [50-60]% by volume
                                                        FRANCE
                                                                  C8B CALCIUM ANTAGONIST COMBS                         [70-80]% by value / [50-60]% by volume
                                                        GERMANY   M3B MUSCLE RELAXANTS,CENTRAL                         [40-50]% by value / [20-30]% by volume
                                                                  A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS [70-80]% by value / [70-80]% by volume
                                                        GREECE
                                     swallowing
                                                                  C8B CALCIUM ANTAGONIST COMBS                         [70-80]% by value / [70-80]% by volume
                                                        HUNGARY   C8B CALCIUM ANTAGONIST COMBS                         [40-50]% by value / [20-30]% by volume
                                                        ICELAND   C7A BETA-BLOCKING AGENTS, PLAIN                      [30-40]% by value / [20-30]% by volume
                                                        ITALY     09C1 MOUTH INFECTION TREATMENT                       [10-20]% by value / [40-50]% by volume
                                                        LITHUANIA C7A B-BLOCKING AGENTS,PLAIN                          [30-40]% by value / [30-40]% by volume
                                                                  05A1 TONICS                                                         [70-80]%
                                                        PORTUGAL
CDMO services for FDPs segmented                                  A5B HEPATIC PROCT LIPOTROPIC                         [70-80]% by value / [50-60]% by volume
by the delivery mechanism used, i e.
                                                        SLOVAKIA  A13A TONICS                                        [90-100]% by value / [90-100]% by volume
                                                                  03D3 ANTIDIARR ELECTROL                                             [70-80]%
                                                        SPAIN
                                                                  A7G ORAL ELECTROL. REPLACER                         [80-90]% by value / [90-100]% by volume
                                                                  C8B CALCIUM ANTAGONIST COMBS                       [90-100]% by value / [90-100]% by volume
                                                        SWEDEN    C8B CALCIUM ANTAGONISTS, COMBINATIONS                [40-50]% by value / [40-50]% by volume
                                                        CYPRUS    C5A TOPICAL ANTI-HAEMORRHOIDALS                      [70-80]% by value / [80-90]% by volume
                                                        FRANCE    83E1 LEG CARE PRODUCTS                               [50-60]% by value / [50-60]% by volume
                                                        GREECE    G1B GYNAECOLOG ANTIFUNGALS                           [60-70]% by value / [40-50]% by volume
                                                                  02D1 MOUTH PAIN RELIEF                                              [30-40]%
                                                        ITALY
                                                                  G4X ALL OTH UROLOGICAL PRODS                         [20-30]% by value / [40-50]% by volume
                                                                  10A1 ANTIHAEMORRHOIDS                                               [30-40]%
                                                        LATVIA
                                     absorption through
                                     the skin                     C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [20-30]% by volume
                                                                  10A1 ANTIHAEMORRHOIDS                                [30-40]% by value / [30-40]% by volume
                                                        POLAND
                                                                  C5A TOPICAL ANTIHAEMORRHOIDL                         [30-40]% by value / [30-40]% by volume
                                                                  10A1 ANTIHAEMORRHOIDS                                [20-30]% by value / [30-40]% by volume
 ---pagebreak--- ROMANIA
              C5A TOPICAL ANTIHAEMORRHOIDL      [50-60]% by value / [40-50]% by volume
              G1B GYNAECOLOG ANTIFUNGALS        [10-20]% by value / [30-40]% by volume
SLOVAKIA      C5A TOPICAL ANTIHAEMORRHOIDL      [20-30]% by value / [30-40]% by volume
              C8B CALCIUM ANTAGONIST COMBS    [90-100]% by value / [90-100]% by volume
BELGIUM
              S1X OTHER OPHTHALMOLOGICALS       [80-90]% by value / [10-20]% by volume
              C5A TOPICAL ANTI-HAEMORRHOIDALS   [70-80]% by value / [80-90]% by volume
CYPRUS
              C7A BETA-BLOCKING AGENTS, PLAIN   [30-40]% by value / [20-30]% by volume
              A13A TONICS                       [70-80]% by value / [70-80]% by volume
CZECH REPUBLIC
              S1K DRY EYE PRODUCTS              [30-40]% by value / [30-40]% by volume
DENMARK       S1X OTHER OPHTHALMOLOGICALS              Potentially up to [70-80]%
ESTONIA       C7A B-BLOCKING AGENTS,PLAIN       [40-50]% by value / [30-40]% by volume
FINLAND       C8B CALCIUM ANTAGONIST COMBS    [90-100]% by value / [90-100]% by volume
              83E1 LEG CARE PRODUCTS            [50-60]% by value / [50-60]% by volume
FRANCE
              C8B CALCIUM ANTAGONIST COMBS      [70-80]% by value / [50-60]% by volume
              S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
GERMANY       M3B MUSCLE RELAXANTS,CENTRAL     [40-50]% by value / [20-30]% by volume
              C8B CALCIUM ANTAGONIST COMBS      [70-80]% by value / [70-80]% by volume
GREECE
              G1B GYNAECOLOG ANTIFUNGALS        [60-70]% by value / [40-50]% by volume
              S1X OTHER OPHTHALMOLOGICALS       [50-60]% by value / [50-60]% by volume
              B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
HUNGARY
              C8B CALCIUM ANTAGONIST COMBS      [40-50]% by value / [20-30]% by volume
              G1B GYNAECOLOG ANTIFUNGALS        [20-30]% by value / [60-70]% by volume
ICELAND       C7A BETA-BLOCKING AGENTS, PLAIN   [30-40]% by value / [20-30]% by volume
              02D1 MOUTH PAIN RELIEF                           [30-40]%
              09C1 MOUTH INFECTION TREATMENT    [10-20]% by value / [40-50]% by volume
              10A1 ANTIHAEMORRHOIDS             [20-30]% by value / [30-40]% by volume
 ---pagebreak---                                           C5A TOPICAL ANTIHAEMORRHOIDL      [30-40]% by value / [30-40]% by volume
                              ITALY
                                          G4X ALL OTH UROLOGICAL PRODS      [20-30]% by value / [40-50]% by volume
                                          S1X OTHER OPHTHALMOLOGICALS         [40-50]% by value / [0-5]% by volume
CMO services (excluding CDO
                            -
services)                                 S2A ANTI-INFECTIVES - EAR         [40-50]% by value / [10-20]% by volume
                                          S2C STEROID/ANTI-INFECT-EAR       [20-30]% by value / [30-40]% by volume
                                          10A1 ANTIHAEMORRHOIDS                            [30-40]%
                              LATVIA
                                          C5A TOPICAL ANTIHAEMORRHOIDL      [30-40]% by value / [20-30]% by volume
                              LITHUANIA   C7A B-BLOCKING AGENTS,PLAIN       [30-40]% by value / [30-40]% by volume
                              NETHERLANDS S1X OTHER OPHTHALMOLOGICALS     [90-100]% by value / [90-100]% by volume
                                          B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
                              NORWAY
                                          S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [30-40]% by volume
                                          10A1 ANTIHAEMORRHOIDS             [30-40]% by value / [30-40]% by volume
                                          12D2 GYNAECOLOGICAL ANTIFUNGAL    [80-90]% by value / [30-40]% by volume
                              POLAND
                                          C5A TOPICAL ANTIHAEMORRHOIDL      [30-40]% by value / [30-40]% by volume
                                          G1B GYNAECOLOG ANTIFUNGALS        [50-60]% by value / [20-30]% by volume
                                          05A1 TONICS                                      [70-80]%
                              PORTUGAL
                                          A5B HEPATIC PROCT LIPOTROPIC      [70-80]% by value / [50-60]% by volume
                                          S1X OTHER OPHTHALMOLOGICALS      [90-100]% by value / [70-80]% by volume
                                          10A1 ANTIHAEMORRHOIDS             [20-30]% by value / [30-40]% by volume
                              ROMANIA
                                          C5A TOPICAL ANTIHAEMORRHOIDL      [50-60]% by value / [40-50]% by volume
                                          G1B GYNAECOLOG ANTIFUNGALS        [10-20]% by value / [30-40]% by volume
                                          A13A TONICS                     [90-100]% by value / [90-100]% by volume
                              SLOVAKIA
                                          C5A TOPICAL ANTIHAEMORRHOIDL      [20-30]% by value / [30-40]% by volume
                                          03D3 ANTIDIARR ELECTROL                          [70-80]%
                                          A7G ORAL ELECTROL. REPLACER      [80-90]% by value / [90-100]% by volume
                              SPAIN
                                          B6X OTHER HAEMATOLOGICAL AGENTS    [40-50]% by value / <[0-5]% by volume
 ---pagebreak---        C8B CALCIUM ANTAGONIST COMBS          [90-100]% by value / [90-100]% by volume
       B6X OTHER HAEMATOLOGICAL AGENTS        [70-80]% by value / [90-100]% by volume
SWEDEN
       C8B CALCIUM ANTAGONISTS, COMBINATIONS   [40-50]% by value / [40-50]% by volume
       S1X OTHER OPHTHALMOLOGICALS           [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                                                                                                                                                                             Case M.10247 - CVC/Cooper
                                                                                           Appendix 7.1
                                                 (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                                     Upstream Market (Target)                                                                                      Downstream FDP Market (Recordati)
    Upstream Hypothetical Market  Upstream Hypothetical Market Sub-         Geographic                       Geographic
                                                                                         Share (2020, EEA                                      Product Market (ATC4/CHC4)                       Share (2020)
           Segment (CDMO)                   Segment (CDMO)                    Market                           Market
                                                                        At leat EEA-wide <1[0-5]%
                                                                                                                                                                                         [70-80]% by value / [0-5]% by
CDMO services for FDPs           -                                                                        AUSTRIA          A11X3 VITAMIN E PLAIN
                                                                                                                                                                                                   volume
                                                                                                                                                                                       [80-90]% by value / [10-20]% by
CDMO services for FDPs           -                                                                        BELGIUM          S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                        [30-40]% by value / <[0-5]% by
CDMO services for FDPs           -                                                                        FRANCE           A11X3 VITAMIN E PLAIN
                                                                                                                                                                                                   volume
                                                                                                                                                                                     [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                                                        FRANCE           S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                       [40-50]% by value / [20-30]% by
CDMO services for FDPs           -                                                                        ITALY            30C1Z OTHER MODULES
                                                                                                                                                                                                   volume
                                                                                                                                                                                         [40-50]% by value / [0-5]% by
CDMO services for FDPs           -                                                                        ITALY            S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                     [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                                                        NETHERLANDS      S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                      [90-100]% by value / [30-40]% by
CDMO services for FDPs           -                                                                        NORWAY           S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                      [90-100]% by value / [70-80]% by
CDMO services for FDPs           -                                                                        PORTUGAL         S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
                                                                                                                                                                                     [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                                                        SWEDEN           S1X2 OTH OPHTHALM TOPICAL
                                                                                                                                                                                                   volume
CDMO services for FDPs segmented                                                                                                                                                     [90-100]% by value / [90-100]% by
                                 solid and powder pharmaceuticals                                         BELGIUM          C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                                                                                                   volume
CDMO services for FDPs segmented                                                                                                                                                     [90-100]% by value / [90-100]% by
                                 solid and powder pharmaceuticals                                         FINLAND          C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                                                                                                   volume
CDMO services for FDPs segmented                                                                                                                                                       [20-30]% by value / [30-40]% by
                                 solid and powder pharmaceuticals                                         FRANCE           01A4E EFFERVESCENT
by its pharmaceutical form, i e.                                                                                                                                                                   volume
CDMO services for FDPs segmented                                                                                                                                                       [30-40]% by value / [40-50]% by
                                 solid and powder pharmaceuticals                                         FRANCE           01A4P POWDERS
by its pharmaceutical form, i e.                                                                                                                                                                   volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                                [50-60]% by value / [50-60]% by
                                 solid and powder pharmaceuticals      FRANCE   83E1 LEG CARE PRODUCTS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                               [90-100]% by value / [80-90]% by
                                 solid and powder pharmaceuticals      FRANCE   C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [70-80]% by value / [70-80]% by
                                 solid and powder pharmaceuticals      GREECE   C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [50-60]% by value / [40-50]% by
                                 solid and powder pharmaceuticals      HUNGARY  C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                <[0-5]% by value / [90-100]% by
                                 solid and powder pharmaceuticals      ITALY    A7E9 INFLAM BOWEL DIS PRD OTH
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                              [90-100]% by value / [90-100]% by
                                 solid and powder pharmaceuticals      PORTUGAL 03C4Q ENEMAS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [50-60]% by value / [40-50]% by
                                 solid and powder pharmaceuticals      PORTUGAL 03F1M MIXTURES (ORAL)
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                              [90-100]% by value / [90-100]% by
                                 solid and powder pharmaceuticals      PORTUGAL 05A1Z OTHER FORMS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [50-60]% by value / [50-60]% by
                                 solid and powder pharmaceuticals      PORTUGAL A2B9 ALL OTHER ANTIULCERANTS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [70-80]% by value / [60-70]% by
                                 solid and powder pharmaceuticals      PORTUGAL A6A4 LAXATIVE ENEMAS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [30-40]% by value / [20-30]% by
                                 solid and powder pharmaceuticals      ROMANIA  03C1Z OTHER FORMS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [60-70]% by value / [40-50]% by
                                 solid and powder pharmaceuticals      SPAIN    03C1Z OTHER FORMS
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [40-50]% by value / [30-40]% by
                                 solid and powder pharmaceuticals      SPAIN    03F1M MIXTURES (ORAL)
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                              [90-100]% by value / [90-100]% by
                                 solid and powder pharmaceuticals      SPAIN    C8B2 CALC ANTAG/B BLOCKR COMB
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                  [70-80]% by value / [0-5]% by
                                 liquid and semi-solid pharmaceuticals AUSTRIA  A11X3 VITAMIN E PLAIN
by its pharmaceutical form, i e.                                                                                            volume
CDMO services for FDPs segmented                                                                                [80-90]% by value / [10-20]% by
                                 liquid and semi-solid pharmaceuticals BELGIUM  S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                               [90-100]% by value / [90-100]% by
                                 liquid and semi-solid pharmaceuticals FRANCE    01A9Z OTHER FORMS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                [50-60]% by value / [50-60]% by
                                 liquid and semi-solid pharmaceuticals FRANCE    83E1 LEG CARE PRODUCTS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                  [30-40]% by value / <[0-5]% by
                                 liquid and semi-solid pharmaceuticals FRANCE    A11X3 VITAMIN E PLAIN
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                               [90-100]% by value / [90-100]% by
                                 liquid and semi-solid pharmaceuticals FRANCE    S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [50-60]% by value / [40-50]% by
                                 liquid and semi-solid pharmaceuticals ITALY     02D1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [40-50]% by value / [40-50]% by
                                 liquid and semi-solid pharmaceuticals ITALY     02D1Z OTHER FORMS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [60-70]% by value / [10-20]% by
                                 liquid and semi-solid pharmaceuticals ITALY     02E1L LIQUIDS (TOPICAL)
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [10-20]% by value / [40-50]% by
                                 liquid and semi-solid pharmaceuticals ITALY     09C1G RINSES/GARGLES
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [20-30]% by value / [40-50]% by
                                 liquid and semi-solid pharmaceuticals ITALY     10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [40-50]% by value / [20-30]% by
                                 liquid and semi-solid pharmaceuticals ITALY     30C1Z OTHER MODULES
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [50-60]% by value / [60-70]% by
                                 liquid and semi-solid pharmaceuticals ITALY     C5A1 A-HAEMORRHOIDL+CORTICOID
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                   [40-50]% by value / [0-5]% by
                                 liquid and semi-solid pharmaceuticals ITALY     S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [40-50]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals LATVIA    10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [30-40]% by value / [20-30]% by
                                 liquid and semi-solid pharmaceuticals LATVIA    10A1S SUPPOSITORIES
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals LATVIA    C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.                                                                                             volume
CDMO services for FDPs segmented                                                                                 [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.                                                                                             volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                 liquid and semi-solid pharmaceuticals NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals NORWAY      S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals POLAND      10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [20-30]% by
                                 liquid and semi-solid pharmaceuticals POLAND      10A1S SUPPOSITORIES
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [70-80]% by
                                 liquid and semi-solid pharmaceuticals POLAND      12D2S SUPPOSITORIES
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [40-50]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals POLAND      C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [10-20]% by
                                 liquid and semi-solid pharmaceuticals PORTUGAL    02D1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [50-60]% by value / [40-50]% by
                                 liquid and semi-solid pharmaceuticals PORTUGAL    03F1M MIXTURES (ORAL)
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [50-60]% by value / [50-60]% by
                                 liquid and semi-solid pharmaceuticals PORTUGAL    A2B9 ALL OTHER ANTIULCERANTS
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [50-60]% by value / [50-60]% by
                                 liquid and semi-solid pharmaceuticals PORTUGAL    G4E9 ERECTILE DYSFUNC PRD OTH
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [70-80]% by
                                 liquid and semi-solid pharmaceuticals PORTUGAL    S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals ROMANIA     10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [60-70]% by value / [50-60]% by
                                 liquid and semi-solid pharmaceuticals ROMANIA     C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals SLOVAKIA    10A1S SUPPOSITORIES
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals SLOVAKIA    C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.                                                                                              volume
CDMO services for FDPs segmented                                                                                   [40-50]% by value / [30-40]% by
                                 liquid and semi-solid pharmaceuticals SPAIN       03F1M MIXTURES (ORAL)
by its pharmaceutical form, i e.                                                                                              volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                                   [40-50]% by value / [50-60]% by
                                 liquid and semi-solid pharmaceuticals SPAIN       G4E9 ERECTILE DYSFUNC PRD OTH
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                 liquid and semi-solid pharmaceuticals SWEDEN      S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                   [80-90]% by value / [10-20]% by
                                 sterile liquid pharmaceuticals        BELGIUM     S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                 sterile liquid pharmaceuticals        FRANCE      S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                   [30-40]% by value / [30-40]% by
                                 sterile liquid pharmaceu icals        ITALY       S1G1 OCUL.A-ALLERG ANTIHIST.
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                     [40-50]% by value / [0-5]% by
                                 sterile liquid pharmaceu icals        ITALY       S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                 sterile liquid pharmaceu icals        NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [30-40]% by
                                 sterile liquid pharmaceu icals        NORWAY      S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [70-80]% by
                                 sterile liquid pharmaceu icals        PORTUGAL    S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                 sterile liquid pharmaceu icals        SWEDEN      S1X2 OTH OPHTHALM TOPICAL
by its pharmaceutical form, i e.                                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [40-50]% by value / [30-40]% by
                                                                       LATVIA      10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [30-40]% by value / [20-30]% by
                                                                       LATVIA      10A1S SUPPOSITORIES
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [30-40]% by value / [30-40]% by
                                                                       LATVIA      C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [30-40]% by value / [30-40]% by
                                                                       LITHUANIA   C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [60-70]% by value / [70-80]% by
                                                                       PORTUGAL    02E1K NON HEAT/COLD PATCHES
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
CDMO services for FDPs segmented medicated confectionary                                                           [30-40]% by value / [30-40]% by
                                                                       ROMANIA     10A1O OINTMENTS/CREAMS
by its pharmaceutical form, i e. pharmaceuticals                                                                               volume
 ---pagebreak--- CDMO services for FDPs segmented       medicated confectionary                                                       [60-70]% by value / [50-60]% by
                                                                         ROMANIA     C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.       pharmaceuticals                                                                           volume
CDMO services for FDPs segmented       medicated confectionary                                                       [30-40]% by value / [30-40]% by
                                                                         SLOVAKIA    10A1S SUPPOSITORIES
by its pharmaceutical form, i e.       pharmaceuticals                                                                           volume
CDMO services for FDPs segmented       medicated confectionary                                                       [30-40]% by value / [30-40]% by
                                                                         SLOVAKIA    C5A2 A-HAEMORRHOID W/O CORTIC
by its pharmaceutical form, i e.       pharmaceuticals                                                                           volume
CDMO services for FDPs segmented                                                                                     [80-90]% by value / [10-20]% by
                                       sterile environment               BELGIUM     S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                       sterile environment               FRANCE      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                     [30-40]% by value / [30-40]% by
                                       sterile environment               ITALY       S1G1 OCUL.A-ALLERG ANTIHIST.
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                       [40-50]% by value / [0-5]% by
                                       sterile environment               ITALY       S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                       sterile environment               NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                    [90-100]% by value / [30-40]% by
                                       sterile environment               NORWAY      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                    [90-100]% by value / [70-80]% by
                                       sterile environment               PORTUGAL    S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                       sterile environment               SWEDEN      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e.                                                                                           volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         BELGIUM     C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                             [80-90]% by value / [10-20]% by
                                                                         BELGIUM     S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         FINLAND     C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce he FDP                                                                  volume
CDMO services for FDPs segmented       nature of the technology/know-how                                            [90-100]% by value / [80-90]% by
                                                                         FRANCE      C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce he FDP                                                                  volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         FRANCE      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce he FDP                                                                  volume
 ---pagebreak--- CDMO services for FDPs segmented       nature of the technology/know-how                                             [70-80]% by value / [70-80]% by
                                                                         GREECE      C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                             [50-60]% by value / [40-50]% by
                                                                         HUNGARY     C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                               [40-50]% by value / [0-5]% by
                                                                         ITALY       S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                            [90-100]% by value / [30-40]% by
                                                                         NORWAY      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                            [90-100]% by value / [70-80]% by
                                                                         POLAND      12D2S SUPPOSITORIES
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                             [60-70]% by value / [70-80]% by
                                                                         PORTUGAL    02E1K NON HEAT/COLD PATCHES
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                             [50-60]% by value / [50-60]% by
                                                                         PORTUGAL    G4E9 ERECTILE DYSFUNC PRD OTH
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                            [90-100]% by value / [70-80]% by
                                                                         PORTUGAL    S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         SPAIN       C8B2 CALC ANTAG/B BLOCKR COMB
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                             [40-50]% by value / [50-60]% by
                                                                         SPAIN       G4E9 ERECTILE DYSFUNC PRD OTH
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented       nature of the technology/know-how                                           [90-100]% by value / [90-100]% by
                                                                         SWEDEN      S1X2 OTH OPHTHALM TOPICAL
by the conditions of manufacture, i.e. needed to produce the FDP                                                                 volume
CDMO services for FDPs segmented                                                                                       [70-80]% by value / [0-5]% by
                                       chemically-syn hesized APIs       AUSTRIA     A11X3 VITAMIN E PLAIN
by the type of API used, i.e.                                                                                                    volume
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                       chemically-syn hesized APIs       BELGIUM     C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                                    volume
CDMO services for FDPs segmented                                                                                     [80-90]% by value / [10-20]% by
                                       chemically-syn hesized APIs       BELGIUM     S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                                    volume
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                       chemically-syn hesized APIs       FINLAND     C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                     [20-30]% by value / [30-40]% by
                                 chemically-syn hesized APIs FRANCE  01A4E EFFERVESCENT
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [30-40]% by value / [40-50]% by
                                 chemically-syn hesized APIs FRANCE  01A4P POWDERS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                   [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs FRANCE  01A9Z OTHER FORMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [30-40]% by value / <[0-5]% by
                                 chemically-syn hesized APIs FRANCE  A11X3 VITAMIN E PLAIN
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                    [90-100]% by value / [80-90]% by
                                 chemically-syn hesized APIs FRANCE  C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                   [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs FRANCE  S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [70-80]% by value / [70-80]% by
                                 chemically-syn hesized APIs GREECE  C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [50-60]% by value / [40-50]% by
                                 chemically-syn hesized APIs HUNGARY C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [50-60]% by value / [40-50]% by
                                 chemically-syn hesized APIs ITALY   02D1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [40-50]% by value / [40-50]% by
                                 chemically-syn hesized APIs ITALY   02D1Z OTHER FORMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [60-70]% by value / [10-20]% by
                                 chemically-syn hesized APIs ITALY   02E1L LIQUIDS (TOPICAL)
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [10-20]% by value / [40-50]% by
                                 chemically-syn hesized APIs ITALY   09C1G RINSES/GARGLES
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [20-30]% by value / [40-50]% by
                                 chemically-syn hesized APIs ITALY   10A1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [40-50]% by value / [20-30]% by
                                 chemically-syn hesized APIs ITALY   30C1Z OTHER MODULES
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     <[0-5]% by value / [90-100]% by
                                 chemically-syn hesized APIs ITALY   A7E9 INFLAM BOWEL DIS PRD OTH
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [50-60]% by value / [60-70]% by
                                 chemically-syn hesized APIs ITALY   C5A1 A-HAEMORRHOIDL+CORTICOID
by the type of API used, i.e.                                                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                         [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs ITALY       S1G1 OCUL.A-ALLERG ANTIHIST.
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                          [40-50]% by value / [0-5]% by
                                 chemically-syn hesized APIs ITALY       S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [40-50]% by value / [30-40]% by
                                 chemically-syn hesized APIs LATVIA      10A1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [20-30]% by
                                 chemically-syn hesized APIs LATVIA      10A1S SUPPOSITORIES
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs LATVIA      C5A2 A-HAEMORRHOID W/O CORTIC
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs LITHUANIA   C5A2 A-HAEMORRHOID W/O CORTIC
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                       [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                        [90-100]% by value / [30-40]% by
                                 chemically-syn hesized APIs NORWAY      S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs POLAND      10A1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [20-30]% by
                                 chemically-syn hesized APIs POLAND      10A1S SUPPOSITORIES
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                        [90-100]% by value / [70-80]% by
                                 chemically-syn hesized APIs POLAND      12D2S SUPPOSITORIES
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [40-50]% by value / [30-40]% by
                                 chemically-syn hesized APIs POLAND      C5A2 A-HAEMORRHOID W/O CORTIC
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [30-40]% by value / [10-20]% by
                                 chemically-syn hesized APIs PORTUGAL    02D1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                         [60-70]% by value / [70-80]% by
                                 chemically-syn hesized APIs PORTUGAL    02E1K NON HEAT/COLD PATCHES
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                       [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs PORTUGAL    03C4Q ENEMAS
by the type of API used, i.e.                                                                                       volume
CDMO services for FDPs segmented                                                                       [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs PORTUGAL    05A1Z OTHER FORMS
by the type of API used, i.e.                                                                                       volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                      [50-60]% by value / [50-60]% by
                                 chemically-syn hesized APIs PORTUGAL A2B9 ALL OTHER ANTIULCERANTS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [70-80]% by value / [60-70]% by
                                 chemically-syn hesized APIs PORTUGAL A6A4 LAXATIVE ENEMAS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [50-60]% by value / [50-60]% by
                                 chemically-syn hesized APIs PORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                     [90-100]% by value / [70-80]% by
                                 chemically-syn hesized APIs PORTUGAL S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [30-40]% by value / [20-30]% by
                                 chemically-syn hesized APIs ROMANIA  03C1Z OTHER FORMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs ROMANIA  10A1O OINTMENTS/CREAMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [60-70]% by value / [50-60]% by
                                 chemically-syn hesized APIs ROMANIA  C5A2 A-HAEMORRHOID W/O CORTIC
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs SLOVAKIA 10A1S SUPPOSITORIES
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [30-40]% by value / [30-40]% by
                                 chemically-syn hesized APIs SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [60-70]% by value / [40-50]% by
                                 chemically-syn hesized APIs SPAIN    03C1Z OTHER FORMS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                    [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs SPAIN    C8B2 CALC ANTAG/B BLOCKR COMB
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [40-50]% by value / [50-60]% by
                                 chemically-syn hesized APIs SPAIN    G4E9 ERECTILE DYSFUNC PRD OTH
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                    [90-100]% by value / [90-100]% by
                                 chemically-syn hesized APIs SWEDEN   S1X2 OTH OPHTHALM TOPICAL
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [50-60]% by value / [50-60]% by
                                 biopharmaceutical APIs      FRANCE   83E1 LEG CARE PRODUCTS
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [50-60]% by value / [40-50]% by
                                 biopharmaceutical APIs      PORTUGAL 03F1M MIXTURES (ORAL)
by the type of API used, i.e.                                                                                    volume
CDMO services for FDPs segmented                                                                      [40-50]% by value / [30-40]% by
                                 biopharmaceutical APIs      SPAIN    03F1M MIXTURES (ORAL)
by the type of API used, i.e.                                                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented                                                           [70-80]% by value / [0-5]% by
                                     swallowing AUSTRIA  A11X3 VITAMIN E PLAIN
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                       [90-100]% by value / [90-100]% by
                                     swallowing BELGIUM  C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                       [90-100]% by value / [90-100]% by
                                     swallowing FINLAND  C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [20-30]% by value / [30-40]% by
                                     swallowing FRANCE   01A4E EFFERVESCENT
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [30-40]% by value / [40-50]% by
                                     swallowing FRANCE   01A4P POWDERS
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                       [90-100]% by value / [90-100]% by
                                     swallowing FRANCE   01A9Z OTHER FORMS
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [50-60]% by value / [50-60]% by
                                     swallowing FRANCE   83E1 LEG CARE PRODUCTS
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                          [30-40]% by value / <[0-5]% by
                                     swallowing FRANCE   A11X3 VITAMIN E PLAIN
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                        [90-100]% by value / [80-90]% by
                                     swallowing FRANCE   C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [70-80]% by value / [70-80]% by
                                     swallowing GREECE   C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [50-60]% by value / [40-50]% by
                                     swallowing HUNGARY  C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [10-20]% by value / [40-50]% by
                                     swallowing ITALY    09C1G RINSES/GARGLES
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [40-50]% by value / [20-30]% by
                                     swallowing ITALY    30C1Z OTHER MODULES
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         <[0-5]% by value / [90-100]% by
                                     swallowing ITALY    A7E9 INFLAM BOWEL DIS PRD OTH
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                       [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL 03C4Q ENEMAS
by the delivery mechanism used, i.e.                                                                 volume
CDMO services for FDPs segmented                                                         [50-60]% by value / [40-50]% by
                                     swallowing PORTUGAL 03F1M MIXTURES (ORAL)
by the delivery mechanism used, i.e.                                                                 volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                         [90-100]% by value / [90-100]% by
                                     swallowing                  PORTUGAL  05A1Z OTHER FORMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [50-60]% by value / [50-60]% by
                                     swallowing                  PORTUGAL  A2B9 ALL OTHER ANTIULCERANTS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [70-80]% by value / [60-70]% by
                                     swallowing                  PORTUGAL  A6A4 LAXATIVE ENEMAS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [20-30]% by
                                     swallowing                  ROMANIA   03C1Z OTHER FORMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [60-70]% by value / [40-50]% by
                                     swallowing                  SPAIN     03C1Z OTHER FORMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [40-50]% by value / [30-40]% by
                                     swallowing                  SPAIN     03F1M MIXTURES (ORAL)
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                         [90-100]% by value / [90-100]% by
                                     swallowing                  SPAIN     C8B2 CALC ANTAG/B BLOCKR COMB
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [50-60]% by value / [50-60]% by
                                     absorption through the skin FRANCE    83E1 LEG CARE PRODUCTS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [50-60]% by value / [40-50]% by
                                     absorption through the skin ITALY     02D1O OINTMENTS/CREAMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [40-50]% by value / [40-50]% by
                                     absorption through the skin ITALY     02D1Z OTHER FORMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [60-70]% by value / [10-20]% by
                                     absorption through the skin ITALY     02E1L LIQUIDS (TOPICAL)
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [40-50]% by value / [30-40]% by
                                     absorption through the skin LATVIA    10A1O OINTMENTS/CREAMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [20-30]% by
                                     absorption through the skin LATVIA    10A1S SUPPOSITORIES
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin LATVIA    C5A2 A-HAEMORRHOID W/O CORTIC
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin POLAND    10A1O OINTMENTS/CREAMS
by the delivery mechanism used, i.e.                                                                                 volume
 ---pagebreak--- CDMO services for FDPs segmented                                                                          [30-40]% by value / [20-30]% by
                                     absorption through the skin POLAND   10A1S SUPPOSITORIES
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [40-50]% by value / [30-40]% by
                                     absorption through the skin POLAND   C5A2 A-HAEMORRHOID W/O CORTIC
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [10-20]% by
                                     absorption through the skin PORTUGAL 02D1O OINTMENTS/CREAMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin ROMANIA  10A1O OINTMENTS/CREAMS
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [60-70]% by value / [50-60]% by
                                     absorption through the skin ROMANIA  C5A2 A-HAEMORRHOID W/O CORTIC
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin SLOVAKIA 10A1S SUPPOSITORIES
by the delivery mechanism used, i.e.                                                                                 volume
CDMO services for FDPs segmented                                                                          [30-40]% by value / [30-40]% by
                                     absorption through the skin SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC
by the delivery mechanism used, i.e.                                                                                 volume
CMO services (excluding CDO                                                                             [90-100]% by value / [90-100]% by
                                     -                           BELGIUM  C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                                                            volume
CMO services (excluding CDO                                                                               [80-90]% by value / [10-20]% by
                                     -                           BELGIUM  S1X2 OTH OPHTHALM TOPICAL
services)                                                                                                            volume
CMO services (excluding CDO                                                                             [90-100]% by value / [90-100]% by
                                     -                           FINLAND  C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                                                            volume
CMO services (excluding CDO                                                                               [20-30]% by value / [30-40]% by
                                     -                           FRANCE   01A4E EFFERVESCENT
services)                                                                                                            volume
CMO services (excluding CDO                                                                               [30-40]% by value / [40-50]% by
                                     -                           FRANCE   01A4P POWDERS
services)                                                                                                            volume
CMO services (excluding CDO                                                                             [90-100]% by value / [90-100]% by
                                     -                           FRANCE   01A9Z OTHER FORMS
services)                                                                                                            volume
CMO services (excluding CDO                                                                               [50-60]% by value / [50-60]% by
                                     -                           FRANCE   83E1 LEG CARE PRODUCTS
services)                                                                                                            volume
CMO services (excluding CDO                                                                              [90-100]% by value / [80-90]% by
                                     -                           FRANCE   C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                                                            volume
CMO services (excluding CDO                                                                             [90-100]% by value / [90-100]% by
                                     -                           FRANCE   S1X2 OTH OPHTHALM TOPICAL
services)                                                                                                            volume
 ---pagebreak--- CMO services (excluding CDO                                              [70-80]% by value / [70-80]% by
                            - GREECE      C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                            volume
CMO services (excluding CDO                                              [50-60]% by value / [40-50]% by
                            - HUNGARY     C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                            volume
CMO services (excluding CDO                                              [50-60]% by value / [40-50]% by
                            - ITALY       02D1O OINTMENTS/CREAMS
services)                                                                            volume
CMO services (excluding CDO                                              [40-50]% by value / [40-50]% by
                            - ITALY       02D1Z OTHER FORMS
services)                                                                            volume
CMO services (excluding CDO                                              [60-70]% by value / [10-20]% by
                            - ITALY       02E1L LIQUIDS (TOPICAL)
services)                                                                            volume
CMO services (excluding CDO                                              [10-20]% by value / [40-50]% by
                            - ITALY       09C1G RINSES/GARGLES
services)                                                                            volume
CMO services (excluding CDO                                              [20-30]% by value / [40-50]% by
                            - ITALY       10A1O OINTMENTS/CREAMS
services)                                                                            volume
CMO services (excluding CDO                                              <[0-5]% by value / [90-100]% by
                            - ITALY       A7E9 INFLAM BOWEL DIS PRD OTH
services)                                                                            volume
CMO services (excluding CDO                                              [50-60]% by value / [60-70]% by
                            - ITALY       C5A1 A-HAEMORRHOIDL+CORTICOID
services)                                                                            volume
CMO services (excluding CDO                                              [30-40]% by value / [30-40]% by
                            - ITALY       S1G1 OCUL.A-ALLERG ANTIHIST.
services)                                                                            volume
CMO services (excluding CDO                                                [40-50]% by value / [0-5]% by
                            - ITALY       S1X2 OTH OPHTHALM TOPICAL
services)                                                                            volume
CMO services (excluding CDO                                              [40-50]% by value / [30-40]% by
                            - LATVIA      10A1O OINTMENTS/CREAMS
services)                                                                            volume
CMO services (excluding CDO                                              [30-40]% by value / [20-30]% by
                            - LATVIA      10A1S SUPPOSITORIES
services)                                                                            volume
CMO services (excluding CDO                                              [30-40]% by value / [30-40]% by
                            - LATVIA      C5A2 A-HAEMORRHOID W/O CORTIC
services)                                                                            volume
CMO services (excluding CDO                                              [30-40]% by value / [30-40]% by
                            - LITHUANIA   C5A2 A-HAEMORRHOID W/O CORTIC
services)                                                                            volume
CMO services (excluding CDO                                             [90-100]% by value / [90-100]% by
                            - NETHERLANDS S1X2 OTH OPHTHALM TOPICAL
services)                                                                            volume
 ---pagebreak--- CMO services (excluding CDO                                           [90-100]% by value / [30-40]% by
                            - NORWAY   S1X2 OTH OPHTHALM TOPICAL
services)                                                                         volume
CMO services (excluding CDO                                            [30-40]% by value / [30-40]% by
                            - POLAND   10A1O OINTMENTS/CREAMS
services)                                                                         volume
CMO services (excluding CDO                                            [30-40]% by value / [20-30]% by
                            - POLAND   10A1S SUPPOSITORIES
services)                                                                         volume
CMO services (excluding CDO                                           [90-100]% by value / [70-80]% by
                            - POLAND   12D2S SUPPOSITORIES
services)                                                                         volume
CMO services (excluding CDO                                            [40-50]% by value / [30-40]% by
                            - POLAND   C5A2 A-HAEMORRHOID W/O CORTIC
services)                                                                         volume
CMO services (excluding CDO                                            [30-40]% by value / [10-20]% by
                            - PORTUGAL 02D1O OINTMENTS/CREAMS
services)                                                                         volume
CMO services (excluding CDO                                            [60-70]% by value / [70-80]% by
                            - PORTUGAL 02E1K NON HEAT/COLD PATCHES
services)                                                                         volume
CMO services (excluding CDO                                          [90-100]% by value / [90-100]% by
                            - PORTUGAL 03C4Q ENEMAS
services)                                                                         volume
CMO services (excluding CDO                                            [50-60]% by value / [40-50]% by
                            - PORTUGAL 03F1M MIXTURES (ORAL)
services)                                                                         volume
CMO services (excluding CDO                                          [90-100]% by value / [90-100]% by
                            - PORTUGAL 05A1Z OTHER FORMS
services)                                                                         volume
CMO services (excluding CDO                                            [50-60]% by value / [50-60]% by
                            - PORTUGAL A2B9 ALL OTHER ANTIULCERANTS
services)                                                                         volume
CMO services (excluding CDO                                            [70-80]% by value / [60-70]% by
                            - PORTUGAL A6A4 LAXATIVE ENEMAS
services)                                                                         volume
CMO services (excluding CDO                                            [50-60]% by value / [50-60]% by
                            - PORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH
services)                                                                         volume
CMO services (excluding CDO                                           [90-100]% by value / [70-80]% by
                            - PORTUGAL S1X2 OTH OPHTHALM TOPICAL
services)                                                                         volume
CMO services (excluding CDO                                            [30-40]% by value / [20-30]% by
                            - ROMANIA  03C1Z OTHER FORMS
services)                                                                         volume
CMO services (excluding CDO                                            [30-40]% by value / [30-40]% by
                            - ROMANIA  10A1O OINTMENTS/CREAMS
services)                                                                         volume
 ---pagebreak--- CMO services (excluding CDO                                           [60-70]% by value / [50-60]% by
                            - ROMANIA  C5A2 A-HAEMORRHOID W/O CORTIC
services)                                                                        volume
CMO services (excluding CDO                                           [30-40]% by value / [30-40]% by
                            - SLOVAKIA 10A1S SUPPOSITORIES
services)                                                                        volume
CMO services (excluding CDO                                           [30-40]% by value / [30-40]% by
                            - SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC
services)                                                                        volume
CMO services (excluding CDO                                           [60-70]% by value / [40-50]% by
                            - SPAIN    03C1Z OTHER FORMS
services)                                                                        volume
CMO services (excluding CDO                                           [40-50]% by value / [30-40]% by
                            - SPAIN    03F1M MIXTURES (ORAL)
services)                                                                        volume
CMO services (excluding CDO                                          [90-100]% by value / [90-100]% by
                            - SPAIN    C8B2 CALC ANTAG/B BLOCKR COMB
services)                                                                        volume
CMO services (excluding CDO                                           [40-50]% by value / [50-60]% by
                            - SPAIN    G4E9 ERECTILE DYSFUNC PRD OTH
services)                                                                        volume
CMO services (excluding CDO                                          [90-100]% by value / [90-100]% by
                            - SWEDEN   S1X2 OTH OPHTHALM TOPICAL
services)                                                                        volume
 ---pagebreak---                                                                                                                                                                       Case M.10247 - CVC/Cooper
                                                     Appendix 7.1
                                       (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                         Upstream Market (Target)                                                                           Downstream FDP Market (Recordati)
                                      Upstream
  Upstream Hypothetical Market       Hypothetical     Geographic                    Geographic
                                                                   are (2020, EE                                          Molecule-level Category                         Share (2020)
        Segment (CDMO)               Market Sub-         Market                      Market
                                   Segment (CDMO)
                                                                                                 A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->              [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 TOCOFERSOLAN                                                               volume
                                                                                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 PRODUCTS --> BETAINE                                                       volume
                                                                                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 PRODUCTS --> CARGLUMIC ACID                                                volume
                                                                                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 PRODUCTS --> MERCAPTAMINE                                                  volume
                                                                                                 B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                   [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 HAEMATOLOGIC AGENTS --> HEMIN                                              volume
                                                                                                 C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER               [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               AUSTRIA
                                                                                                 CARDIOVASCULAR PRD --> IBUPROFEN                                           volume
                                                                                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               BELGIUM
                                                                                                 PRODUCTS --> BETAINE                                                       volume
                                                                                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                                               BELGIUM
                                                                                                 PRODUCTS --> CARGLUMIC ACID                                                volume
 ---pagebreak---                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [10-20]% by value / [60-70]% by
CDMO services for FDPs - BELGIUM
                                 PRODUCTS --> MERCAPTAMINE                                            volume
                                 S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM       [90-100]% by value / [90-100]% by
CDMO services for FDPs - BELGIUM
                                 TOPICAL --> MERCAPTAMINE                                             volume
                                 A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->       [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 TOCOFERSOLAN                                                         volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 PRODUCTS --> BETAINE                                                 volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [50-60]% by value / [50-60]% by
CDMO services for FDPs - FRANCE
                                 PRODUCTS --> CARGLUMIC ACID                                          volume
                                 B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 HAEMATOLOGIC AGENTS --> HEMIN                                        volume
                                 C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER        [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 CARDIOVASCULAR PRD --> IBUPROFEN                                     volume
                                 H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 --> PASIREOTIDE                                                      volume
                                 H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &  [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 SIMILAR --> OSILODROSTAT                                             volume
                                 L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->    [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 CHLORMETHINE                                                         volume
 ---pagebreak---                                  S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM                [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE
                                 TOPICAL --> MERCAPTAMINE                                                      volume
                                                                                                  [90-100]% by value / [90-100]% by
CDMO services for FDPs - FRANCE  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
                                                                                                               volume
                                 A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->                [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 TOCOFERSOLAN                                                                  volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 PRODUCTS --> BETAINE                                                          volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 PRODUCTS --> CARGLUMIC ACID                                                   volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC            [5-10]% by value / [30-40]% by
CDMO services for FDPs - GERMANY
                                 PRODUCTS --> MERCAPTAMINE                                                     volume
                                 C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER                 [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 CARDIOVASCULAR PRD --> IBUPROFEN                                              volume
                                 H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES           [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 --> PASIREOTIDE                                                               volume
                                 H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &           [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 SIMILAR --> OSILODROSTAT                                                      volume
                                 K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 HEMIN                                                                         volume
 ---pagebreak---                                  L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->       [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 CHLORMETHINE                                                            volume
                                 L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.         [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 ANTIBIOTICS --> DACTINOMYCIN                                            volume
                                 S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
CDMO services for FDPs - GERMANY
                                 TOPICAL --> MERCAPTAMINE                                                volume
                                                                                             [60-70]% by value / [90-100]% by
CDMO services for FDPs - GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
                                                                                                         volume
                                 B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
CDMO services for FDPs - HUNGARY
                                 HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                                                                              [50-60]% by value / [50-60]% by
CDMO services for FDPs - ITALY   30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS
                                                                                                         volume
                                 A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                 TOCOFERSOLAN                                                            volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                 PRODUCTS --> BETAINE                                                    volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [80-90]% by
CDMO services for FDPs - ITALY
                                 PRODUCTS --> CARGLUMIC ACID                                             volume
                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                 PRODUCTS --> MERCAPTAMINE                                               volume
 ---pagebreak---                                      B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. - [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     -> ARGATROBAN                                                                 volume
                                     B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                     [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     HAEMATOLOGIC AGENTS --> HEMIN                                                 volume
                                     H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES           [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     --> PASIREOTIDE                                                               volume
                                     L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->             [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     CHLORMETHINE                                                                  volume
                                     L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.               [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     ANTIBIOTICS --> DACTINOMYCIN                                                  volume
                                     S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM                [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY
                                     TOPICAL --> MERCAPTAMINE                                                      volume
                                                                                                      [90-100]% by value / [90-100]% by
CDMO services for FDPs - ITALY       V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
                                                                                                                   volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [90-100]% by value / [90-100]% by
CDMO services for FDPs - NETHERLANDS
                                     PRODUCTS --> BETAINE                                                          volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC            [70-80]% by value / [70-80]% by
CDMO services for FDPs - NETHERLANDS
                                     PRODUCTS --> CARGLUMIC ACID                                                   volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [90-100]% by value / [90-100]% by
CDMO services for FDPs - NETHERLANDS
                                     PRODUCTS --> MERCAPTAMINE                                                     volume
 ---pagebreak---                                      B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
CDMO services for FDPs - NETHERLANDS
                                     HAEMATOLOGIC AGENTS --> HEMIN                                       volume
                                     H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
CDMO services for FDPs - NETHERLANDS
                                     --> PASIREOTIDE                                                     volume
                                     S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM       [90-100]% by value / [90-100]% by
CDMO services for FDPs - NETHERLANDS
                                     TOPICAL --> MERCAPTAMINE                                            volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - NORWAY
                                     PRODUCTS --> BETAINE                                                volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - NORWAY
                                     PRODUCTS --> CARGLUMIC ACID                                         volume
                                     B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
CDMO services for FDPs - NORWAY
                                     HAEMATOLOGIC AGENTS --> HEMIN                                       volume
                                     H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
CDMO services for FDPs - NORWAY
                                     --> PASIREOTIDE                                                     volume
                                     S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM       [90-100]% by value / [90-100]% by
CDMO services for FDPs - NORWAY
                                     TOPICAL --> MERCAPTAMINE                                            volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - POLAND
                                     PRODUCTS --> BETAINE                                                volume
                                     A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - POLAND
                                     PRODUCTS --> CARGLUMIC ACID                                         volume
 ---pagebreak---                                   A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - POLAND
                                  PRODUCTS --> MERCAPTAMINE                                           volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - PORTUGAL
                                  PRODUCTS --> BETAINE                                                volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - PORTUGAL
                                  PRODUCTS --> CARGLUMIC ACID                                         volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - PORTUGAL
                                  PRODUCTS --> MERCAPTAMINE                                           volume
                                  S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM       [90-100]% by value / [90-100]% by
CDMO services for FDPs - PORTUGAL
                                  TOPICAL --> MERCAPTAMINE                                            volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - SLOVAKIA
                                  PRODUCTS --> BETAINE                                                volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - SLOVAKIA
                                  PRODUCTS --> CARGLUMIC ACID                                         volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - SLOVAKIA
                                  PRODUCTS --> MERCAPTAMINE                                           volume
                                  A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->       [90-100]% by value / [90-100]% by
CDMO services for FDPs - SPAIN
                                  TOCOFERSOLAN                                                        volume
                                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - SPAIN
                                  PRODUCTS --> BETAINE                                                volume
 ---pagebreak---                                 A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [70-80]% by value / [60-70]% by
CDMO services for FDPs - SPAIN
                                PRODUCTS --> CARGLUMIC ACID                                          volume
                                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [30-40]% by value / [80-90]% by
CDMO services for FDPs - SPAIN
                                PRODUCTS --> MERCAPTAMINE                                            volume
                                B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
CDMO services for FDPs - SPAIN
                                HAEMATOLOGIC AGENTS --> HEMIN                                        volume
                                                                                        [90-100]% by value / [90-100]% by
CDMO services for FDPs - SPAIN  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
                                                                                                     volume
                                A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->       [90-100]% by value / [90-100]% by
CDMO services for FDPs - SWEDEN
                                TOCOFERSOLAN                                                         volume
                                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
CDMO services for FDPs - SWEDEN
                                PRODUCTS --> BETAINE                                                 volume
                                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [70-80]% by value / [70-80]% by
CDMO services for FDPs - SWEDEN
                                PRODUCTS --> CARGLUMIC ACID                                          volume
                                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [10-20]% by value / [70-80]% by
CDMO services for FDPs - SWEDEN
                                PRODUCTS --> MERCAPTAMINE                                            volume
                                B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
CDMO services for FDPs - SWEDEN
                                HAEMATOLOGIC AGENTS --> HEMIN                                        volume
                                H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
CDMO services for FDPs - SWEDEN
                                --> PASIREOTIDE                                                      volume
 ---pagebreak---                                                            S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
CDMO services for FDPs           -                SWEDEN
                                                           TOPICAL --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [10-20]% by value / [60-70]% by
                                                  BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented solid and powder          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                  BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals           AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented solid and powder          C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                                  BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals           COMB --> FELODIPINE!METOPROLOL                                         volume
CDMO services for FDPs segmented solid and powder          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                  BULGARIA
by its pharmaceutical form, i.e. pharmaceuticals           AGENTS,PLAIN --> METOPROLOL                                            volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG               [90-100]% by value / [90-100]% by
                                                  BULGARIA
by its pharmaceutical form, i.e. pharmaceuticals           ANTIFUNGALS --> FENTICONAZOLE                                             volume
CDMO services for FDPs segmented solid and powder CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->          [60-70]% by value / [60-70]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented solid and powder CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->          [70-80]% by value / [80-90]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                                 volume
CDMO services for FDPs segmented solid and powder CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->        [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                       volume
CDMO services for FDPs segmented solid and powder CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented solid and powder CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC CHARCOAL!IRON METAL                                                       volume
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder CZECH    CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONIN       [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC E!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VIT               volume
                                                           AMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder CZECH                                                                 [90-100]% by value / [90-100]% by
                                                           CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC                                                                           volume
                                                           PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder CZECH                                                                 [90-100]% by value / [90-100]% by
                                                           CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC                                                                           volume
                                                           PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
CDMO services for FDPs segmented solid and powder CZECH    07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->       [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ASCORBIC ACID!XANTOFYL!ZEAXANTHIN                                         volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                 volume
CDMO services for FDPs segmented solid and powder CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                  volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder CZECH                                                               [90-100]% by value / [90-100]% by
                                                           ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC                                                                         volume
                                                           E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented solid and powder CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                volume
CDMO services for FDPs segmented solid and powder CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [70-80]% by value / [60-70]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented solid and powder CZECH    G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC PRD --> PROPIVERINE                                                     volume
CDMO services for FDPs segmented solid and powder CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [60-70]% by value / [60-70]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ANALGESICS --> ACETYLSALICYLIC ACID                                     volume
CDMO services for FDPs segmented solid and powder CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC          [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals  REPUBLIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                      volume
CDMO services for FDPs segmented solid and powder          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [60-70]% by value / [50-60]% by
                                                  ESTONIA
by its pharmaceutical form, i.e. pharmaceuticals           AGENTS,PLAIN --> METOPROLOL                                             volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [10-20]% by
                                                  FINLAND
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented solid and powder         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR   [90-100]% by value / [90-100]% by
                                                  FINLAND
by its pharmaceutical form, i.e. pharmaceuticals          COMB --> FELODIPINE!METOPROLOL                                           volume
CDMO services for FDPs segmented solid and powder         01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT -->         [20-30]% by value / [30-40]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          ACETYLCYSTEINE                                                           volume
CDMO services for FDPs segmented solid and powder         01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS -->              [30-40]% by value / [40-50]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          ACETYLCYSTEINE                                                           volume
                                                          05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                     [90-100]% by value / [90-100]% by
                                                  FRANCE  COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
by its pharmaceutical form, i.e. pharmaceuticals                                                                                   volume
                                                          BILOBA!PYRIDOXINE
                                                          10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS
CDMO services for FDPs segmented solid and powder                                                                     [90-100]% by value / [90-100]% by
                                                  FRANCE  HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                   volume
                                                          E!VITIS VINIFERA
CDMO services for FDPs segmented solid and powder         10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO   [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          BILOBA!HEPTAMINOL!TROXERUTIN                                             volume
CDMO services for FDPs segmented solid and powder         83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->         [50-60]% by value / [50-60]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          COMPOSITION UNKNOWN                                                      volume
CDMO services for FDPs segmented solid and powder         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented solid and powder         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC       [50-60]% by value / [50-60]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          PRODUCTS --> CARGLUMIC ACID                                              volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder        A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W       [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         ELECTRO --> MACROGOL(S)                                                 volume
CDMO services for FDPs segmented solid and powder        A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR -->  [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         MACROGOL(S)!POTASSIUM!SODIUM                                            volume
CDMO services for FDPs segmented solid and powder        C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE             [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                 volume
CDMO services for FDPs segmented solid and powder        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder        C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented solid and powder        G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL -->   [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         METRONIDAZOLE!NEOMYCIN!NYSTATIN                                         volume
CDMO services for FDPs segmented solid and powder        G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented solid and powder        H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented solid and powder        H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &     [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         SIMILAR --> OSILODROSTAT                                                volume
CDMO services for FDPs segmented solid and powder        J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR    [10-20]% by value / [80-90]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         TYPE --> ERYTHROMYCIN                                                   volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder                                                                        [30-40]% by value / [30-40]% by
                                                  FRANCE  R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE
by its pharmaceutical form, i.e. pharmaceuticals                                                                                    volume
CDMO services for FDPs segmented solid and powder         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC     [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          ACID!BENZOIC ACID!BROMINE!CODEINE                                         volume
CDMO services for FDPs segmented solid and powder         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC     [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          ACID!BROMOFORM!CODEINE                                                    volume
CDMO services for FDPs segmented solid and powder         R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB -->              [90-100]% by value / [90-100]% by
                                                  FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL                                    volume
CDMO services for FDPs segmented solid and powder                                                                      [90-100]% by value / [90-100]% by
                                                  FRANCE  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                    volume
CDMO services for FDPs segmented solid and powder         03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO   [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          OVATA                                                                     volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->  [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS                        volume
                                                          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented solid and powder                                                                      [90-100]% by value / [90-100]% by
                                                  GERMANY LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR
by its pharmaceutical form, i.e. pharmaceuticals                                                                                    volume
                                                          JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->  [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          LACTOBACILLUS HELVETICUS                                                  volume
CDMO services for FDPs segmented solid and powder         04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          CALCIUM!MAGNESIUM!POTASSIUM                                               volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented solid and powder         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented solid and powder         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [5-10]% by value / [30-40]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          PRODUCTS --> MERCAPTAMINE                                               volume
                                                          A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented solid and powder                                                                   [90-100]% by value / [90-100]% by
                                                  GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                  volume
                                                          HELVETICUS
                                                          A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented solid and powder                                                                   [90-100]% by value / [90-100]% by
                                                  GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                  volume
                                                          HELVETICUS VAR JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented solid and powder         A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-    [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          ORGANISM --> LACTOBACILLUS HELVETICUS                                   volume
CDMO services for FDPs segmented solid and powder         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR   [60-70]% by value / [50-60]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented solid and powder         H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES    [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented solid and powder         H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &    [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          SIMILAR --> OSILODROSTAT                                                volume
CDMO services for FDPs segmented solid and powder         L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.        [90-100]% by value / [90-100]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          ANTIBIOTICS --> DACTINOMYCIN                                            volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder         M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                 [70-80]% by value / [60-70]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          RELAXANTS,CENTRAL --> METHOCARBAMOL                                     volume
CDMO services for FDPs segmented solid and powder         N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->      [60-70]% by value / [60-70]% by
                                                  GERMANY
by its pharmaceutical form, i.e. pharmaceuticals          CARIPRAZINE                                                             volume
CDMO services for FDPs segmented solid and powder                                                                     [60-70]% by value / [90-100]% by
                                                  GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                  volume
CDMO services for FDPs segmented solid and powder         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                  GREECE
by its pharmaceutical form, i.e. pharmaceuticals          FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                  GREECE
by its pharmaceutical form, i.e. pharmaceuticals          FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  GREECE
by its pharmaceutical form, i.e. pharmaceuticals          COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented solid and powder         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                  GREECE
by its pharmaceutical form, i.e. pharmaceuticals          ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented solid and powder         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                  GREECE
by its pharmaceutical form, i.e. pharmaceuticals          ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented solid and powder         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [50-60]% by value / [30-40]% by
                                                  HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals          COMB --> FELODIPINE!METOPROLOL                                          volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  IRELAND
by its pharmaceutical form, i.e. pharmaceuticals          PRD --> FLAVOXATE                                                        volume
                                                          02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented solid and powder                                                                     [90-100]% by value / [90-100]% by
                                                  ITALY   ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL
by its pharmaceutical form, i.e. pharmaceuticals                                                                                   volume
                                                          SULFONE!GLUCOSAMINE
                                                          02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented solid and powder                                                                     [90-100]% by value / [90-100]% by
                                                  ITALY   ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL
by its pharmaceutical form, i.e. pharmaceuticals                                                                                   volume
                                                          SULFONE!GLUCOSAMINE
CDMO services for FDPs segmented solid and powder         03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          TILACTASE                                                                volume
CDMO services for FDPs segmented solid and powder         03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS -->          [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          DIMETICONE!LOPERAMIDE                                                    volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [70-80]% by value / [70-80]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [80-90]% by value / [80-90]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CDMO services for FDPs segmented solid and powder         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [50-60]% by value / [50-60]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals          COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
 ---pagebreak---                                                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented solid and powder                                                                   [90-100]% by value / [90-100]% by
                                                  ITALY HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                 volume
                                                        TRIGLYCERIDES (UNSPECIFIED)
CDMO services for FDPs segmented solid and powder       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [60-70]% by value / [60-70]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented solid and powder       04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS -->        [50-60]% by value / [70-80]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        DIMETHYL SULFONE                                                         volume
CDMO services for FDPs segmented solid and powder       04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS -->        [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        DIMETHYL SULFONE                                                         volume
                                                        04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO
CDMO services for FDPs segmented solid and powder                                                                   [90-100]% by value / [90-100]% by
                                                  ITALY OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                 volume
                                                        E
CDMO services for FDPs segmented solid and powder       04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO     [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E                             volume
CDMO services for FDPs segmented solid and powder       04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->        [50-60]% by value / [50-60]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ARGININE                                                                 volume
CDMO services for FDPs segmented solid and powder       04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE                             volume
CDMO services for FDPs segmented solid and powder       04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->        [50-60]% by value / [60-70]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        LYSINE                                                                   volume
CDMO services for FDPs segmented solid and powder       04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS -->        [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        INOSITOL                                                                 volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->   [80-90]% by value / [80-90]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->     [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder       11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS -->                 [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE                      volume
                                                        11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC
CDMO services for FDPs segmented solid and powder       ACID!MATRICARIA                                            [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI               volume
                                                        BER OFFICINALE
                                                        11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC
CDMO services for FDPs segmented solid and powder       ACID!MATRICARIA                                            [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI               volume
                                                        BER OFFICINALE
CDMO services for FDPs segmented solid and powder       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
CDMO services for FDPs segmented solid and powder       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->   [50-60]% by value / [60-70]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->   [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder       12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        DIOSCOREA VILLOSA                                                       volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        PRODUCTS --> BETAINE                                                        volume
CDMO services for FDPs segmented solid and powder       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC         [90-100]% by value / [80-90]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        PRODUCTS --> CARGLUMIC ACID                                                 volume
CDMO services for FDPs segmented solid and powder       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        PRODUCTS --> MERCAPTAMINE                                                   volume
CDMO services for FDPs segmented solid and powder       A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->             [60-70]% by value / [60-70]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        DOMPERIDONE                                                                 volume
CDMO services for FDPs segmented solid and powder       A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST         [20-30]% by value / [30-40]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        CORTICOSTER PROD --> BUDESONIDE                                             volume
CDMO services for FDPs segmented solid and powder       A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM       [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        BOWEL DIS PRD OTH --> CROMOGLICIC ACID                                      volume
CDMO services for FDPs segmented solid and powder       A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS -->       [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        DIMETICONE!LOPERAMIDE                                                       volume
CDMO services for FDPs segmented solid and powder       A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES -- [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        > TILACTASE                                                                 volume
CDMO services for FDPs segmented solid and powder       C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA         [70-80]% by value / [70-80]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        RED) --> LOVASTATIN                                                         volume
CDMO services for FDPs segmented solid and powder       C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC         [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        PREPS --> ALPROSTADIL ALFADEX                                               volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder       C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB       [40-50]% by value / [50-60]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ACTIV --> CINNARIZINE                                                   volume
CDMO services for FDPs segmented solid and powder       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [20-30]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        AGENTS,PLAIN --> BISOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [20-30]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder       D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented solid and powder       G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [60-70]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented solid and powder       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented solid and powder       J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL -- [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        > CEFTIBUTEN                                                            volume
CDMO services for FDPs segmented solid and powder       J1D CEPHALOSPORINS & COMBS --> J1D2                        [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        CEPHALOSPORINS,PARENT. --> CEFODIZIME                                   volume
CDMO services for FDPs segmented solid and powder       L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.         [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        ANTIBIOTICS --> DACTINOMYCIN                                            volume
CDMO services for FDPs segmented solid and powder       N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals        CARIPRAZINE                                                             volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder             R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES          [30-40]% by value / [30-40]% by
                                                  ITALY
by its pharmaceutical form, i.e. pharmaceuticals              SYSTEMIC --> RUPATADINE                                                 volume
CDMO services for FDPs segmented solid and powder                                                                        [90-100]% by value / [90-100]% by
                                                  ITALY       V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                      volume
CDMO services for FDPs segmented solid and powder             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                                                  LATVIA
by its pharmaceutical form, i.e. pharmaceuticals              AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [70-80]% by value / [70-80]% by
                                                  LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals              AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder             G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                  LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals              ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented solid and powder             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING            [90-100]% by value / [90-100]% by
                                                  LUXEMBOURG
by its pharmaceutical form, i.e. pharmaceuticals              AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [70-80]% by value / [70-80]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented solid and powder             G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              PRD --> FLAVOXATE                                                       volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              --> PASIREOTIDE                                                      volume
CDMO services for FDPs segmented solid and powder             N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->   [80-90]% by value / [80-90]% by
                                                  NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals              CARIPRAZINE                                                          volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                                  NORWAY
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> BETAINE                                                 volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                                  NORWAY
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> CARGLUMIC ACID                                          volume
CDMO services for FDPs segmented solid and powder             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [30-40]% by value / [10-20]% by
                                                  NORWAY
by its pharmaceutical form, i.e. pharmaceuticals              AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented solid and powder             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES  [90-100]% by value / [90-100]% by
                                                  NORWAY
by its pharmaceutical form, i.e. pharmaceuticals              --> PASIREOTIDE                                                      volume
CDMO services for FDPs segmented solid and powder             01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC  [90-100]% by value / [90-100]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals              ACID!LACTOFERRIN                                                     volume
CDMO services for FDPs segmented solid and powder             01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC  [90-100]% by value / [90-100]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals              ACID!LACTOFERRIN!MENTHOL                                             volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> BETAINE                                                 volume
CDMO services for FDPs segmented solid and powder             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals              PRODUCTS --> CARGLUMIC ACID                                          volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented solid and powder          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [20-30]% by
                                                  POLAND
by its pharmaceutical form, i.e. pharmaceuticals           AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented solid and powder          01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS -->        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           TIBEZONIUM                                                               volume
CDMO services for FDPs segmented solid and powder          01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM      [70-80]% by value / [80-90]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           OFFICINALE                                                               volume
CDMO services for FDPs segmented solid and powder                                                                      [90-100]% by value / [90-100]% by
                                                  PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM
by its pharmaceutical form, i.e. pharmaceuticals                                                                                    volume
CDMO services for FDPs segmented solid and powder                                                                      [90-100]% by value / [90-100]% by
                                                  PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM
by its pharmaceutical form, i.e. pharmaceuticals                                                                                    volume
CDMO services for FDPs segmented solid and powder          03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC           [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           ACID!DODECYL SULFOACETIC ACID                                            volume
CDMO services for FDPs segmented solid and powder          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented solid and powder          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented solid and powder          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           LACTOBACILLUS LACTIS                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented solid and powder          05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC              [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           ACID!CAFFEINE!GLUCURONAMIDE                                              volume
CDMO services for FDPs segmented solid and powder          A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN -->       [30-40]% by value / [10-20]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           COLECALCIFEROL                                                           volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> CARGLUMIC ACID                                              volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented solid and powder          A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS -->        [50-60]% by value / [50-60]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           SUCRALFATE                                                               volume
CDMO services for FDPs segmented solid and powder          A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT         [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE                      volume
CDMO services for FDPs segmented solid and powder          A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS -->     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           CITRIC ACID!DODECYL SULFOACETIC ACID                                     volume
CDMO services for FDPs segmented solid and powder          C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL                               volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented solid and powder          M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PLN --> DEXIBUPROFEN                                                    volume
CDMO services for FDPs segmented solid and powder          M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT              [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           PREPARATIONS --> COLCHICINE                                             volume
CDMO services for FDPs segmented solid and powder          N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           CARIPRAZINE                                                             volume
CDMO services for FDPs segmented solid and powder                                                                     [90-100]% by value / [90-100]% by
                                                  PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM
by its pharmaceutical form, i.e. pharmaceuticals                                                                                   volume
CDMO services for FDPs segmented solid and powder          R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           SISYMBRIUM OFFICINALE                                                   volume
CDMO services for FDPs segmented solid and powder          R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals           TIBEZONIUM                                                              volume
CDMO services for FDPs segmented solid and powder          03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           FRUCTOOLIGSACCHARIDES!MALTODEXTRIN                                      volume
CDMO services for FDPs segmented solid and powder          03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           INULIN!MALTODEXTRIN                                                     volume
CDMO services for FDPs segmented solid and powder          04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT -->          [30-40]% by value / [20-30]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           CALCIUM!COLECALCIFEROL                                                  volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented solid and powder          C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE              [80-90]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           THERAPY,SYSTEM. --> DIOSMIN                                             volume
CDMO services for FDPs segmented solid and powder          D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented solid and powder          G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL -->   [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           METRONIDAZOLE!NEOMYCIN!NYSTATIN                                         volume
CDMO services for FDPs segmented solid and powder          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                  ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals           ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented solid and powder          02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->        [80-90]% by value / [80-90]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ACETYLSALICYLIC ACID                                                    volume
CDMO services for FDPs segmented solid and powder          02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                               volume
CDMO services for FDPs segmented solid and powder          02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                     volume
CDMO services for FDPs segmented solid and powder          02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->   [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ACETYLSALICYLIC ACID                                                    volume
CDMO services for FDPs segmented solid and powder          02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->   [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ACETYLSALICYLIC ACID!ASCORBIC ACID                                      volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           CHARCOAL + IRON METAL                                                     volume
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E
CDMO services for FDPs segmented solid and powder                                                                         [70-80]% by value / [80-90]% by
                                                  SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           E!XANTOFYL!ZEAXANTHIN
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           ACID!TAURINE!XANTOFYL!ZINC
CDMO services for FDPs segmented solid and powder          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL                 volume
CDMO services for FDPs segmented solid and powder          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                    volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented solid and powder                                                                       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                     volume
                                                           E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented solid and powder          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                  volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented solid and powder          A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented solid and powder          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [60-70]% by value / [30-40]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented solid and powder          G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           PRD --> PROPIVERINE                                                     volume
CDMO services for FDPs segmented solid and powder          N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [80-90]% by value / [80-90]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ANALGESICS --> ACETYLSALICYLIC ACID                                     volume
CDMO services for FDPs segmented solid and powder          N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC          [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                      volume
CDMO services for FDPs segmented solid and powder          S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals           HYALURONIC ACID!MALVA SYLVESTRIS                                        volume
CDMO services for FDPs segmented solid and powder          03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS -->               [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                  volume
CDMO services for FDPs segmented solid and powder          03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                 [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                    volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder       03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                  [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                    volume
CDMO services for FDPs segmented solid and powder                                                                       [70-80]% by value / [0-5]% by
                                                  SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE
by its pharmaceutical form, i.e. pharmaceuticals                                                                                  volume
CDMO services for FDPs segmented solid and powder       03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->              [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                      volume
CDMO services for FDPs segmented solid and powder       03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        LACTOBACILLUS LACTIS                                                      volume
CDMO services for FDPs segmented solid and powder       03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        LACTOBACILLUS REUTERI                                                     volume
CDMO services for FDPs segmented solid and powder       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        LACTOBACILLUS REUTERI                                                     volume
CDMO services for FDPs segmented solid and powder       03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS -->     [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        LACTOBACILLUS REUTERI                                                     volume
CDMO services for FDPs segmented solid and powder       08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS       [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        SALIVARIUS                                                                volume
CDMO services for FDPs segmented solid and powder       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        PRODUCTS --> BETAINE                                                      volume
CDMO services for FDPs segmented solid and powder       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC       [70-80]% by value / [60-70]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals        PRODUCTS --> CARGLUMIC ACID                                               volume
 ---pagebreak--- CDMO services for FDPs segmented solid and powder        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [30-40]% by value / [80-90]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals         PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented solid and powder        A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->        [70-80]% by value / [70-80]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals         CINITAPRIDE                                                            volume
CDMO services for FDPs segmented solid and powder        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [80-90]% by value / [80-90]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals         AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented solid and powder        C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals         COMB --> FELODIPINE!METOPROLOL                                         volume
CDMO services for FDPs segmented solid and powder        N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->   [90-100]% by value / [90-100]% by
                                                  SPAIN
by its pharmaceutical form, i.e. pharmaceuticals         CARIPRAZINE                                                            volume
CDMO services for FDPs segmented solid and powder                                                                  [90-100]% by value / [90-100]% by
                                                  SPAIN  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                volume
CDMO services for FDPs segmented solid and powder        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals         PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented solid and powder        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [70-80]% by value / [70-80]% by
                                                  SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals         PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented solid and powder        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [10-20]% by value / [70-80]% by
                                                  SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals         PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented solid and powder        H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES    [90-100]% by value / [90-100]% by
                                                  SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals         --> PASIREOTIDE                                                        volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid          A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->       [90-100]% by value / [90-100]% by
                                                       AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals                TOCOFERSOLAN                                                         volume
CDMO services for FDPs segmented liquid and semi-solid          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
                                                       AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals                HAEMATOLOGIC AGENTS --> HEMIN                                        volume
CDMO services for FDPs segmented liquid and semi-solid          C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER        [90-100]% by value / [90-100]% by
                                                       AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals                CARDIOVASCULAR PRD --> IBUPROFEN                                     volume
CDMO services for FDPs segmented liquid and semi-solid          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [60-70]% by value / [50-60]% by
                                                       BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals                AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented liquid and semi-solid          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM       [90-100]% by value / [90-100]% by
                                                       BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals                TOPICAL --> MERCAPTAMINE                                             volume
CDMO services for FDPs segmented liquid and semi-solid          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG          [90-100]% by value / [90-100]% by
                                                       BULGARIA
by its pharmaceutical form, i.e. pharmaceuticals                ANTIFUNGALS --> FENTICONAZOLE                                        volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->  [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ASCORBIC ACID!XANTOFYL!ZEAXANTHIN                                    volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->  [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC              volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->  [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN               volume
                                                                07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented liquid and semi-solid CZECH                                                            [90-100]% by value / [90-100]% by
                                                                ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC                                                                      volume
                                                                E!XANTOFYL!ZEAXANTHIN
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                  volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC LIDOCAINE!TRIBENOSIDE                                                     volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->            [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC LIDOCAINE!TRIBENOSIDE                                                     volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS       [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ACULEATUS!SODIUM                                                          volume
                                                                88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES
CDMO services for FDPs segmented liquid and semi-solid CZECH                                                                 [90-100]% by value / [90-100]% by
                                                                NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC                                                                           volume
                                                                (DULCIS)!VITAMIN E!ZINC
CDMO services for FDPs segmented liquid and semi-solid CZECH    88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES         [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC              volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O      [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC CORTIC --> LIDOCAINE!TRIBENOSIDE                                          volume
CDMO services for FDPs segmented liquid and semi-solid CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG               [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals       REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                             volume
CDMO services for FDPs segmented liquid and semi-solid          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [30-40]% by value / [10-20]% by
                                                       FINLAND
by its pharmaceutical form, i.e. pharmaceuticals                AGENTS,PLAIN --> METOPROLOL                                               volume
                                                                01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                       [90-100]% by value / [90-100]% by
                                                       FRANCE   CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM
by its pharmaceutical form, i.e. pharmaceuticals                                                                                          volume
                                                                USITATISSIMUM!PROPOLIS
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid        01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->     [80-90]% by value / [80-90]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              SODIUM                                                                   volume
CDMO services for FDPs segmented liquid and semi-solid        02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              BARBADENSIS!HYALURONIC ACID                                              volume
CDMO services for FDPs segmented liquid and semi-solid        02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE  [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              BARBADENSIS!HYALURONIC ACID                                              volume
                                                              02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC
CDMO services for FDPs segmented liquid and semi-solid                                                                    [90-100]% by value / [90-100]% by
                                                       FRANCE ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA
by its pharmaceutical form, i.e. pharmaceuticals                                                                                       volume
                                                              GLABRA!HYALURONIC ACID!MENTHOL
CDMO services for FDPs segmented liquid and semi-solid        02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE       [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              BARBADENSIS!HYALURONIC ACID                                              volume
                                                              05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                    [90-100]% by value / [90-100]% by
                                                       FRANCE COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
by its pharmaceutical form, i.e. pharmaceuticals                                                                                       volume
                                                              BILOBA!PYRIDOXINE
CDMO services for FDPs segmented liquid and semi-solid        09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
CDMO services for FDPs segmented liquid and semi-solid        09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                          volume
CDMO services for FDPs segmented liquid and semi-solid        10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO   [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              BILOBA!HEPTAMINOL!TROXERUTIN                                             volume
CDMO services for FDPs segmented liquid and semi-solid        83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->         [50-60]% by value / [50-60]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              COMPOSITION UNKNOWN                                                      volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid        87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED        [50-60]% by value / [70-80]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              GUM&G --> COMPOSITION UNKNOWN                                          volume
CDMO services for FDPs segmented liquid and semi-solid        A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->         [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              TOCOFERSOLAN                                                           volume
CDMO services for FDPs segmented liquid and semi-solid        A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                  volume
CDMO services for FDPs segmented liquid and semi-solid        A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                        volume
CDMO services for FDPs segmented liquid and semi-solid        B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH              [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              HAEMATOLOGIC AGENTS --> HEMIN                                          volume
CDMO services for FDPs segmented liquid and semi-solid        C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE            [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                volume
CDMO services for FDPs segmented liquid and semi-solid        C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER          [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CARDIOVASCULAR PRD --> IBUPROFEN                                       volume
CDMO services for FDPs segmented liquid and semi-solid        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [40-50]% by value / [20-30]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented liquid and semi-solid        H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES    [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              --> PASIREOTIDE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid        L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->      [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals              CHLORMETHINE                                                           volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM              [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals               TOPICAL --> MERCAPTAMINE                                                    volume
CDMO services for FDPs segmented liquid and semi-solid         S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->   [90-100]% by value / [90-100]% by
                                                       FRANCE
by its pharmaceutical form, i.e. pharmaceuticals               RIFAMYCIN                                                                   volume
CDMO services for FDPs segmented liquid and semi-solid         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-   [60-70]% by value / [50-60]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               PROPANOL                                                                    volume
CDMO services for FDPs segmented liquid and semi-solid         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-        [40-50]% by value / [40-50]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               PROPANOL                                                                    volume
CDMO services for FDPs segmented liquid and semi-solid                                                                        [90-100]% by value / [90-100]% by
                                                       GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                           volume
CDMO services for FDPs segmented liquid and semi-solid                                                                          [50-60]% by value / [20-30]% by
                                                       GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                           volume
CDMO services for FDPs segmented liquid and semi-solid         06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               SALICYLIC ACID                                                              volume
CDMO services for FDPs segmented liquid and semi-solid         12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS -->       [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               LIDOCAINE!PRILOCAINE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid         18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS -->         [70-80]% by value / [20-30]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               MENTHA ARVENSIS                                                             volume
CDMO services for FDPs segmented liquid and semi-solid         A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->              [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               TOCOFERSOLAN                                                                volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid         C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER              [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               CARDIOVASCULAR PRD --> IBUPROFEN                                            volume
CDMO services for FDPs segmented liquid and semi-solid         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING            [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC                                     volume
CDMO services for FDPs segmented liquid and semi-solid         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING              [70-80]% by value / [60-70]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               AGENTS --> ZINC                                                             volume
CDMO services for FDPs segmented liquid and semi-solid         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE        [30-40]% by value / [0-5]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               PRD --> OXYBUTYNIN                                                          volume
CDMO services for FDPs segmented liquid and semi-solid         G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL      [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               PRODS --> LIDOCAINE!PRILOCAINE                                              volume
CDMO services for FDPs segmented liquid and semi-solid         H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES        [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               --> PASIREOTIDE                                                             volume
CDMO services for FDPs segmented liquid and semi-solid         H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --   [40-50]% by value / [10-20]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               > DEXAMETHASONE                                                             volume
CDMO services for FDPs segmented liquid and semi-solid         L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->          [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               CHLORMETHINE                                                                volume
CDMO services for FDPs segmented liquid and semi-solid         M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &        [50-60]% by value / [50-60]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               ANALG --> 2-PROPANOL                                                        volume
CDMO services for FDPs segmented liquid and semi-solid         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM             [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               TOPICAL --> MERCAPTAMINE                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid         V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL             [90-100]% by value / [90-100]% by
                                                       GERMANY
by its pharmaceutical form, i.e. pharmaceuticals               PREPARATIONS --> MENTHA ARVENSIS                                        volume
CDMO services for FDPs segmented liquid and semi-solid         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                       GREECE
by its pharmaceutical form, i.e. pharmaceuticals               FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented liquid and semi-solid         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                       GREECE
by its pharmaceutical form, i.e. pharmaceuticals               FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented liquid and semi-solid         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                       GREECE
by its pharmaceutical form, i.e. pharmaceuticals               ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented liquid and semi-solid         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                       GREECE
by its pharmaceutical form, i.e. pharmaceuticals               ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented liquid and semi-solid         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                       HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals               HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented liquid and semi-solid         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                       HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals               ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented liquid and semi-solid         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE   [30-40]% by value / [5-10]% by
                                                       IRELAND
by its pharmaceutical form, i.e. pharmaceuticals               PRD --> OXYBUTYNIN                                                      volume
CDMO services for FDPs segmented liquid and semi-solid         01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals               ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER                        volume
CDMO services for FDPs segmented liquid and semi-solid         02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals               BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS                  volume
 ---pagebreak---                                                              02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented liquid and semi-solid                                                                    [90-100]% by value / [90-100]% by
                                                       ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                       volume
                                                             COMMUNIS
CDMO services for FDPs segmented liquid and semi-solid       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE        [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             BARBADENSIS!BENZETHONIUM CHLORIDE                                         volume
CDMO services for FDPs segmented liquid and semi-solid       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE        [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             BARBADENSIS!ENOXOLONE!HYALURONIC ACID                                     volume
                                                             02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented liquid and semi-solid                                                                    [90-100]% by value / [90-100]% by
                                                       ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                       volume
                                                             COMMUNIS
CDMO services for FDPs segmented liquid and semi-solid       02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             DICLOFENAC                                                                volume
CDMO services for FDPs segmented liquid and semi-solid       02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS -->    [40-50]% by value / [40-50]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             NAPROXEN                                                                  volume
CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->        [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                    volume
CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->          [70-80]% by value / [70-80]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             COLECALCIFEROL!LACTOBACILLUS REUTERI                                      volume
CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->          [80-90]% by value / [80-90]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             LACTOBACILLUS REUTERI                                                     volume
                                                             03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented liquid and semi-solid                                                                    [90-100]% by value / [90-100]% by
                                                       ITALY ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                       volume
                                                             ACIDOPHILUS
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [50-60]% by value / [50-60]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
                                                             03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented liquid and semi-solid                                                                   [90-100]% by value / [90-100]% by
                                                       ITALY HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                      volume
                                                             TRIGLYCERIDES (UNSPECIFIED)
CDMO services for FDPs segmented liquid and semi-solid       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [60-70]% by value / [60-70]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented liquid and semi-solid       03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC    [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             MEDICINES                                                                volume
CDMO services for FDPs segmented liquid and semi-solid       06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS -->      [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER                              volume
CDMO services for FDPs segmented liquid and semi-solid       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->   [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented liquid and semi-solid       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->    [80-90]% by value / [80-90]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented liquid and semi-solid       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->      [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented liquid and semi-solid       07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid       07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             HYALURONIC ACID!SODIUM!TROMETAMOL                                        volume
                                                             07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                   [90-100]% by value / [90-100]% by
                                                       ITALY EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA
by its pharmaceutical form, i.e. pharmaceuticals                                                                                      volume
                                                             CHAMOMILLA!PHOSPHORIC ACID!SODIUM
                                                             09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->
CDMO services for FDPs segmented liquid and semi-solid                                                                   [90-100]% by value / [90-100]% by
                                                       ITALY CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA
by its pharmaceutical form, i.e. pharmaceuticals                                                                                      volume
                                                             PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL
CDMO services for FDPs segmented liquid and semi-solid       09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->   [60-70]% by value / [80-90]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             COMPOSITION UNKNOWN                                                      volume
CDMO services for FDPs segmented liquid and semi-solid       10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FLUOCINOLONE ACETONIDE!KETOCAINE                                         volume
CDMO services for FDPs segmented liquid and semi-solid       10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FLUOCINOLONE ACETONIDE!KETOCAINE                                         volume
CDMO services for FDPs segmented liquid and semi-solid       11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS -->                  [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE                       volume
                                                             11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC
CDMO services for FDPs segmented liquid and semi-solid       ACID!MATRICARIA                                             [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                volume
                                                             BER OFFICINALE
                                                             11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC
CDMO services for FDPs segmented liquid and semi-solid       ACID!MATRICARIA                                             [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                volume
                                                             BER OFFICINALE
CDMO services for FDPs segmented liquid and semi-solid       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                    [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             OINTMENTS/CREAMS --> FENTICONAZOLE                                       volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->         [50-60]% by value / [60-70]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FENTICONAZOLE                                                                 volume
CDMO services for FDPs segmented liquid and semi-solid       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->         [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             FENTICONAZOLE                                                                 volume
CDMO services for FDPs segmented liquid and semi-solid       18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS -->             [20-30]% by value / [30-40]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             BORAGO OFFICINALIS                                                            volume
CDMO services for FDPs segmented liquid and semi-solid                                                                          [50-60]% by value / [50-60]% by
                                                       ITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS
by its pharmaceutical form, i.e. pharmaceuticals                                                                                           volume
                                                             87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH
CDMO services for FDPs segmented liquid and semi-solid                                                                        [90-100]% by value / [90-100]% by
                                                       ITALY --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA
by its pharmaceutical form, i.e. pharmaceuticals                                                                                           volume
                                                             PIPERITA!XYLITOL
CDMO services for FDPs segmented liquid and semi-solid       A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->                [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             TOCOFERSOLAN                                                                  volume
CDMO services for FDPs segmented liquid and semi-solid       A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->               [60-70]% by value / [60-70]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             DOMPERIDONE                                                                   volume
CDMO services for FDPs segmented liquid and semi-solid       B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. - [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             -> ARGATROBAN                                                                 volume
CDMO services for FDPs segmented liquid and semi-solid       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                     [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             HAEMATOLOGIC AGENTS --> HEMIN                                                 volume
CDMO services for FDPs segmented liquid and semi-solid       C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB             [40-50]% by value / [50-60]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             ACTIV --> CINNARIZINE                                                         volume
 ---pagebreak---                                                              C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
CDMO services for FDPs segmented liquid and semi-solid                                                                     [90-100]% by value / [90-100]% by
                                                       ITALY HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE
by its pharmaceutical form, i.e. pharmaceuticals                                                                                          volume
                                                             ACETONIDE!KETOCAINE
CDMO services for FDPs segmented liquid and semi-solid       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                 [30-40]% by value / [20-30]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             AGENTS,PLAIN --> METOPROLOL                                                  volume
CDMO services for FDPs segmented liquid and semi-solid       D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT          [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             ANTIFUNG --> FENTICONAZOLE                                                   volume
CDMO services for FDPs segmented liquid and semi-solid       G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [60-70]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             ANTIFUNGALS --> FENTICONAZOLE                                                volume
CDMO services for FDPs segmented liquid and semi-solid       G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL      [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             PRODS --> LIDOCAINE!PRILOCAINE                                               volume
CDMO services for FDPs segmented liquid and semi-solid       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES        [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             --> PASIREOTIDE                                                              volume
CDMO services for FDPs segmented liquid and semi-solid       L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->          [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             CHLORMETHINE                                                                 volume
CDMO services for FDPs segmented liquid and semi-solid       M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &        [50-60]% by value / [40-50]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals             ANALG --> NAPROXEN                                                           volume
                                                                                                                             [60-70]% by value / [60-70]% by
CDMO services for FDPs segmented liquid and semi-solid       R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF -->
                                                       ITALY                                                                 volume (CVC share [70-80]% by
by its pharmaceutical form, i.e. pharmaceuticals             BUDESONIDE
                                                                                                                               value / [70-80]% by volume)
                                                                                                                             [60-70]% by value / [50-60]% by
CDMO services for FDPs segmented liquid and semi-solid
                                                       ITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE     volume (CVC share [60-70]% by
by its pharmaceutical form, i.e. pharmaceuticals
                                                                                                                               value / [60-70]% by volume)
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid           R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES               [30-40]% by value / [30-40]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals                 SYSTEMIC --> RUPATADINE                                                      volume
CDMO services for FDPs segmented liquid and semi-solid           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM               [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals                 TOPICAL --> MERCAPTAMINE                                                     volume
CDMO services for FDPs segmented liquid and semi-solid           S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->    [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals                 CIPROFLOXACIN                                                                volume
CDMO services for FDPs segmented liquid and semi-solid           S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR -- [90-100]% by value / [90-100]% by
                                                       ITALY
by its pharmaceutical form, i.e. pharmaceuticals                 > CIPROFLOXACIN!FLUOCINOLONE ACETONIDE                                       volume
CDMO services for FDPs segmented liquid and semi-solid           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->            [90-100]% by value / [90-100]% by
                                                       LATVIA
by its pharmaceutical form, i.e. pharmaceuticals                 LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->               [90-100]% by value / [90-100]% by
                                                       LATVIA
by its pharmaceutical form, i.e. pharmaceuticals                 LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O         [90-100]% by value / [90-100]% by
                                                       LATVIA
by its pharmaceutical form, i.e. pharmaceuticals                 CORTIC --> LIDOCAINE!TRIBENOSIDE                                             volume
CDMO services for FDPs segmented liquid and semi-solid           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->            [90-100]% by value / [90-100]% by
                                                       LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals                 LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->               [90-100]% by value / [90-100]% by
                                                       LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals                 LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented liquid and semi-solid           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O         [90-100]% by value / [90-100]% by
                                                       LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals                 CORTIC --> LIDOCAINE!TRIBENOSIDE                                             volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid             G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG         [90-100]% by value / [90-100]% by
                                                       LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals                   ANTIFUNGALS --> FENTICONAZOLE                                       volume
CDMO services for FDPs segmented liquid and semi-solid             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING        [90-100]% by value / [90-100]% by
                                                       LUXEMBOURG
by its pharmaceutical form, i.e. pharmaceuticals                   AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented liquid and semi-solid             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                       NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals                   HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented liquid and semi-solid             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                                       NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals                   --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented liquid and semi-solid             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                                       NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals                   TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented liquid and semi-solid             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                       NORWAY
by its pharmaceutical form, i.e. pharmaceuticals                   HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented liquid and semi-solid             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [30-40]% by value / [10-20]% by
                                                       NORWAY
by its pharmaceutical form, i.e. pharmaceuticals                   AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented liquid and semi-solid             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                                       NORWAY
by its pharmaceutical form, i.e. pharmaceuticals                   --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented liquid and semi-solid             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                                       NORWAY
by its pharmaceutical form, i.e. pharmaceuticals                   TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented liquid and semi-solid             10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->     [50-60]% by value / [60-70]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                   LIDOCAINE!TRIBENOSIDE                                               volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                    [90-100]% by value / [90-100]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                OINTMENTS/CREAMS --> FENTICONAZOLE                                       volume
CDMO services for FDPs segmented liquid and semi-solid          12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->  [90-100]% by value / [90-100]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented liquid and semi-solid          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O       [70-80]% by value / [60-70]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CDMO services for FDPs segmented liquid and semi-solid          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                                                       POLAND
by its pharmaceutical form, i.e. pharmaceuticals                ANTIFUNGALS --> FENTICONAZOLE                                            volume
                                                                02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                         volume
                                                                ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                                02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                         volume
                                                                ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                                02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented liquid and semi-solid          BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS       [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC                    volume
                                                                ACID!XANTHAN GUM!XYLITOL
                                                                02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                         volume
                                                                ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS LACTIS                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented liquid and semi-solid          06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) -->  [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA                 volume
CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                LIDOCAINE + TRIBENOSIDE                                                  volume
CDMO services for FDPs segmented liquid and semi-solid          A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS -->        [50-60]% by value / [50-60]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                SUCRALFATE                                                               volume
CDMO services for FDPs segmented liquid and semi-solid          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CDMO services for FDPs segmented liquid and semi-solid          G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD    [50-60]% by value / [50-60]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                OTH --> ALPROSTADIL                                                      volume
CDMO services for FDPs segmented liquid and semi-solid          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM           [90-100]% by value / [90-100]% by
                                                       PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals                TOPICAL --> MERCAPTAMINE                                                 volume
CDMO services for FDPs segmented liquid and semi-solid          06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->  [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                LIDOCAINE + TRIBENOSIDE                                                  volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                + TRIBENOSIDE                                                           volume
CDMO services for FDPs segmented liquid and semi-solid          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented liquid and semi-solid          D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT        [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented liquid and semi-solid          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                                                       ROMANIA
by its pharmaceutical form, i.e. pharmaceuticals                ANTIFUNGALS --> FENTICONAZOLE                                           volume
                                                                07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                        volume
                                                                E!XANTOFYL!ZEAXANTHIN
                                                                07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC
by its pharmaceutical form, i.e. pharmaceuticals                                                                                        volume
                                                                ACID!TAURINE!XANTOFYL!ZINC
CDMO services for FDPs segmented liquid and semi-solid          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL               volume
CDMO services for FDPs segmented liquid and semi-solid          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                  volume
                                                                07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented liquid and semi-solid                                                                      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by its pharmaceutical form, i.e. pharmaceuticals                                                                                        volume
                                                                E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented liquid and semi-solid          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS      [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                ACULEATUS!SODIUM                                                         volume
CDMO services for FDPs segmented liquid and semi-solid          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CDMO services for FDPs segmented liquid and semi-solid          S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC -->  [90-100]% by value / [90-100]% by
                                                       SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals                HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS -->     [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals                LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented liquid and semi-solid          86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-           [40-50]% by value / [10-20]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals                AERO+SPRAY --> COMPOSITION UNKNOWN                                       volume
 ---pagebreak--- CDMO services for FDPs segmented liquid and semi-solid        86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-        [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              AERO+SPRAY --> DIMETICONE!JOJOBA OIL                                    volume
CDMO services for FDPs segmented liquid and semi-solid        A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented liquid and semi-solid        A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->         [70-80]% by value / [70-80]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              CINITAPRIDE                                                             volume
CDMO services for FDPs segmented liquid and semi-solid        B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented liquid and semi-solid        G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [40-50]% by value / [50-60]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              OTH --> ALPROSTADIL                                                     volume
CDMO services for FDPs segmented liquid and semi-solid        G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                       SPAIN
by its pharmaceutical form, i.e. pharmaceuticals              PRODS --> LIDOCAINE!PRILOCAINE                                          volume
CDMO services for FDPs segmented liquid and semi-solid        A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                       SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals              TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented liquid and semi-solid        B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                       SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals              HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented liquid and semi-solid        H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                       SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals              --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented liquid and semi-solid        S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                       SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals              TOPICAL --> MERCAPTAMINE                                                volume
 ---pagebreak--- CDMO services for FDPs segmented sterile liquid           B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                 [90-100]% by value / [90-100]% by
                                                 AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals          HAEMATOLOGIC AGENTS --> HEMIN                                             volume
CDMO services for FDPs segmented sterile liquid           C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER             [90-100]% by value / [90-100]% by
                                                 AUSTRIA
by its pharmaceutical form, i.e. pharmaceuticals          CARDIOVASCULAR PRD --> IBUPROFEN                                          volume
CDMO services for FDPs segmented sterile liquid           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [60-70]% by value / [50-60]% by
                                                 BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM            [90-100]% by value / [90-100]% by
                                                 BELGIUM
by its pharmaceutical form, i.e. pharmaceuticals          TOPICAL --> MERCAPTAMINE                                                  volume
CDMO services for FDPs segmented sterile liquid  CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
by its pharmaceutical form, i.e. pharmaceuticals REPUBLIC CHARCOAL!IRON METAL                                                       volume
CDMO services for FDPs segmented sterile liquid  CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [70-80]% by value / [60-70]% by
by its pharmaceutical form, i.e. pharmaceuticals REPUBLIC AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [60-70]% by value / [50-60]% by
                                                 ESTONIA
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [30-40]% by value / [10-20]% by
                                                 FINLAND
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                 [90-100]% by value / [90-100]% by
                                                 FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          HAEMATOLOGIC AGENTS --> HEMIN                                             volume
CDMO services for FDPs segmented sterile liquid           C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER             [90-100]% by value / [90-100]% by
                                                 FRANCE
by its pharmaceutical form, i.e. pharmaceuticals          CARDIOVASCULAR PRD --> IBUPROFEN                                          volume
 ---pagebreak--- CDMO services for FDPs segmented sterile liquid          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                    [40-50]% by value / [20-30]% by
                                                 FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         AGENTS,PLAIN --> METOPROLOL                                                   volume
CDMO services for FDPs segmented sterile liquid          H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES           [90-100]% by value / [90-100]% by
                                                 FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         --> PASIREOTIDE                                                               volume
CDMO services for FDPs segmented sterile liquid          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM                [90-100]% by value / [90-100]% by
                                                 FRANCE
by its pharmaceutical form, i.e. pharmaceuticals         TOPICAL --> MERCAPTAMINE                                                      volume
CDMO services for FDPs segmented sterile liquid          C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER                 [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         CARDIOVASCULAR PRD --> IBUPROFEN                                              volume
CDMO services for FDPs segmented sterile liquid          H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES           [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         --> PASIREOTIDE                                                               volume
CDMO services for FDPs segmented sterile liquid          H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --      [40-50]% by value / [10-20]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         > DEXAMETHASONE                                                               volume
CDMO services for FDPs segmented sterile liquid          K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         HEMIN                                                                         volume
CDMO services for FDPs segmented sterile liquid          M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S        [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL                             volume
CDMO services for FDPs segmented sterile liquid          M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S        [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         PLN --> PHENYLBUTAZONE                                                        volume
CDMO services for FDPs segmented sterile liquid          M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                       [70-80]% by value / [60-70]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         RELAXANTS,CENTRAL --> METHOCARBAMOL                                           volume
 ---pagebreak--- CDMO services for FDPs segmented sterile liquid          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                                 GERMANY
by its pharmaceutical form, i.e. pharmaceuticals         TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented sterile liquid          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                 HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals         HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented sterile liquid          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [50-60]% by value / [30-40]% by
                                                 HUNGARY
by its pharmaceutical form, i.e. pharmaceuticals         AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented sterile liquid          07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS -->           [70-80]% by value / [60-70]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         NAPHAZOLINE!THONZYLAMINE                                            volume
CDMO services for FDPs segmented sterile liquid          07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> [90-100]% by value / [90-100]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         HYALURONIC ACID!MALVA SYLVESTRIS                                    volume
CDMO services for FDPs segmented sterile liquid          07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> [90-100]% by value / [90-100]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         HYALURONIC ACID!SODIUM!TROMETAMOL                                   volume
                                                         07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS -->
CDMO services for FDPs segmented sterile liquid                                                                 [90-100]% by value / [90-100]% by
                                                 ITALY   EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA
by its pharmaceutical form, i.e. pharmaceuticals                                                                             volume
                                                         CHAMOMILLA!PHOSPHORIC ACID!SODIUM
CDMO services for FDPs segmented sterile liquid          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented sterile liquid          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [30-40]% by value / [20-30]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented sterile liquid          H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals         --> PASIREOTIDE                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented sterile liquid              S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-            [70-80]% by value / [60-70]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals             ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE                       volume
CDMO services for FDPs segmented sterile liquid              S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                                 ITALY
by its pharmaceutical form, i.e. pharmaceuticals             TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented sterile liquid              C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [70-80]% by value / [70-80]% by
                                                 LITHUANIA
by its pharmaceutical form, i.e. pharmaceuticals             AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented sterile liquid              C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING        [90-100]% by value / [90-100]% by
                                                 LUXEMBOURG
by its pharmaceutical form, i.e. pharmaceuticals             AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented sterile liquid              B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                 NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals             HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented sterile liquid              H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                                 NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals             --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented sterile liquid              S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                                 NETHERLANDS
by its pharmaceutical form, i.e. pharmaceuticals             TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented sterile liquid              B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                                 NORWAY
by its pharmaceutical form, i.e. pharmaceuticals             HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented sterile liquid              C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [30-40]% by value / [10-20]% by
                                                 NORWAY
by its pharmaceutical form, i.e. pharmaceuticals             AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented sterile liquid              H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                                 NORWAY
by its pharmaceutical form, i.e. pharmaceuticals             --> PASIREOTIDE                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented sterile liquid           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM            [90-100]% by value / [90-100]% by
                                                 NORWAY
by its pharmaceutical form, i.e. pharmaceuticals          TOPICAL --> MERCAPTAMINE                                                  volume
CDMO services for FDPs segmented sterile liquid           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [30-40]% by value / [20-30]% by
                                                 POLAND
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM            [90-100]% by value / [90-100]% by
                                                 PORTUGAL
by its pharmaceutical form, i.e. pharmaceuticals          TOPICAL --> MERCAPTAMINE                                                  volume
CDMO services for FDPs segmented sterile liquid           02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                                 SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals          CHARCOAL + IRON METAL                                                     volume
CDMO services for FDPs segmented sterile liquid           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [60-70]% by value / [30-40]% by
                                                 SLOVAKIA
by its pharmaceutical form, i.e. pharmaceuticals          AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented sterile liquid           B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                 [90-100]% by value / [90-100]% by
                                                 SPAIN
by its pharmaceutical form, i.e. pharmaceuticals          HAEMATOLOGIC AGENTS --> HEMIN                                             volume
CDMO services for FDPs segmented sterile liquid           B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                 [90-100]% by value / [90-100]% by
                                                 SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals          HAEMATOLOGIC AGENTS --> HEMIN                                             volume
CDMO services for FDPs segmented sterile liquid           H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES       [90-100]% by value / [90-100]% by
                                                 SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals          --> PASIREOTIDE                                                           volume
CDMO services for FDPs segmented sterile liquid           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM            [90-100]% by value / [90-100]% by
                                                 SWEDEN
by its pharmaceutical form, i.e. pharmaceuticals          TOPICAL --> MERCAPTAMINE                                                  volume
                                 medicated
CDMO services for FDPs segmented                 CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [90-100]% by value / [90-100]% by
                                 confectionary
by its pharmaceutical form, i.e.                 REPUBLIC LIDOCAINE!TRIBENOSIDE                                                     volume
                                 pharmaceuticals
 ---pagebreak---                                  medicated
CDMO services for FDPs segmented                 CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                 confectionary
by its pharmaceutical form, i.e.                 REPUBLIC LIDOCAINE!TRIBENOSIDE                                                    volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                 CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS      [90-100]% by value / [90-100]% by
                                 confectionary
by its pharmaceutical form, i.e.                 REPUBLIC ACULEATUS!SODIUM                                                         volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                 CZECH    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                 confectionary
by its pharmaceutical form, i.e.                 REPUBLIC CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          BARBADENSIS!HYALURONIC ACID                                              volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE  [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          BARBADENSIS!HYALURONIC ACID                                              volume
                                 pharmaceuticals
                                 medicated                02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC
CDMO services for FDPs segmented                                                                                      [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE   ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA
by its pharmaceutical form, i.e.                                                                                                   volume
                                 pharmaceuticals          GLABRA!HYALURONIC ACID!MENTHOL
                                 medicated
CDMO services for FDPs segmented                          02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE       [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          BARBADENSIS!HYALURONIC ACID                                              volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                          volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED          [50-60]% by value / [70-80]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                          GUM&G --> COMPOSITION UNKNOWN                                            volume
                                 pharmaceuticals
 ---pagebreak---                                  medicated
CDMO services for FDPs segmented                         A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->      [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                         CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                       volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                         A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->      [90-100]% by value / [90-100]% by
                                 confectionary   FRANCE
by its pharmaceutical form, i.e.                         CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                             volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                                                                                        [90-100]% by value / [90-100]% by
                                 confectionary   GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC
by its pharmaceutical form, i.e.                                                                                                     volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                                                                                          [50-60]% by value / [20-30]% by
                                 confectionary   GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC
by its pharmaceutical form, i.e.                                                                                                     volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING             [90-100]% by value / [90-100]% by
                                 confectionary   GERMANY
by its pharmaceutical form, i.e.                         AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC                                     volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING               [70-80]% by value / [60-70]% by
                                 confectionary   GERMANY
by its pharmaceutical form, i.e.                         AGENTS --> ZINC                                                             volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                 confectionary   ITALY
by its pharmaceutical form, i.e.                         -> FLURBIPROFEN                                                             volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                         03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC       [90-100]% by value / [90-100]% by
                                 confectionary   ITALY
by its pharmaceutical form, i.e.                         MEDICINES                                                                   volume
                                 pharmaceuticals
                                 medicated               87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH
CDMO services for FDPs segmented                                                                                        [90-100]% by value / [90-100]% by
                                 confectionary   ITALY   --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA
by its pharmaceutical form, i.e.                                                                                                     volume
                                 pharmaceuticals         PIPERITA!XYLITOL
                                 medicated
CDMO services for FDPs segmented                         M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &       [90-100]% by value / [90-100]% by
                                 confectionary   ITALY
by its pharmaceutical form, i.e.                         ANALG --> FLURBIPROFEN                                                      volume
                                 pharmaceuticals
 ---pagebreak---                                  medicated
CDMO services for FDPs segmented                           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->           [90-100]% by value / [90-100]% by
                                 confectionary   LATVIA
by its pharmaceutical form, i.e.                           LIDOCAINE!TRIBENOSIDE                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->              [90-100]% by value / [90-100]% by
                                 confectionary   LATVIA
by its pharmaceutical form, i.e.                           LIDOCAINE!TRIBENOSIDE                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O        [90-100]% by value / [90-100]% by
                                 confectionary   LATVIA
by its pharmaceutical form, i.e.                           CORTIC --> LIDOCAINE!TRIBENOSIDE                                           volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->           [90-100]% by value / [90-100]% by
                                 confectionary   LITHUANIA
by its pharmaceutical form, i.e.                           LIDOCAINE!TRIBENOSIDE                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->              [90-100]% by value / [90-100]% by
                                 confectionary   LITHUANIA
by its pharmaceutical form, i.e.                           LIDOCAINE!TRIBENOSIDE                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O        [90-100]% by value / [90-100]% by
                                 confectionary   LITHUANIA
by its pharmaceutical form, i.e.                           CORTIC --> LIDOCAINE!TRIBENOSIDE                                           volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS -->           [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL
by its pharmaceutical form, i.e.                           TIBEZONIUM                                                                 volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                                                                                          [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL  01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM
by its pharmaceutical form, i.e.                                                                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                                                                                          [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL  01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM
by its pharmaceutical form, i.e.                                                                                                      volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                           02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL
by its pharmaceutical form, i.e.                           -> FLURBIPROFEN                                                            volume
                                 pharmaceuticals
 ---pagebreak---                                  medicated
CDMO services for FDPs segmented                          A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN -->       [30-40]% by value / [10-20]% by
                                 confectionary   PORTUGAL
by its pharmaceutical form, i.e.                          COLECALCIFEROL                                                           volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &    [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL
by its pharmaceutical form, i.e.                          ANALG --> FLURBIPROFEN                                                   volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->    [90-100]% by value / [90-100]% by
                                 confectionary   PORTUGAL
by its pharmaceutical form, i.e.                          TIBEZONIUM                                                               volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                 confectionary   ROMANIA
by its pharmaceutical form, i.e.                          LIDOCAINE + TRIBENOSIDE                                                  volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE [90-100]% by value / [90-100]% by
                                 confectionary   ROMANIA
by its pharmaceutical form, i.e.                          + TRIBENOSIDE                                                            volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                 confectionary   ROMANIA
by its pharmaceutical form, i.e.                          CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                 confectionary   SLOVAKIA
by its pharmaceutical form, i.e.                          LIDOCAINE!TRIBENOSIDE                                                    volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                 confectionary   SLOVAKIA
by its pharmaceutical form, i.e.                          LIDOCAINE!TRIBENOSIDE                                                    volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS      [90-100]% by value / [90-100]% by
                                 confectionary   SLOVAKIA
by its pharmaceutical form, i.e.                          ACULEATUS!SODIUM                                                         volume
                                 pharmaceuticals
                                 medicated
CDMO services for FDPs segmented                          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                 confectionary   SLOVAKIA
by its pharmaceutical form, i.e.                          CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
                                 pharmaceuticals
 ---pagebreak--- CDMO services for FDPs segmented                        H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &       [90-100]% by value / [90-100]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  SIMILAR --> OSILODROSTAT                                                  volume
CDMO services for FDPs segmented                        J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR      [10-20]% by value / [80-90]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  TYPE --> ERYTHROMYCIN                                                     volume
CDMO services for FDPs segmented                        R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC     [90-100]% by value / [90-100]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  ACID!BENZOIC ACID!BROMINE!CODEINE                                         volume
CDMO services for FDPs segmented                        R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC     [90-100]% by value / [90-100]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  ACID!BROMOFORM!CODEINE                                                    volume
CDMO services for FDPs segmented                        R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB -->              [90-100]% by value / [90-100]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL                                    volume
CDMO services for FDPs segmented                        S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> [90-100]% by value / [90-100]% by
                                       toxicity FRANCE
by the conditions of manufacture, i.e.                  RIFAMYCIN                                                                 volume
CDMO services for FDPs segmented                        H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &       [90-100]% by value / [90-100]% by
                                       toxicity GERMANY
by the conditions of manufacture, i.e.                  SIMILAR --> OSILODROSTAT                                                  volume
CDMO services for FDPs segmented                        L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.           [90-100]% by value / [90-100]% by
                                       toxicity GERMANY
by the conditions of manufacture, i.e.                  ANTIBIOTICS --> DACTINOMYCIN                                              volume
CDMO services for FDPs segmented                        J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --   [90-100]% by value / [90-100]% by
                                       toxicity ITALY
by the conditions of manufacture, i.e.                  > CEFTIBUTEN                                                              volume
CDMO services for FDPs segmented                        J1D CEPHALOSPORINS & COMBS --> J1D2                          [90-100]% by value / [90-100]% by
                                       toxicity ITALY
by the conditions of manufacture, i.e.                  CEPHALOSPORINS,PARENT. --> CEFODIZIME                                     volume
 ---pagebreak--- CDMO services for FDPs segmented                                    L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.     [90-100]% by value / [90-100]% by
                                       toxicity            ITALY
by the conditions of manufacture, i.e.                              ANTIBIOTICS --> DACTINOMYCIN                                        volume
CDMO services for FDPs segmented                                    B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment AUSTRIA
by the conditions of manufacture, i.e.                              HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                    C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER       [90-100]% by value / [90-100]% by
                                       sterile environment AUSTRIA
by the conditions of manufacture, i.e.                              CARDIOVASCULAR PRD --> IBUPROFEN                                    volume
CDMO services for FDPs segmented                                    S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment BELGIUM
by the conditions of manufacture, i.e.                              TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                           CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [70-80]% by value / [60-70]% by
                                       sterile environment
by the conditions of manufacture, i.e.                     REPUBLIC AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented                                    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [60-70]% by value / [50-60]% by
                                       sterile environment ESTONIA
by the conditions of manufacture, i.e.                              AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented                                    B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment FRANCE
by the conditions of manufacture, i.e.                              HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                    C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER       [90-100]% by value / [90-100]% by
                                       sterile environment FRANCE
by the conditions of manufacture, i.e.                              CARDIOVASCULAR PRD --> IBUPROFEN                                    volume
CDMO services for FDPs segmented                                    H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                       sterile environment FRANCE
by the conditions of manufacture, i.e.                              --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented                                    S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment FRANCE
by the conditions of manufacture, i.e.                              TOPICAL --> MERCAPTAMINE                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                                   C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER                 [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             CARDIOVASCULAR PRD --> IBUPROFEN                                              volume
CDMO services for FDPs segmented                                   H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES           [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             --> PASIREOTIDE                                                               volume
CDMO services for FDPs segmented                                   H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --      [40-50]% by value / [10-20]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             > DEXAMETHASONE                                                               volume
CDMO services for FDPs segmented                                   K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             HEMIN                                                                         volume
CDMO services for FDPs segmented                                   M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S        [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL                             volume
CDMO services for FDPs segmented                                   M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S        [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             PLN --> PHENYLBUTAZONE                                                        volume
CDMO services for FDPs segmented                                   M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                       [70-80]% by value / [60-70]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             RELAXANTS,CENTRAL --> METHOCARBAMOL                                           volume
CDMO services for FDPs segmented                                   S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM                [90-100]% by value / [90-100]% by
                                       sterile environment GERMANY
by the conditions of manufacture, i.e.                             TOPICAL --> MERCAPTAMINE                                                      volume
CDMO services for FDPs segmented                                   B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                     [90-100]% by value / [90-100]% by
                                       sterile environment HUNGARY
by the conditions of manufacture, i.e.                             HAEMATOLOGIC AGENTS --> HEMIN                                                 volume
CDMO services for FDPs segmented                                   C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                    [50-60]% by value / [30-40]% by
                                       sterile environment HUNGARY
by the conditions of manufacture, i.e.                             AGENTS,PLAIN --> METOPROLOL                                                   volume
 ---pagebreak--- CDMO services for FDPs segmented                                       07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS -->           [70-80]% by value / [60-70]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 NAPHAZOLINE!THONZYLAMINE                                            volume
CDMO services for FDPs segmented                                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                       C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC [90-100]% by value / [90-100]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 PREPS --> ALPROSTADIL ALFADEX                                       volume
CDMO services for FDPs segmented                                       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented                                       J1D CEPHALOSPORINS & COMBS --> J1D2                    [90-100]% by value / [90-100]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 CEPHALOSPORINS,PARENT. --> CEFODIZIME                               volume
CDMO services for FDPs segmented                                       S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-            [70-80]% by value / [60-70]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE                       volume
CDMO services for FDPs segmented                                       S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment ITALY
by the conditions of manufacture, i.e.                                 TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                                       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [70-80]% by value / [70-80]% by
                                       sterile environment LITHUANIA
by the conditions of manufacture, i.e.                                 AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented                                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment NETHERLANDS
by the conditions of manufacture, i.e.                                 HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                       sterile environment NETHERLANDS
by the conditions of manufacture, i.e.                                 --> PASIREOTIDE                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented                                       S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment NETHERLANDS
by the conditions of manufacture, i.e.                                 TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment NORWAY
by the conditions of manufacture, i.e.                                 HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                       sterile environment NORWAY
by the conditions of manufacture, i.e.                                 --> PASIREOTIDE                                                     volume
CDMO services for FDPs segmented                                       S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment NORWAY
by the conditions of manufacture, i.e.                                 TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                                       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [30-40]% by value / [20-30]% by
                                       sterile environment POLAND
by the conditions of manufacture, i.e.                                 AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented                                       S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM      [90-100]% by value / [90-100]% by
                                       sterile environment PORTUGAL
by the conditions of manufacture, i.e.                                 TOPICAL --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                                       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING          [60-70]% by value / [30-40]% by
                                       sterile environment SLOVAKIA
by the conditions of manufacture, i.e.                                 AGENTS,PLAIN --> METOPROLOL                                         volume
CDMO services for FDPs segmented                                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment SPAIN
by the conditions of manufacture, i.e.                                 HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH           [90-100]% by value / [90-100]% by
                                       sterile environment SWEDEN
by the conditions of manufacture, i.e.                                 HAEMATOLOGIC AGENTS --> HEMIN                                       volume
CDMO services for FDPs segmented                                       H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES [90-100]% by value / [90-100]% by
                                       sterile environment SWEDEN
by the conditions of manufacture, i.e.                                 --> PASIREOTIDE                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented                                    S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
                                       sterile environment SWEDEN
by the conditions of manufacture, i.e.                              TOPICAL --> MERCAPTAMINE                                               volume
                                       nature of the
CDMO services for FDPs segmented       technology/know-             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH              [90-100]% by value / [90-100]% by
                                                           AUSTRIA
by the conditions of manufacture, i.e. how needed to                HAEMATOLOGIC AGENTS --> HEMIN                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                           BELGIUM
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                            volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                                           BELGIUM
by the conditions of manufacture, i.e. how needed to                COMB --> FELODIPINE!METOPROLOL                                         volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
                                                           BELGIUM
by the conditions of manufacture, i.e. how needed to                TOPICAL --> MERCAPTAMINE                                               volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                           BULGARIA
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                            volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG            [90-100]% by value / [90-100]% by
                                                           BULGARIA
by the conditions of manufacture, i.e. how needed to                ANTIFUNGALS --> FENTICONAZOLE                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-    CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [70-80]% by value / [60-70]% by
by the conditions of manufacture, i.e. how needed to       REPUBLIC AGENTS,PLAIN --> METOPROLOL                                            volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-    CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG            [90-100]% by value / [90-100]% by
by the conditions of manufacture, i.e. how needed to       REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                           ESTONIA
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                            volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [10-20]% by
                                                        FINLAND
by the conditions of manufacture, i.e. how needed to            AGENTS,PLAIN --> METOPROLOL                                              volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                        FINLAND
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        FRANCE
by the conditions of manufacture, i.e. how needed to            HAEMATOLOGIC AGENTS --> HEMIN                                            volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                                                        FRANCE
by the conditions of manufacture, i.e. how needed to            AGENTS,PLAIN --> METOPROLOL                                              volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                        FRANCE
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                        FRANCE
by the conditions of manufacture, i.e. how needed to            TOPICAL --> MERCAPTAMINE                                                 volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS -->   [90-100]% by value / [90-100]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            LIDOCAINE!PRILOCAINE                                                     volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR    [60-70]% by value / [50-60]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE     [30-40]% by value / [0-5]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            PRD --> OXYBUTYNIN                                                       volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            PRODS --> LIDOCAINE!PRILOCAINE                                           volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-         L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.         [90-100]% by value / [90-100]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            ANTIBIOTICS --> DACTINOMYCIN                                            volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                        GERMANY
by the conditions of manufacture, i.e. how needed to            TOPICAL --> MERCAPTAMINE                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                        GREECE
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                        GREECE
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                        GREECE
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                        GREECE
by the conditions of manufacture, i.e. how needed to            ANTIFUNG --> FENTICONAZOLE                                              volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                        GREECE
by the conditions of manufacture, i.e. how needed to            ANTIFUNGALS --> FENTICONAZOLE                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        HUNGARY
by the conditions of manufacture, i.e. how needed to            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [50-60]% by value / [30-40]% by
                                                        HUNGARY
by the conditions of manufacture, i.e. how needed to            AGENTS,PLAIN --> METOPROLOL                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                        HUNGARY
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                          volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [90-100]% by value / [90-100]% by
                                                        HUNGARY
by the conditions of manufacture, i.e. how needed to            ANTIFUNGALS --> FENTICONAZOLE                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE        [30-40]% by value / [5-10]% by
                                                        IRELAND
by the conditions of manufacture, i.e. how needed to            PRD --> OXYBUTYNIN                                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            -> FLURBIPROFEN                                                              volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->      [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->       [80-90]% by value / [80-90]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->         [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                       [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            OINTMENTS/CREAMS --> FENTICONAZOLE                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->       [50-60]% by value / [60-70]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->       [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            FENTICONAZOLE                                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                   [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to            HAEMATOLOGIC AGENTS --> HEMIN                                                volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                 [30-40]% by value / [20-30]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           AGENTS,PLAIN --> METOPROLOL                                                  volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT          [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           ANTIFUNG --> FENTICONAZOLE                                                   volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [60-70]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           ANTIFUNGALS --> FENTICONAZOLE                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL      [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           PRODS --> LIDOCAINE!PRILOCAINE                                               volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.            [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           ANTIBIOTICS --> DACTINOMYCIN                                                 volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &      [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           ANALG --> FLURBIPROFEN                                                       volume
                                       produce the FDP
                                       nature of the
                                                                                                                               [60-70]% by value / [60-70]% by
CDMO services for FDPs segmented       technology/know-        R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF -->
                                                        ITALY                                                                  volume (CVC share [70-80]% by
by the conditions of manufacture, i.e. how needed to           BUDESONIDE
                                                                                                                                 value / [70-80]% by volume)
                                       produce the FDP
                                       nature of the
                                                                                                                               [60-70]% by value / [50-60]% by
CDMO services for FDPs segmented       technology/know-
                                                        ITALY  R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE     volume (CVC share [60-70]% by
by the conditions of manufacture, i.e. how needed to
                                                                                                                                 value / [60-70]% by volume)
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM             [90-100]% by value / [90-100]% by
                                                        ITALY
by the conditions of manufacture, i.e. how needed to           TOPICAL --> MERCAPTAMINE                                                     volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                 [40-50]% by value / [20-30]% by
                                                        LATVIA
by the conditions of manufacture, i.e. how needed to           AGENTS,PLAIN --> METOPROLOL                                                  volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [70-80]% by value / [70-80]% by
                                                        LITHUANIA
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                        LITHUANIA
by the conditions of manufacture, i.e. how needed to                ANTIFUNGALS --> FENTICONAZOLE                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING            [90-100]% by value / [90-100]% by
                                                        LUXEMBOURG
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        NETHERLANDS
by the conditions of manufacture, i.e. how needed to                HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                        NETHERLANDS
by the conditions of manufacture, i.e. how needed to                TOPICAL --> MERCAPTAMINE                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        NORWAY
by the conditions of manufacture, i.e. how needed to                HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [10-20]% by
                                                        NORWAY
by the conditions of manufacture, i.e. how needed to                AGENTS,PLAIN --> METOPROLOL                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                        NORWAY
by the conditions of manufacture, i.e. how needed to                TOPICAL --> MERCAPTAMINE                                                volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                                                        POLAND
by the conditions of manufacture, i.e. how needed to                OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-             12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> [90-100]% by value / [90-100]% by
                                                        POLAND
by the conditions of manufacture, i.e. how needed to                FENTICONAZOLE                                                           volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                  [30-40]% by value / [20-30]% by
                                                        POLAND
by the conditions of manufacture, i.e. how needed to             AGENTS,PLAIN --> METOPROLOL                                                 volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [90-100]% by value / [90-100]% by
                                                        POLAND
by the conditions of manufacture, i.e. how needed to             ANTIFUNGALS --> FENTICONAZOLE                                               volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the conditions of manufacture, i.e. how needed to             -> FLURBIPROFEN                                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD       [50-60]% by value / [50-60]% by
                                                        PORTUGAL
by the conditions of manufacture, i.e. how needed to             OTH --> ALPROSTADIL                                                         volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &       [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the conditions of manufacture, i.e. how needed to             ANALG --> FLURBIPROFEN                                                      volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM              [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the conditions of manufacture, i.e. how needed to             TOPICAL --> MERCAPTAMINE                                                    volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->     [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the conditions of manufacture, i.e. how needed to             FENTICONAZOLE                                                               volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT           [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the conditions of manufacture, i.e. how needed to             ANTIFUNG --> FENTICONAZOLE                                                  volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the conditions of manufacture, i.e. how needed to             ANTIFUNGALS --> FENTICONAZOLE                                               volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                  [60-70]% by value / [30-40]% by
                                                        SLOVAKIA
by the conditions of manufacture, i.e. how needed to             AGENTS,PLAIN --> METOPROLOL                                                 volume
                                       produce the FDP
 ---pagebreak---                                        nature of the
CDMO services for FDPs segmented       technology/know-         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        SPAIN
by the conditions of manufacture, i.e. how needed to            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [80-90]% by value / [80-90]% by
                                                        SPAIN
by the conditions of manufacture, i.e. how needed to            AGENTS,PLAIN --> METOPROLOL                                             volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                        SPAIN
by the conditions of manufacture, i.e. how needed to            COMB --> FELODIPINE!METOPROLOL                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [40-50]% by value / [50-60]% by
                                                        SPAIN
by the conditions of manufacture, i.e. how needed to            OTH --> ALPROSTADIL                                                     volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                        SPAIN
by the conditions of manufacture, i.e. how needed to            PRODS --> LIDOCAINE!PRILOCAINE                                          volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                                        SWEDEN
by the conditions of manufacture, i.e. how needed to            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
                                       produce the FDP
                                       nature of the
CDMO services for FDPs segmented       technology/know-         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                        SWEDEN
by the conditions of manufacture, i.e. how needed to            TOPICAL --> MERCAPTAMINE                                                volume
                                       produce the FDP
CDMO services for FDPs segmented       chemically-              A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                        AUSTRIA
by the type of API used, i.e.          synthesized APIs         TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented       chemically-              A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                        AUSTRIA
by the type of API used, i.e.          synthesized APIs         PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented       chemically-              A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                        AUSTRIA
by the type of API used, i.e.          synthesized APIs         PRODUCTS --> CARGLUMIC ACID                                             volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  AUSTRIA
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented chemically-               C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER          [90-100]% by value / [90-100]% by
                                                  AUSTRIA
by the type of API used, i.e.    synthesized APIs          CARDIOVASCULAR PRD --> IBUPROFEN                                       volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [10-20]% by value / [60-70]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented chemically-               C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          COMB --> FELODIPINE!METOPROLOL                                         volume
CDMO services for FDPs segmented chemically-               S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
                                                  BELGIUM
by the type of API used, i.e.    synthesized APIs          TOPICAL --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                                  BULGARIA
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented chemically-               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG            [90-100]% by value / [90-100]% by
                                                  BULGARIA
by the type of API used, i.e.    synthesized APIs          ANTIFUNGALS --> FENTICONAZOLE                                          volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-      CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->          [60-70]% by value / [60-70]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented chemically-      CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->          [70-80]% by value / [80-90]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                                 volume
CDMO services for FDPs segmented chemically-      CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->        [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                       volume
CDMO services for FDPs segmented chemically-      CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented chemically-      CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC CHARCOAL!IRON METAL                                                       volume
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented chemically-      CZECH    CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONIN       [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC E!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VIT               volume
                                                           AMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented chemically-      CZECH                                                                 [90-100]% by value / [90-100]% by
                                                           CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the type of API used, i.e.    synthesized APIs REPUBLIC                                                                           volume
                                                           PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented chemically-      CZECH                                                                 [90-100]% by value / [90-100]% by
                                                           CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the type of API used, i.e.    synthesized APIs REPUBLIC                                                                           volume
                                                           PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
CDMO services for FDPs segmented chemically-      CZECH    07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->       [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ASCORBIC ACID!XANTOFYL!ZEAXANTHIN                                         volume
CDMO services for FDPs segmented chemically-      CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                   volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-      CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                  volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented chemically-      CZECH                                                               [90-100]% by value / [90-100]% by
                                                           ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by the type of API used, i.e.    synthesized APIs REPUBLIC                                                                         volume
                                                           E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented chemically-      CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                volume
CDMO services for FDPs segmented chemically-      CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-      CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-      CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS     [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ACULEATUS!SODIUM                                                        volume
CDMO services for FDPs segmented chemically-      CZECH    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented chemically-      CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [70-80]% by value / [60-70]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented chemically-      CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented chemically-      CZECH    G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC PRD --> PROPIVERINE                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-      CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC             [60-70]% by value / [60-70]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ANALGESICS --> ACETYLSALICYLIC ACID                                      volume
CDMO services for FDPs segmented chemically-      CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC           [90-100]% by value / [90-100]% by
by the type of API used, i.e.    synthesized APIs REPUBLIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                       volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [60-70]% by value / [50-60]% by
                                                  ESTONIA
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [10-20]% by
                                                  FINLAND
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented chemically-               C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR   [90-100]% by value / [90-100]% by
                                                  FINLAND
by the type of API used, i.e.    synthesized APIs          COMB --> FELODIPINE!METOPROLOL                                           volume
CDMO services for FDPs segmented chemically-               01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT -->         [20-30]% by value / [30-40]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs          ACETYLCYSTEINE                                                           volume
CDMO services for FDPs segmented chemically-               01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS -->              [30-40]% by value / [40-50]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs          ACETYLCYSTEINE                                                           volume
                                                           01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS -->
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  FRANCE   CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                           USITATISSIMUM!PROPOLIS
CDMO services for FDPs segmented chemically-               01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->     [80-90]% by value / [80-90]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs          SODIUM                                                                   volume
CDMO services for FDPs segmented chemically-               02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs          BARBADENSIS!HYALURONIC ACID                                              volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-             02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE  [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        BARBADENSIS!HYALURONIC ACID                                              volume
                                                         02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC
CDMO services for FDPs segmented chemically-                                                                         [90-100]% by value / [90-100]% by
                                                  FRANCE ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA
by the type of API used, i.e.    synthesized APIs                                                                                 volume
                                                         GLABRA!HYALURONIC ACID!MENTHOL
CDMO services for FDPs segmented chemically-             02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE       [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        BARBADENSIS!HYALURONIC ACID                                              volume
CDMO services for FDPs segmented chemically-             09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
CDMO services for FDPs segmented chemically-             09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                          volume
CDMO services for FDPs segmented chemically-             87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED          [50-60]% by value / [70-80]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        GUM&G --> COMPOSITION UNKNOWN                                            volume
CDMO services for FDPs segmented chemically-             A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->           [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        TOCOFERSOLAN                                                             volume
CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC       [50-60]% by value / [50-60]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> CARGLUMIC ACID                                              volume
CDMO services for FDPs segmented chemically-             A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->   [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-             A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->  [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                         volume
CDMO services for FDPs segmented chemically-             A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W       [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        ELECTRO --> MACROGOL(S)                                                 volume
CDMO services for FDPs segmented chemically-             A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR -->  [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        MACROGOL(S)!POTASSIUM!SODIUM                                            volume
CDMO services for FDPs segmented chemically-             C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER           [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        CARDIOVASCULAR PRD --> IBUPROFEN                                        volume
CDMO services for FDPs segmented chemically-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented chemically-             C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented chemically-             G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL -->   [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        METRONIDAZOLE!NEOMYCIN!NYSTATIN                                         volume
CDMO services for FDPs segmented chemically-             G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented chemically-             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented chemically-             H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &     [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs        SIMILAR --> OSILODROSTAT                                                volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-              J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR        [10-20]% by value / [80-90]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         TYPE --> ERYTHROMYCIN                                                       volume
CDMO services for FDPs segmented chemically-              L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->           [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         CHLORMETHINE                                                                volume
CDMO services for FDPs segmented chemically-                                                                               [30-40]% by value / [30-40]% by
                                                  FRANCE  R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE
by the type of API used, i.e.    synthesized APIs                                                                                     volume
CDMO services for FDPs segmented chemically-              R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC       [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         ACID!BENZOIC ACID!BROMINE!CODEINE                                           volume
CDMO services for FDPs segmented chemically-              R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC       [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         ACID!BROMOFORM!CODEINE                                                      volume
CDMO services for FDPs segmented chemically-              R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB -->                [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL                                      volume
CDMO services for FDPs segmented chemically-              S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM              [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         TOPICAL --> MERCAPTAMINE                                                    volume
CDMO services for FDPs segmented chemically-              S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->   [90-100]% by value / [90-100]% by
                                                  FRANCE
by the type of API used, i.e.    synthesized APIs         RIFAMYCIN                                                                   volume
CDMO services for FDPs segmented chemically-                                                                             [90-100]% by value / [90-100]% by
                                                  FRANCE  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                     volume
CDMO services for FDPs segmented chemically-              02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-   [60-70]% by value / [50-60]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PROPANOL                                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-              02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-        [40-50]% by value / [40-50]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PROPANOL                                                                    volume
CDMO services for FDPs segmented chemically-              04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         CALCIUM!MAGNESIUM!POTASSIUM                                                 volume
CDMO services for FDPs segmented chemically-                                                                             [90-100]% by value / [90-100]% by
                                                  GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                     volume
CDMO services for FDPs segmented chemically-                                                                               [50-60]% by value / [20-30]% by
                                                  GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                     volume
CDMO services for FDPs segmented chemically-              06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         SALICYLIC ACID                                                              volume
CDMO services for FDPs segmented chemically-              12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS -->       [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         LIDOCAINE!PRILOCAINE                                                        volume
CDMO services for FDPs segmented chemically-              18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS -->         [70-80]% by value / [20-30]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         MENTHA ARVENSIS                                                             volume
CDMO services for FDPs segmented chemically-              A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->              [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         TOCOFERSOLAN                                                                volume
CDMO services for FDPs segmented chemically-              A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PRODUCTS --> BETAINE                                                        volume
CDMO services for FDPs segmented chemically-              A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PRODUCTS --> CARGLUMIC ACID                                                 volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-              A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [5-10]% by value / [30-40]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PRODUCTS --> MERCAPTAMINE                                                   volume
CDMO services for FDPs segmented chemically-              C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER              [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         CARDIOVASCULAR PRD --> IBUPROFEN                                            volume
CDMO services for FDPs segmented chemically-              C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR       [60-70]% by value / [50-60]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         COMB --> FELODIPINE!METOPROLOL                                              volume
CDMO services for FDPs segmented chemically-              D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING            [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC                                     volume
CDMO services for FDPs segmented chemically-              D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING              [70-80]% by value / [60-70]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         AGENTS --> ZINC                                                             volume
CDMO services for FDPs segmented chemically-              G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE        [30-40]% by value / [0-5]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PRD --> OXYBUTYNIN                                                          volume
CDMO services for FDPs segmented chemically-              G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL      [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PRODS --> LIDOCAINE!PRILOCAINE                                              volume
CDMO services for FDPs segmented chemically-              H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES        [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         --> PASIREOTIDE                                                             volume
CDMO services for FDPs segmented chemically-              H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --   [40-50]% by value / [10-20]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         > DEXAMETHASONE                                                             volume
CDMO services for FDPs segmented chemically-              H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &        [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         SIMILAR --> OSILODROSTAT                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-              L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->      [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         CHLORMETHINE                                                           volume
CDMO services for FDPs segmented chemically-              M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL                      volume
CDMO services for FDPs segmented chemically-              M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PLN --> PHENYLBUTAZONE                                                 volume
CDMO services for FDPs segmented chemically-              M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &    [50-60]% by value / [50-60]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         ANALG --> 2-PROPANOL                                                   volume
CDMO services for FDPs segmented chemically-              M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                [70-80]% by value / [60-70]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         RELAXANTS,CENTRAL --> METHOCARBAMOL                                    volume
CDMO services for FDPs segmented chemically-              N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->     [60-70]% by value / [60-70]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         CARIPRAZINE                                                            volume
CDMO services for FDPs segmented chemically-              S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         TOPICAL --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented chemically-                                                                         [60-70]% by value / [90-100]% by
                                                  GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                volume
CDMO services for FDPs segmented chemically-              V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL            [90-100]% by value / [90-100]% by
                                                  GERMANY
by the type of API used, i.e.    synthesized APIs         PREPARATIONS --> MENTHA ARVENSIS                                       volume
CDMO services for FDPs segmented chemically-              06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> [90-100]% by value / [90-100]% by
                                                  GREECE
by the type of API used, i.e.    synthesized APIs         FENTICONAZOLE                                                          volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-              06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                  GREECE
by the type of API used, i.e.    synthesized APIs         FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented chemically-              C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  GREECE
by the type of API used, i.e.    synthesized APIs         COMB --> FELODIPINE!METOPROLOL                                           volume
CDMO services for FDPs segmented chemically-              D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                  GREECE
by the type of API used, i.e.    synthesized APIs         ANTIFUNG --> FENTICONAZOLE                                               volume
CDMO services for FDPs segmented chemically-              G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                  GREECE
by the type of API used, i.e.    synthesized APIs         ANTIFUNGALS --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented chemically-              C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [50-60]% by value / [30-40]% by
                                                  HUNGARY
by the type of API used, i.e.    synthesized APIs         AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented chemically-              C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  HUNGARY
by the type of API used, i.e.    synthesized APIs         COMB --> FELODIPINE!METOPROLOL                                           volume
CDMO services for FDPs segmented chemically-              G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                  HUNGARY
by the type of API used, i.e.    synthesized APIs         ANTIFUNGALS --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented chemically-              G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  IRELAND
by the type of API used, i.e.    synthesized APIs         PRD --> FLAVOXATE                                                        volume
CDMO services for FDPs segmented chemically-              G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE    [30-40]% by value / [5-10]% by
                                                  IRELAND
by the type of API used, i.e.    synthesized APIs         PRD --> OXYBUTYNIN                                                       volume
CDMO services for FDPs segmented chemically-              01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs         ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER                         volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-            02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE     [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS                      volume
                                                        02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                        COMMUNIS
CDMO services for FDPs segmented chemically-            02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE          [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       BARBADENSIS!BENZETHONIUM CHLORIDE                                           volume
CDMO services for FDPs segmented chemically-            02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE          [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       BARBADENSIS!ENOXOLONE!HYALURONIC ACID                                       volume
                                                        02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                        COMMUNIS
CDMO services for FDPs segmented chemically-            02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       -> FLURBIPROFEN                                                             volume
CDMO services for FDPs segmented chemically-            02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) -->   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DICLOFENAC                                                                  volume
CDMO services for FDPs segmented chemically-            02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS -->      [40-50]% by value / [40-50]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       NAPROXEN                                                                    volume
                                                        02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  ITALY ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                        SULFONE!GLUCOSAMINE
                                                        02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  ITALY ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                        SULFONE!GLUCOSAMINE
 ---pagebreak--- CDMO services for FDPs segmented chemically-            03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS -->        [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DIMETICONE!LOPERAMIDE                                                  volume
CDMO services for FDPs segmented chemically-            03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC  [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       MEDICINES                                                              volume
CDMO services for FDPs segmented chemically-            04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS -->      [50-60]% by value / [70-80]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DIMETHYL SULFONE                                                       volume
CDMO services for FDPs segmented chemically-            04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS -->      [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DIMETHYL SULFONE                                                       volume
                                                        04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO
CDMO services for FDPs segmented chemically-                                                                      [90-100]% by value / [90-100]% by
                                                  ITALY OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN
by the type of API used, i.e.    synthesized APIs                                                                              volume
                                                        E
CDMO services for FDPs segmented chemically-            04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E                           volume
CDMO services for FDPs segmented chemically-            04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [50-60]% by value / [50-60]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ARGININE                                                               volume
CDMO services for FDPs segmented chemically-            04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE                           volume
CDMO services for FDPs segmented chemically-            04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [50-60]% by value / [60-70]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       LYSINE                                                                 volume
CDMO services for FDPs segmented chemically-            04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS -->      [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       INOSITOL                                                               volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-                                   06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS -->      [90-100]% by value / [90-100]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER                              volume
CDMO services for FDPs segmented chemically-      At least EEA                 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->   [90-100]% by value / [90-100]% by
                                                               <[10-20]% ITALY
by the type of API used, i.e.    synthesized APIs      wide                    FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented chemically-                                   06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->    [80-90]% by value / [80-90]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented chemically-                                   06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->      [90-100]% by value / [90-100]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented chemically-                                   07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS -->                [70-80]% by value / [60-70]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              NAPHAZOLINE!THONZYLAMINE                                                 volume
CDMO services for FDPs segmented chemically-                                   07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
CDMO services for FDPs segmented chemically-                                   07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              HYALURONIC ACID!SODIUM!TROMETAMOL                                        volume
                                                                               07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS -->
CDMO services for FDPs segmented chemically-                                                                                               [90-100]% by value / [90-100]% by
                                                                         ITALY EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA
by the type of API used, i.e.    synthesized APIs                                                                                                       volume
                                                                               CHAMOMILLA!PHOSPHORIC ACID!SODIUM
                                                                               09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->
CDMO services for FDPs segmented chemically-                                                                                               [90-100]% by value / [90-100]% by
                                                                         ITALY CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA
by the type of API used, i.e.    synthesized APIs                                                                                                       volume
                                                                               PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL
CDMO services for FDPs segmented chemically-                                   09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->   [60-70]% by value / [80-90]% by
                                                                         ITALY
by the type of API used, i.e.    synthesized APIs                              COMPOSITION UNKNOWN                                                      volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-            10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       FLUOCINOLONE ACETONIDE!KETOCAINE                                        volume
CDMO services for FDPs segmented chemically-            10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       FLUOCINOLONE ACETONIDE!KETOCAINE                                        volume
CDMO services for FDPs segmented chemically-            12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
CDMO services for FDPs segmented chemically-            12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->   [50-60]% by value / [60-70]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented chemically-            12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented chemically-                                                                         [50-60]% by value / [50-60]% by
                                                  ITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS
by the type of API used, i.e.    synthesized APIs                                                                               volume
                                                        87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH
CDMO services for FDPs segmented chemically-                                                                       [90-100]% by value / [90-100]% by
                                                  ITALY --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA
by the type of API used, i.e.    synthesized APIs                                                                               volume
                                                        PIPERITA!XYLITOL
CDMO services for FDPs segmented chemically-            A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented chemically-            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented chemically-            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [80-90]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       PRODUCTS --> CARGLUMIC ACID                                             volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC          [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       PRODUCTS --> MERCAPTAMINE                                                     volume
CDMO services for FDPs segmented chemically-            A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->               [60-70]% by value / [60-70]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DOMPERIDONE                                                                   volume
CDMO services for FDPs segmented chemically-            A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST           [20-30]% by value / [30-40]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       CORTICOSTER PROD --> BUDESONIDE                                               volume
CDMO services for FDPs segmented chemically-            A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM         [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       BOWEL DIS PRD OTH --> CROMOGLICIC ACID                                        volume
CDMO services for FDPs segmented chemically-            A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS -->         [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       DIMETICONE!LOPERAMIDE                                                         volume
CDMO services for FDPs segmented chemically-            B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. - [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       -> ARGATROBAN                                                                 volume
CDMO services for FDPs segmented chemically-            C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA           [70-80]% by value / [70-80]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       RED) --> LOVASTATIN                                                           volume
CDMO services for FDPs segmented chemically-            C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC           [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       PREPS --> ALPROSTADIL ALFADEX                                                 volume
CDMO services for FDPs segmented chemically-            C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB             [40-50]% by value / [50-60]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ACTIV --> CINNARIZINE                                                         volume
                                                        C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
CDMO services for FDPs segmented chemically-                                                                             [90-100]% by value / [90-100]% by
                                                  ITALY HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE
by the type of API used, i.e.    synthesized APIs                                                                                     volume
                                                        ACETONIDE!KETOCAINE
 ---pagebreak--- CDMO services for FDPs segmented chemically-            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [20-30]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       AGENTS,PLAIN --> BISOPROLOL                                             volume
CDMO services for FDPs segmented chemically-            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [20-30]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented chemically-            D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented chemically-            G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [60-70]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented chemically-            G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       PRODS --> LIDOCAINE!PRILOCAINE                                          volume
CDMO services for FDPs segmented chemically-            H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented chemically-            J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL -- [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       > CEFTIBUTEN                                                            volume
CDMO services for FDPs segmented chemically-            J1D CEPHALOSPORINS & COMBS --> J1D2                        [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       CEPHALOSPORINS,PARENT. --> CEFODIZIME                                   volume
CDMO services for FDPs segmented chemically-            L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->       [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       CHLORMETHINE                                                            volume
CDMO services for FDPs segmented chemically-            M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &   [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ANALG --> FLURBIPROFEN                                                  volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-            M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &          [50-60]% by value / [40-50]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ANALG --> NAPROXEN                                                             volume
CDMO services for FDPs segmented chemically-            N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->         [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       CARIPRAZINE                                                                    volume
                                                                                                                          [60-70]% by value / [60-70]% by
CDMO services for FDPs segmented chemically-            R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF -->
                                                  ITALY                                                                  volume (CVC share [70-80]% by
by the type of API used, i.e.    synthesized APIs       BUDESONIDE
                                                                                                                            value / [70-80]% by volume)
                                                                                                                          [60-70]% by value / [50-60]% by
CDMO services for FDPs segmented chemically-
                                                  ITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE      volume (CVC share [60-70]% by
by the type of API used, i.e.    synthesized APIs
                                                                                                                            value / [60-70]% by volume)
CDMO services for FDPs segmented chemically-            R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES               [30-40]% by value / [30-40]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       SYSTEMIC --> RUPATADINE                                                        volume
CDMO services for FDPs segmented chemically-            S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-                     [70-80]% by value / [60-70]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE                                  volume
CDMO services for FDPs segmented chemically-            S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM               [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       TOPICAL --> MERCAPTAMINE                                                       volume
CDMO services for FDPs segmented chemically-            S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->    [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       CIPROFLOXACIN                                                                  volume
CDMO services for FDPs segmented chemically-            S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR -- [90-100]% by value / [90-100]% by
                                                  ITALY
by the type of API used, i.e.    synthesized APIs       > CIPROFLOXACIN!FLUOCINOLONE ACETONIDE                                         volume
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  ITALY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                      volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-                 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->    [90-100]% by value / [90-100]% by
                                                  LATVIA
by the type of API used, i.e.    synthesized APIs            LIDOCAINE!TRIBENOSIDE                                                volume
CDMO services for FDPs segmented chemically-                 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->       [90-100]% by value / [90-100]% by
                                                  LATVIA
by the type of API used, i.e.    synthesized APIs            LIDOCAINE!TRIBENOSIDE                                                volume
CDMO services for FDPs segmented chemically-                 C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O [90-100]% by value / [90-100]% by
                                                  LATVIA
by the type of API used, i.e.    synthesized APIs            CORTIC --> LIDOCAINE!TRIBENOSIDE                                     volume
CDMO services for FDPs segmented chemically-                 C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [40-50]% by value / [20-30]% by
                                                  LATVIA
by the type of API used, i.e.    synthesized APIs            AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented chemically-                 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->    [90-100]% by value / [90-100]% by
                                                  LITHUANIA
by the type of API used, i.e.    synthesized APIs            LIDOCAINE!TRIBENOSIDE                                                volume
CDMO services for FDPs segmented chemically-                 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->       [90-100]% by value / [90-100]% by
                                                  LITHUANIA
by the type of API used, i.e.    synthesized APIs            LIDOCAINE!TRIBENOSIDE                                                volume
CDMO services for FDPs segmented chemically-                 C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O [90-100]% by value / [90-100]% by
                                                  LITHUANIA
by the type of API used, i.e.    synthesized APIs            CORTIC --> LIDOCAINE!TRIBENOSIDE                                     volume
CDMO services for FDPs segmented chemically-                 C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [70-80]% by value / [70-80]% by
                                                  LITHUANIA
by the type of API used, i.e.    synthesized APIs            AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented chemically-                 G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG          [90-100]% by value / [90-100]% by
                                                  LITHUANIA
by the type of API used, i.e.    synthesized APIs            ANTIFUNGALS --> FENTICONAZOLE                                        volume
CDMO services for FDPs segmented chemically-                 C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING         [90-100]% by value / [90-100]% by
                                                  LUXEMBOURG
by the type of API used, i.e.    synthesized APIs            AGENTS,PLAIN --> METOPROLOL                                          volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented chemically-                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [70-80]% by value / [70-80]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented chemically-                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented chemically-                  G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented chemically-                  H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented chemically-                  N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->      [80-90]% by value / [80-90]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             CARIPRAZINE                                                             volume
CDMO services for FDPs segmented chemically-                  S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                  NETHERLANDS
by the type of API used, i.e.    synthesized APIs             TOPICAL --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented chemically-                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NORWAY
by the type of API used, i.e.    synthesized APIs             PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented chemically-                  A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  NORWAY
by the type of API used, i.e.    synthesized APIs             PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented chemically-                  C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [10-20]% by
                                                  NORWAY
by the type of API used, i.e.    synthesized APIs             AGENTS,PLAIN --> METOPROLOL                                             volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-             H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES     [90-100]% by value / [90-100]% by
                                                  NORWAY
by the type of API used, i.e.    synthesized APIs        --> PASIREOTIDE                                                         volume
CDMO services for FDPs segmented chemically-             S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                                                  NORWAY
by the type of API used, i.e.    synthesized APIs        TOPICAL --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented chemically-             01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        ACID!LACTOFERRIN                                                        volume
CDMO services for FDPs segmented chemically-             01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        ACID!LACTOFERRIN!MENTHOL                                                volume
CDMO services for FDPs segmented chemically-             10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [50-60]% by value / [60-70]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-             10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-             12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
CDMO services for FDPs segmented chemically-             12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> CARGLUMIC ACID                                             volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented chemically-               C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O       [70-80]% by value / [60-70]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs          CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [20-30]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented chemically-               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                                                  POLAND
by the type of API used, i.e.    synthesized APIs          ANTIFUNGALS --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented chemically-               01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS -->        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          TIBEZONIUM                                                               volume
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM
by the type of API used, i.e.    synthesized APIs                                                                                   volume
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                           02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                           ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                           02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the type of API used, i.e.    synthesized APIs                                                                                   volume
                                                           ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                           02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented chemically-               BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS       [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC                    volume
                                                           ACID!XANTHAN GUM!XYLITOL
 ---pagebreak---                                                            02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented chemically-                                                                              [90-100]% by value / [90-100]% by
                                                  PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the type of API used, i.e.    synthesized APIs                                                                                      volume
                                                           ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
CDMO services for FDPs segmented chemically-               02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          -> FLURBIPROFEN                                                             volume
CDMO services for FDPs segmented chemically-               03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC              [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          ACID!DODECYL SULFOACETIC ACID                                               volume
CDMO services for FDPs segmented chemically-               05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC                 [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          ACID!CAFFEINE!GLUCURONAMIDE                                                 volume
CDMO services for FDPs segmented chemically-               06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) -->     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA                    volume
CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->           [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          LIDOCAINE + TRIBENOSIDE                                                     volume
CDMO services for FDPs segmented chemically-               A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN -->          [30-40]% by value / [10-20]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          COLECALCIFEROL                                                              volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> BETAINE                                                        volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> CARGLUMIC ACID                                                 volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> MERCAPTAMINE                                                   volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS -->       [50-60]% by value / [50-60]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          SUCRALFATE                                                              volume
CDMO services for FDPs segmented chemically-               A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT        [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE                     volume
CDMO services for FDPs segmented chemically-               A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS -->    [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          CITRIC ACID!DODECYL SULFOACETIC ACID                                    volume
CDMO services for FDPs segmented chemically-               C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented chemically-               C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC    [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL                              volume
CDMO services for FDPs segmented chemically-               G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented chemically-               G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [50-60]% by value / [50-60]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          OTH --> ALPROSTADIL                                                     volume
CDMO services for FDPs segmented chemically-               M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PLN --> DEXIBUPROFEN                                                    volume
CDMO services for FDPs segmented chemically-               M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &   [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          ANALG --> FLURBIPROFEN                                                  volume
CDMO services for FDPs segmented chemically-               M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT              [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          PREPARATIONS --> COLCHICINE                                             volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->     [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          CARIPRAZINE                                                              volume
CDMO services for FDPs segmented chemically-                                                                           [90-100]% by value / [90-100]% by
                                                  PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM
by the type of API used, i.e.    synthesized APIs                                                                                   volume
CDMO services for FDPs segmented chemically-               R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->    [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          TIBEZONIUM                                                               volume
CDMO services for FDPs segmented chemically-               S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM           [90-100]% by value / [90-100]% by
                                                  PORTUGAL
by the type of API used, i.e.    synthesized APIs          TOPICAL --> MERCAPTAMINE                                                 volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->              [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          FRUCTOOLIGSACCHARIDES!MALTODEXTRIN                                       volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->              [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          INULIN!MALTODEXTRIN                                                      volume
CDMO services for FDPs segmented chemically-               04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT -->           [30-40]% by value / [20-30]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          CALCIUM!COLECALCIFEROL                                                   volume
CDMO services for FDPs segmented chemically-               06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->  [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          LIDOCAINE + TRIBENOSIDE                                                  volume
CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          + TRIBENOSIDE                                                            volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O  [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          CORTIC --> LIDOCAINE!TRIBENOSIDE                                      volume
CDMO services for FDPs segmented chemically-               C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE            [80-90]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          THERAPY,SYSTEM. --> DIOSMIN                                           volume
CDMO services for FDPs segmented chemically-               D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT     [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          ANTIFUNG --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented chemically-               G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          METRONIDAZOLE!NEOMYCIN!NYSTATIN                                       volume
CDMO services for FDPs segmented chemically-               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG           [90-100]% by value / [90-100]% by
                                                  ROMANIA
by the type of API used, i.e.    synthesized APIs          ANTIFUNGALS --> FENTICONAZOLE                                         volume
CDMO services for FDPs segmented chemically-               02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->      [80-90]% by value / [80-90]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ACETYLSALICYLIC ACID                                                  volume
CDMO services for FDPs segmented chemically-               02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                             volume
CDMO services for FDPs segmented chemically-               02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                   volume
CDMO services for FDPs segmented chemically-               02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ACETYLSALICYLIC ACID                                                  volume
CDMO services for FDPs segmented chemically-               02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ACETYLSALICYLIC ACID!ASCORBIC ACID                                    volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          CHARCOAL + IRON METAL                                                     volume
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  SLOVAKIA CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                           03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  SLOVAKIA CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E
CDMO services for FDPs segmented chemically-                                                                              [70-80]% by value / [80-90]% by
                                                  SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           E!XANTOFYL!ZEAXANTHIN
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           ACID!TAURINE!XANTOFYL!ZINC
CDMO services for FDPs segmented chemically-               07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL                 volume
CDMO services for FDPs segmented chemically-               07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                    volume
                                                           07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented chemically-                                                                            [90-100]% by value / [90-100]% by
                                                  SLOVAKIA ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by the type of API used, i.e.    synthesized APIs                                                                                    volume
                                                           E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented chemically-               07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                  volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented chemically-               10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS     [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ACULEATUS!SODIUM                                                        volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented chemically-               C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented chemically-               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [60-70]% by value / [30-40]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented chemically-               G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          PRD --> PROPIVERINE                                                     volume
CDMO services for FDPs segmented chemically-               N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [80-90]% by value / [80-90]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ANALGESICS --> ACETYLSALICYLIC ACID                                     volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-               N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC          [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                       volume
CDMO services for FDPs segmented chemically-               S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> [90-100]% by value / [90-100]% by
                                                  SLOVAKIA
by the type of API used, i.e.    synthesized APIs          HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS -->               [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                 [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                 [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CDMO services for FDPs segmented chemically-                                                                              [70-80]% by value / [0-5]% by
                                                  SPAIN    03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE
by the type of API used, i.e.    synthesized APIs                                                                                   volume
CDMO services for FDPs segmented chemically-               03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CDMO services for FDPs segmented chemically-               A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          TOCOFERSOLAN                                                             volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented chemically-               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [70-80]% by value / [60-70]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs          PRODUCTS --> CARGLUMIC ACID                                              volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [30-40]% by value / [80-90]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented chemically-             A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->         [70-80]% by value / [70-80]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        CINITAPRIDE                                                             volume
CDMO services for FDPs segmented chemically-             C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [80-90]% by value / [80-90]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented chemically-             C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented chemically-             G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [40-50]% by value / [50-60]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        OTH --> ALPROSTADIL                                                     volume
CDMO services for FDPs segmented chemically-             G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        PRODS --> LIDOCAINE!PRILOCAINE                                          volume
CDMO services for FDPs segmented chemically-             N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                                                  SPAIN
by the type of API used, i.e.    synthesized APIs        CARIPRAZINE                                                             volume
CDMO services for FDPs segmented chemically-                                                                        [90-100]% by value / [90-100]% by
                                                  SPAIN  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the type of API used, i.e.    synthesized APIs                                                                                volume
CDMO services for FDPs segmented chemically-             A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                                  SWEDEN
by the type of API used, i.e.    synthesized APIs        TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented chemically-             A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                                  SWEDEN
by the type of API used, i.e.    synthesized APIs        PRODUCTS --> BETAINE                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented chemically-                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [70-80]% by value / [70-80]% by
                                                   SWEDEN
by the type of API used, i.e.    synthesized APIs           PRODUCTS --> CARGLUMIC ACID                                               volume
CDMO services for FDPs segmented chemically-                A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC        [10-20]% by value / [70-80]% by
                                                   SWEDEN
by the type of API used, i.e.    synthesized APIs           PRODUCTS --> MERCAPTAMINE                                                 volume
CDMO services for FDPs segmented chemically-                H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES       [90-100]% by value / [90-100]% by
                                                   SWEDEN
by the type of API used, i.e.    synthesized APIs           --> PASIREOTIDE                                                           volume
CDMO services for FDPs segmented chemically-                S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM            [90-100]% by value / [90-100]% by
                                                   SWEDEN
by the type of API used, i.e.    synthesized APIs           TOPICAL --> MERCAPTAMINE                                                  volume
CDMO services for FDPs segmented biopharmaceutical          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                 [90-100]% by value / [90-100]% by
                                                   AUSTRIA
by the type of API used, i.e.    APIs                       HAEMATOLOGIC AGENTS --> HEMIN                                             volume
                                                            88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES
CDMO services for FDPs segmented biopharmaceutical CZECH                                                                 [90-100]% by value / [90-100]% by
                                                            NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS
by the type of API used, i.e.    APIs              REPUBLIC                                                                           volume
                                                            (DULCIS)!VITAMIN E!ZINC
CDMO services for FDPs segmented biopharmaceutical CZECH    88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES         [90-100]% by value / [90-100]% by
by the type of API used, i.e.    APIs              REPUBLIC NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC              volume
                                                            05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CDMO services for FDPs segmented biopharmaceutical                                                                       [90-100]% by value / [90-100]% by
                                                   FRANCE   COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
by the type of API used, i.e.    APIs                                                                                                 volume
                                                            BILOBA!PYRIDOXINE
                                                            10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS
CDMO services for FDPs segmented biopharmaceutical                                                                       [90-100]% by value / [90-100]% by
                                                   FRANCE   HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN
by the type of API used, i.e.    APIs                                                                                                 volume
                                                            E!VITIS VINIFERA
CDMO services for FDPs segmented biopharmaceutical          10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO    [90-100]% by value / [90-100]% by
                                                   FRANCE
by the type of API used, i.e.    APIs                       BILOBA!HEPTAMINOL!TROXERUTIN                                              volume
 ---pagebreak--- CDMO services for FDPs segmented biopharmaceutical         83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->         [50-60]% by value / [50-60]% by
                                                   FRANCE
by the type of API used, i.e.    APIs                      COMPOSITION UNKNOWN                                                      volume
CDMO services for FDPs segmented biopharmaceutical         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                                   FRANCE
by the type of API used, i.e.    APIs                      HAEMATOLOGIC AGENTS --> HEMIN                                            volume
CDMO services for FDPs segmented biopharmaceutical         C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE              [90-100]% by value / [90-100]% by
                                                   FRANCE
by the type of API used, i.e.    APIs                      THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                  volume
CDMO services for FDPs segmented biopharmaceutical         03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO  [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      OVATA                                                                    volume
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS                       volume
                                                           03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented biopharmaceutical                                                                     [90-100]% by value / [90-100]% by
                                                   GERMANY LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR
by the type of API used, i.e.    APIs                                                                                               volume
                                                           JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      LACTOBACILLUS HELVETICUS                                                 volume
                                                           A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented biopharmaceutical                                                                     [90-100]% by value / [90-100]% by
                                                   GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by the type of API used, i.e.    APIs                                                                                               volume
                                                           HELVETICUS
                                                           A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented biopharmaceutical                                                                     [90-100]% by value / [90-100]% by
                                                   GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by the type of API used, i.e.    APIs                                                                                               volume
                                                           HELVETICUS VAR JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented biopharmaceutical         A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-      [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      ORGANISM --> LACTOBACILLUS HELVETICUS                                    volume
 ---pagebreak--- CDMO services for FDPs segmented biopharmaceutical         K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      HEMIN                                                                         volume
CDMO services for FDPs segmented biopharmaceutical         L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.               [90-100]% by value / [90-100]% by
                                                   GERMANY
by the type of API used, i.e.    APIs                      ANTIBIOTICS --> DACTINOMYCIN                                                  volume
CDMO services for FDPs segmented biopharmaceutical         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                     [90-100]% by value / [90-100]% by
                                                   HUNGARY
by the type of API used, i.e.    APIs                      HAEMATOLOGIC AGENTS --> HEMIN                                                 volume
CDMO services for FDPs segmented biopharmaceutical         03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS -->           [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      TILACTASE                                                                     volume
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->            [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                        volume
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->              [70-80]% by value / [70-80]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      COLECALCIFEROL!LACTOBACILLUS REUTERI                                          volume
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->              [80-90]% by value / [80-90]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      LACTOBACILLUS REUTERI                                                         volume
                                                           03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented biopharmaceutical                                                                          [90-100]% by value / [90-100]% by
                                                   ITALY   ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS
by the type of API used, i.e.    APIs                                                                                                    volume
                                                           ACIDOPHILUS
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->      [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                        volume
CDMO services for FDPs segmented biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->        [50-60]% by value / [50-60]% by
                                                   ITALY
by the type of API used, i.e.    APIs                      COLECALCIFEROL!LACTOBACILLUS REUTERI                                          volume
 ---pagebreak---                                                          03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented biopharmaceutical                                                                      [90-100]% by value / [90-100]% by
                                                   ITALY HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN
by the type of API used, i.e.    APIs                                                                                                volume
                                                         TRIGLYCERIDES (UNSPECIFIED)
CDMO services for FDPs segmented biopharmaceutical       03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->      [60-70]% by value / [60-70]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    LACTOBACILLUS REUTERI                                                       volume
CDMO services for FDPs segmented biopharmaceutical       11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS -->                     [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE                          volume
                                                         11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC
CDMO services for FDPs segmented biopharmaceutical       ACID!MATRICARIA                                                [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                   volume
                                                         BER OFFICINALE
                                                         11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC
CDMO services for FDPs segmented biopharmaceutical       ACID!MATRICARIA                                                [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                   volume
                                                         BER OFFICINALE
CDMO services for FDPs segmented biopharmaceutical       12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS -->         [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    DIOSCOREA VILLOSA                                                           volume
CDMO services for FDPs segmented biopharmaceutical       18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS -->           [20-30]% by value / [30-40]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    BORAGO OFFICINALIS                                                          volume
CDMO services for FDPs segmented biopharmaceutical       A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES -- [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    > TILACTASE                                                                 volume
CDMO services for FDPs segmented biopharmaceutical       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                   [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    HAEMATOLOGIC AGENTS --> HEMIN                                               volume
CDMO services for FDPs segmented biopharmaceutical       L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.             [90-100]% by value / [90-100]% by
                                                   ITALY
by the type of API used, i.e.    APIs                    ANTIBIOTICS --> DACTINOMYCIN                                                volume
 ---pagebreak--- CDMO services for FDPs segmented biopharmaceutical             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                                   NETHERLANDS
by the type of API used, i.e.    APIs                          HAEMATOLOGIC AGENTS --> HEMIN                                            volume
CDMO services for FDPs segmented biopharmaceutical             B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                                   NORWAY
by the type of API used, i.e.    APIs                          HAEMATOLOGIC AGENTS --> HEMIN                                            volume
CDMO services for FDPs segmented biopharmaceutical             01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM      [70-80]% by value / [80-90]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          OFFICINALE                                                               volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented biopharmaceutical             R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->    [90-100]% by value / [90-100]% by
                                                   PORTUGAL
by the type of API used, i.e.    APIs                          SISYMBRIUM OFFICINALE                                                    volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                   SPAIN
by the type of API used, i.e.    APIs                          LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented biopharmaceutical             03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                                   SPAIN
by the type of API used, i.e.    APIs                          LACTOBACILLUS REUTERI                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented     biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                                       SPAIN
by the type of API used, i.e.        APIs                      LACTOBACILLUS REUTERI                                                   volume
CDMO services for FDPs segmented     biopharmaceutical         03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS -->     [90-100]% by value / [90-100]% by
                                                       SPAIN
by the type of API used, i.e.        APIs                      LACTOBACILLUS REUTERI                                                   volume
CDMO services for FDPs segmented     biopharmaceutical         08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS       [90-100]% by value / [90-100]% by
                                                       SPAIN
by the type of API used, i.e.        APIs                      SALIVARIUS                                                              volume
CDMO services for FDPs segmented     biopharmaceutical         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                                       SPAIN
by the type of API used, i.e.        APIs                      HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented     biopharmaceutical         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                                       SWEDEN
by the type of API used, i.e.        APIs                      HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented                               A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->           [90-100]% by value / [90-100]% by
                                     swallowing        AUSTRIA
by the delivery mechanism used, i.e.                           TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented                               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing        AUSTRIA
by the delivery mechanism used, i.e.                           PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented                               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing        AUSTRIA
by the delivery mechanism used, i.e.                           PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented                               A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing        AUSTRIA
by the delivery mechanism used, i.e.                           PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented                               B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                     swallowing        AUSTRIA
by the delivery mechanism used, i.e.                           HAEMATOLOGIC AGENTS --> HEMIN                                           volume
 ---pagebreak--- CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing BELGIUM
by the delivery mechanism used, i.e.                     PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing BELGIUM
by the delivery mechanism used, i.e.                     PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [10-20]% by value / [60-70]% by
                                     swallowing BELGIUM
by the delivery mechanism used, i.e.                     PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                     swallowing BELGIUM
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented                         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                     swallowing BELGIUM
by the delivery mechanism used, i.e.                     COMB --> FELODIPINE!METOPROLOL                                         volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                     swallowing BULGARIA
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [60-70]% by value / [60-70]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ACETYLSALICYLIC ACID                                                   volume
CDMO services for FDPs segmented                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [70-80]% by value / [80-90]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                              volume
CDMO services for FDPs segmented                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                    volume
CDMO services for FDPs segmented                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->  [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ACETYLSALICYLIC ACID                                                   volume
 ---pagebreak--- CDMO services for FDPs segmented                CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC CHARCOAL!IRON METAL                                                      volume
                                                         03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented                CZECH    CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONIN       [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC E!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VIT              volume
                                                         AMIN E
                                                         03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented                CZECH                                                                 [90-100]% by value / [90-100]% by
                                     swallowing          CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the delivery mechanism used, i.e.            REPUBLIC                                                                          volume
                                                         PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                         03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented                CZECH                                                                 [90-100]% by value / [90-100]% by
                                     swallowing          CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the delivery mechanism used, i.e.            REPUBLIC                                                                          volume
                                                         PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
CDMO services for FDPs segmented                CZECH    07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->       [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ASCORBIC ACID!XANTOFYL!ZEAXANTHIN                                        volume
CDMO services for FDPs segmented                CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                  volume
CDMO services for FDPs segmented                CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                   volume
                                                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented                CZECH                                                                 [90-100]% by value / [90-100]% by
                                     swallowing          ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by the delivery mechanism used, i.e.            REPUBLIC                                                                          volume
                                                         E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented                CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                 volume
                                                         88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES
CDMO services for FDPs segmented                CZECH                                                                 [90-100]% by value / [90-100]% by
                                     swallowing          NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS
by the delivery mechanism used, i.e.            REPUBLIC                                                                          volume
                                                         (DULCIS)!VITAMIN E!ZINC
 ---pagebreak--- CDMO services for FDPs segmented                CZECH    88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES         [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC              volume
CDMO services for FDPs segmented                CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [70-80]% by value / [60-70]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented                CZECH    G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC PRD --> PROPIVERINE                                                       volume
CDMO services for FDPs segmented                CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC              [60-70]% by value / [60-70]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ANALGESICS --> ACETYLSALICYLIC ACID                                       volume
CDMO services for FDPs segmented                CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [90-100]% by value / [90-100]% by
                                     swallowing
by the delivery mechanism used, i.e.            REPUBLIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                        volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [60-70]% by value / [50-60]% by
                                     swallowing ESTONIA
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [30-40]% by value / [10-20]% by
                                     swallowing FINLAND
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                               volume
CDMO services for FDPs segmented                         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR    [90-100]% by value / [90-100]% by
                                     swallowing FINLAND
by the delivery mechanism used, i.e.                     COMB --> FELODIPINE!METOPROLOL                                            volume
CDMO services for FDPs segmented                         01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT -->          [20-30]% by value / [30-40]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                     ACETYLCYSTEINE                                                            volume
CDMO services for FDPs segmented                         01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS -->               [30-40]% by value / [40-50]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                     ACETYLCYSTEINE                                                            volume
 ---pagebreak---                                                        01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM
by the delivery mechanism used, i.e.                                                                                           volume
                                                       USITATISSIMUM!PROPOLIS
CDMO services for FDPs segmented                       02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   BARBADENSIS!HYALURONIC ACID                                             volume
CDMO services for FDPs segmented                       02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE  [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   BARBADENSIS!HYALURONIC ACID                                             volume
                                                       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA
by the delivery mechanism used, i.e.                                                                                           volume
                                                       GLABRA!HYALURONIC ACID!MENTHOL
CDMO services for FDPs segmented                       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE       [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   BARBADENSIS!HYALURONIC ACID                                             volume
                                                       05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
by the delivery mechanism used, i.e.                                                                                           volume
                                                       BILOBA!PYRIDOXINE
CDMO services for FDPs segmented                       09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                   volume
CDMO services for FDPs segmented                       09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                         volume
                                                       10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN
by the delivery mechanism used, i.e.                                                                                           volume
                                                       E!VITIS VINIFERA
CDMO services for FDPs segmented                       10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   BILOBA!HEPTAMINOL!TROXERUTIN                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                       83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->       [50-60]% by value / [50-60]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   COMPOSITION UNKNOWN                                                    volume
CDMO services for FDPs segmented                       87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED        [50-60]% by value / [70-80]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   GUM&G --> COMPOSITION UNKNOWN                                          volume
CDMO services for FDPs segmented                       A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->         [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   TOCOFERSOLAN                                                           volume
CDMO services for FDPs segmented                       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented                       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [50-60]% by value / [50-60]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented                       A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                  volume
CDMO services for FDPs segmented                       A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                        volume
CDMO services for FDPs segmented                       A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W      [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   ELECTRO --> MACROGOL(S)                                                volume
CDMO services for FDPs segmented                       A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   MACROGOL(S)!POTASSIUM!SODIUM                                           volume
CDMO services for FDPs segmented                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH              [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   HAEMATOLOGIC AGENTS --> HEMIN                                          volume
 ---pagebreak--- CDMO services for FDPs segmented                       C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE             [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                 volume
CDMO services for FDPs segmented                       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented                       C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented                       G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented                       H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &     [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   SIMILAR --> OSILODROSTAT                                                volume
CDMO services for FDPs segmented                       J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR    [10-20]% by value / [80-90]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   TYPE --> ERYTHROMYCIN                                                   volume
CDMO services for FDPs segmented                                                                                    [30-40]% by value / [30-40]% by
                                     swallowing FRANCE R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE
by the delivery mechanism used, i.e.                                                                                           volume
CDMO services for FDPs segmented                       R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   ACID!BENZOIC ACID!BROMINE!CODEINE                                       volume
CDMO services for FDPs segmented                       R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC   [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   ACID!BROMOFORM!CODEINE                                                  volume
CDMO services for FDPs segmented                       R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB -->            [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                   CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL                                  volume
 ---pagebreak--- CDMO services for FDPs segmented                        S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> [90-100]% by value / [90-100]% by
                                     swallowing FRANCE
by the delivery mechanism used, i.e.                    RIFAMYCIN                                                                volume
CDMO services for FDPs segmented                                                                                     [90-100]% by value / [90-100]% by
                                     swallowing FRANCE  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the delivery mechanism used, i.e.                                                                                             volume
CDMO services for FDPs segmented                        03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO   [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    OVATA                                                                    volume
CDMO services for FDPs segmented                        03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->  [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS                       volume
                                                        03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented                                                                                     [90-100]% by value / [90-100]% by
                                     swallowing GERMANY LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR
by the delivery mechanism used, i.e.                                                                                             volume
                                                        JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented                        03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->  [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    LACTOBACILLUS HELVETICUS                                                 volume
CDMO services for FDPs segmented                        04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    CALCIUM!MAGNESIUM!POTASSIUM                                              volume
CDMO services for FDPs segmented                        A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->            [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    TOCOFERSOLAN                                                             volume
CDMO services for FDPs segmented                        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented                        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    PRODUCTS --> CARGLUMIC ACID                                              volume
 ---pagebreak--- CDMO services for FDPs segmented                        A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC      [5-10]% by value / [30-40]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    PRODUCTS --> MERCAPTAMINE                                               volume
                                                        A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by the delivery mechanism used, i.e.                                                                                            volume
                                                        HELVETICUS
                                                        A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
by the delivery mechanism used, i.e.                                                                                            volume
                                                        HELVETICUS VAR JUGURTI POLYSACCHARIDE
CDMO services for FDPs segmented                        A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-    [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    ORGANISM --> LACTOBACILLUS HELVETICUS                                   volume
CDMO services for FDPs segmented                        C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR   [60-70]% by value / [50-60]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented                        H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &    [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    SIMILAR --> OSILODROSTAT                                                volume
CDMO services for FDPs segmented                        L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.        [90-100]% by value / [90-100]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    ANTIBIOTICS --> DACTINOMYCIN                                            volume
CDMO services for FDPs segmented                        M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                [70-80]% by value / [60-70]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    RELAXANTS,CENTRAL --> METHOCARBAMOL                                     volume
CDMO services for FDPs segmented                        N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->     [60-70]% by value / [60-70]% by
                                     swallowing GERMANY
by the delivery mechanism used, i.e.                    CARIPRAZINE                                                             volume
CDMO services for FDPs segmented                                                                                   [60-70]% by value / [90-100]% by
                                     swallowing GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the delivery mechanism used, i.e.                                                                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                        C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                     swallowing GREECE
by the delivery mechanism used, i.e.                    COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented                        B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                     swallowing HUNGARY
by the delivery mechanism used, i.e.                    HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented                        C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [50-60]% by value / [30-40]% by
                                     swallowing HUNGARY
by the delivery mechanism used, i.e.                    AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented                        C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                                     swallowing HUNGARY
by the delivery mechanism used, i.e.                    COMB --> FELODIPINE!METOPROLOL                                          volume
CDMO services for FDPs segmented                        G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing IRELAND
by the delivery mechanism used, i.e.                    PRD --> FLAVOXATE                                                       volume
                                                        02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing ITALY   ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL
by the delivery mechanism used, i.e.                                                                                            volume
                                                        SULFONE!GLUCOSAMINE
                                                        02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing ITALY   ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL
by the delivery mechanism used, i.e.                                                                                            volume
                                                        SULFONE!GLUCOSAMINE
CDMO services for FDPs segmented                        03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                    TILACTASE                                                               volume
CDMO services for FDPs segmented                        03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS -->         [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                    DIMETICONE!LOPERAMIDE                                                   volume
CDMO services for FDPs segmented                        03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                    BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                  volume
 ---pagebreak--- CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [70-80]% by value / [70-80]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [80-90]% by value / [80-90]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  LACTOBACILLUS REUTERI                                                    volume
                                                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing ITALY ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS
by the delivery mechanism used, i.e.                                                                                           volume
                                                      ACIDOPHILUS
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [50-60]% by value / [50-60]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
                                                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing ITALY HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN
by the delivery mechanism used, i.e.                                                                                           volume
                                                      TRIGLYCERIDES (UNSPECIFIED)
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [60-70]% by value / [60-70]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                      03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC    [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  MEDICINES                                                                volume
CDMO services for FDPs segmented                      04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS -->        [50-60]% by value / [70-80]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  DIMETHYL SULFONE                                                         volume
CDMO services for FDPs segmented                      04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS -->        [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  DIMETHYL SULFONE                                                         volume
 ---pagebreak---                                                       04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing ITALY OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN
by the delivery mechanism used, i.e.                                                                                           volume
                                                      E
CDMO services for FDPs segmented                      04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO     [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E                             volume
CDMO services for FDPs segmented                      04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->        [50-60]% by value / [50-60]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  ARGININE                                                                 volume
CDMO services for FDPs segmented                      04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE                             volume
CDMO services for FDPs segmented                      04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->        [50-60]% by value / [60-70]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  LYSINE                                                                   volume
                                                      09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->
CDMO services for FDPs segmented                                                                                  [90-100]% by value / [90-100]% by
                                     swallowing ITALY CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA
by the delivery mechanism used, i.e.                                                                                           volume
                                                      PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL
CDMO services for FDPs segmented                      09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->   [60-70]% by value / [80-90]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  COMPOSITION UNKNOWN                                                      volume
CDMO services for FDPs segmented                      11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS -->                  [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE                       volume
                                                      11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC
CDMO services for FDPs segmented                      ACID!MATRICARIA                                             [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                volume
                                                      BER OFFICINALE
                                                      11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC
CDMO services for FDPs segmented                      ACID!MATRICARIA                                             [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI                volume
                                                      BER OFFICINALE
 ---pagebreak--- CDMO services for FDPs segmented                      12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  DIOSCOREA VILLOSA                                                       volume
CDMO services for FDPs segmented                      18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS -->       [20-30]% by value / [30-40]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  BORAGO OFFICINALIS                                                      volume
CDMO services for FDPs segmented                                                                                   [50-60]% by value / [50-60]% by
                                     swallowing ITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS
by the delivery mechanism used, i.e.                                                                                          volume
                                                      87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                     swallowing ITALY --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA
by the delivery mechanism used, i.e.                                                                                          volume
                                                      PIPERITA!XYLITOL
CDMO services for FDPs segmented                      A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->          [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  TOCOFERSOLAN                                                            volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [80-90]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  PRODUCTS --> MERCAPTAMINE                                               volume
CDMO services for FDPs segmented                      A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->         [60-70]% by value / [60-70]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  DOMPERIDONE                                                             volume
CDMO services for FDPs segmented                      A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST     [20-30]% by value / [30-40]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  CORTICOSTER PROD --> BUDESONIDE                                         volume
 ---pagebreak--- CDMO services for FDPs segmented                      A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM       [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  BOWEL DIS PRD OTH --> CROMOGLICIC ACID                                      volume
CDMO services for FDPs segmented                      A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS -->       [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  DIMETICONE!LOPERAMIDE                                                       volume
CDMO services for FDPs segmented                      A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES -- [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  > TILACTASE                                                                 volume
CDMO services for FDPs segmented                      B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                   [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  HAEMATOLOGIC AGENTS --> HEMIN                                               volume
CDMO services for FDPs segmented                      C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA         [70-80]% by value / [70-80]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  RED) --> LOVASTATIN                                                         volume
CDMO services for FDPs segmented                      C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB           [40-50]% by value / [50-60]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  ACTIV --> CINNARIZINE                                                       volume
CDMO services for FDPs segmented                      C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                  [30-40]% by value / [20-30]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  AGENTS,PLAIN --> BISOPROLOL                                                 volume
CDMO services for FDPs segmented                      C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                  [30-40]% by value / [20-30]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  AGENTS,PLAIN --> METOPROLOL                                                 volume
CDMO services for FDPs segmented                      J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --     [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  > CEFTIBUTEN                                                                volume
CDMO services for FDPs segmented                      L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS.             [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                  ANTIBIOTICS --> DACTINOMYCIN                                                volume
 ---pagebreak--- CDMO services for FDPs segmented                            N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> [90-100]% by value / [90-100]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                        CARIPRAZINE                                                          volume
CDMO services for FDPs segmented                            R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES       [30-40]% by value / [30-40]% by
                                     swallowing ITALY
by the delivery mechanism used, i.e.                        SYSTEMIC --> RUPATADINE                                              volume
CDMO services for FDPs segmented                                                                                    [90-100]% by value / [90-100]% by
                                     swallowing ITALY       V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the delivery mechanism used, i.e.                                                                                             volume
CDMO services for FDPs segmented                            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [40-50]% by value / [20-30]% by
                                     swallowing LATVIA
by the delivery mechanism used, i.e.                        AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented                            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING           [70-80]% by value / [70-80]% by
                                     swallowing LITHUANIA
by the delivery mechanism used, i.e.                        AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented                            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING         [90-100]% by value / [90-100]% by
                                     swallowing LUXEMBOURG
by the delivery mechanism used, i.e.                        AGENTS,PLAIN --> METOPROLOL                                          volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        PRODUCTS --> BETAINE                                                 volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [70-80]% by value / [70-80]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        PRODUCTS --> CARGLUMIC ACID                                          volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC [90-100]% by value / [90-100]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        PRODUCTS --> MERCAPTAMINE                                            volume
CDMO services for FDPs segmented                            B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH            [90-100]% by value / [90-100]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        HAEMATOLOGIC AGENTS --> HEMIN                                        volume
 ---pagebreak--- CDMO services for FDPs segmented                            G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented                            N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->      [80-90]% by value / [80-90]% by
                                     swallowing NETHERLANDS
by the delivery mechanism used, i.e.                        CARIPRAZINE                                                             volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing NORWAY
by the delivery mechanism used, i.e.                        PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing NORWAY
by the delivery mechanism used, i.e.                        PRODUCTS --> CARGLUMIC ACID                                             volume
CDMO services for FDPs segmented                            B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                                     swallowing NORWAY
by the delivery mechanism used, i.e.                        HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CDMO services for FDPs segmented                            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [10-20]% by
                                     swallowing NORWAY
by the delivery mechanism used, i.e.                        AGENTS,PLAIN --> METOPROLOL                                             volume
CDMO services for FDPs segmented                            01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                        ACID!LACTOFERRIN                                                        volume
CDMO services for FDPs segmented                            01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                        ACID!LACTOFERRIN!MENTHOL                                                volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                        PRODUCTS --> BETAINE                                                    volume
CDMO services for FDPs segmented                            A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC    [90-100]% by value / [90-100]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                        PRODUCTS --> CARGLUMIC ACID                                             volume
 ---pagebreak--- CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                     PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [20-30]% by
                                     swallowing POLAND
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                              volume
CDMO services for FDPs segmented                         01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS -->        [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     TIBEZONIUM                                                               volume
CDMO services for FDPs segmented                         01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM      [70-80]% by value / [80-90]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     OFFICINALE                                                               volume
CDMO services for FDPs segmented                                                                                     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM
by the delivery mechanism used, i.e.                                                                                              volume
CDMO services for FDPs segmented                                                                                     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM
by the delivery mechanism used, i.e.                                                                                              volume
CDMO services for FDPs segmented                         03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC           [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     ACID!DODECYL SULFOACETIC ACID                                            volume
CDMO services for FDPs segmented                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     LACTOBACILLUS LACTIS                                                     volume
CDMO services for FDPs segmented                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     LACTOBACILLUS LACTIS                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                         05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC              [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     ACID!CAFFEINE!GLUCURONAMIDE                                              volume
CDMO services for FDPs segmented                         A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN -->       [30-40]% by value / [10-20]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     COLECALCIFEROL                                                           volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PRODUCTS --> CARGLUMIC ACID                                              volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented                         A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS -->        [50-60]% by value / [50-60]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     SUCRALFATE                                                               volume
CDMO services for FDPs segmented                         A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT         [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE                      volume
CDMO services for FDPs segmented                         A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS -->     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     CITRIC ACID!DODECYL SULFOACETIC ACID                                     volume
CDMO services for FDPs segmented                         C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC     [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL                               volume
 ---pagebreak--- CDMO services for FDPs segmented                         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PRD --> FLAVOXATE                                                       volume
CDMO services for FDPs segmented                         M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PLN --> DEXIBUPROFEN                                                    volume
CDMO services for FDPs segmented                         M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT              [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     PREPARATIONS --> COLCHICINE                                             volume
CDMO services for FDPs segmented                         N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     CARIPRAZINE                                                             volume
CDMO services for FDPs segmented                                                                                    [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM
by the delivery mechanism used, i.e.                                                                                             volume
CDMO services for FDPs segmented                         R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     SISYMBRIUM OFFICINALE                                                   volume
CDMO services for FDPs segmented                         R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                                     swallowing PORTUGAL
by the delivery mechanism used, i.e.                     TIBEZONIUM                                                              volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                     swallowing ROMANIA
by the delivery mechanism used, i.e.                     FRUCTOOLIGSACCHARIDES!MALTODEXTRIN                                      volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                     swallowing ROMANIA
by the delivery mechanism used, i.e.                     INULIN!MALTODEXTRIN                                                     volume
CDMO services for FDPs segmented                         04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT -->          [30-40]% by value / [20-30]% by
                                     swallowing ROMANIA
by the delivery mechanism used, i.e.                     CALCIUM!COLECALCIFEROL                                                  volume
 ---pagebreak--- CDMO services for FDPs segmented                         C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE                [80-90]% by value / [90-100]% by
                                     swallowing ROMANIA
by the delivery mechanism used, i.e.                     THERAPY,SYSTEM. --> DIOSMIN                                               volume
CDMO services for FDPs segmented                         02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->          [80-90]% by value / [80-90]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented                         02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->        [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                                 volume
CDMO services for FDPs segmented                         02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->        [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                       volume
CDMO services for FDPs segmented                         02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ACETYLSALICYLIC ACID                                                      volume
CDMO services for FDPs segmented                         02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ACETYLSALICYLIC ACID!ASCORBIC ACID                                        volume
CDMO services for FDPs segmented                         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     CHARCOAL + IRON METAL                                                     volume
                                                         03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                      [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
by the delivery mechanism used, i.e.                                                                                               volume
                                                         PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                                         03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                      [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC
by the delivery mechanism used, i.e.                                                                                               volume
                                                         ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E
CDMO services for FDPs segmented                                                                                        [70-80]% by value / [80-90]% by
                                     swallowing SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN
by the delivery mechanism used, i.e.                                                                                               volume
 ---pagebreak---                                                          07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN
by the delivery mechanism used, i.e.                                                                                            volume
                                                         E!XANTOFYL!ZEAXANTHIN
                                                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC
by the delivery mechanism used, i.e.                                                                                            volume
                                                         ACID!TAURINE!XANTOFYL!ZINC
CDMO services for FDPs segmented                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL              volume
CDMO services for FDPs segmented                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                 volume
                                                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CDMO services for FDPs segmented                                                                                   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
by the delivery mechanism used, i.e.                                                                                            volume
                                                         E!XANTOFYL!ZEAXANTHIN
CDMO services for FDPs segmented                         07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                               volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented                         A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [30-40]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     AGENTS,PLAIN --> METOPROLOL                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     PRD --> PROPIVERINE                                                      volume
CDMO services for FDPs segmented                         N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [80-90]% by value / [80-90]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ANALGESICS --> ACETYLSALICYLIC ACID                                      volume
CDMO services for FDPs segmented                         N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC          [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                       volume
CDMO services for FDPs segmented                         S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> [90-100]% by value / [90-100]% by
                                     swallowing SLOVAKIA
by the delivery mechanism used, i.e.                     HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS -->               [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                     FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                 [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                     FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                 [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                     FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CDMO services for FDPs segmented                                                                                        [70-80]% by value / [0-5]% by
                                     swallowing SPAIN    03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE
by the delivery mechanism used, i.e.                                                                                              volume
CDMO services for FDPs segmented                         03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                     FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CDMO services for FDPs segmented                         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->      [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                     LACTOBACILLUS LACTIS                                                     volume
 ---pagebreak--- CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS -->     [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  LACTOBACILLUS REUTERI                                                    volume
CDMO services for FDPs segmented                      08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS       [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  SALIVARIUS                                                               volume
CDMO services for FDPs segmented                      A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->           [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  TOCOFERSOLAN                                                             volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  PRODUCTS --> BETAINE                                                     volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC       [70-80]% by value / [60-70]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  PRODUCTS --> CARGLUMIC ACID                                              volume
CDMO services for FDPs segmented                      A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC       [30-40]% by value / [80-90]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  PRODUCTS --> MERCAPTAMINE                                                volume
CDMO services for FDPs segmented                      A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->          [70-80]% by value / [70-80]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  CINITAPRIDE                                                              volume
CDMO services for FDPs segmented                      B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                  HAEMATOLOGIC AGENTS --> HEMIN                                            volume
 ---pagebreak--- CDMO services for FDPs segmented                       C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [80-90]% by value / [80-90]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                   AGENTS,PLAIN --> METOPROLOL                                            volume
CDMO services for FDPs segmented                       C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                   COMB --> FELODIPINE!METOPROLOL                                         volume
CDMO services for FDPs segmented                       N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->   [90-100]% by value / [90-100]% by
                                     swallowing SPAIN
by the delivery mechanism used, i.e.                   CARIPRAZINE                                                            volume
CDMO services for FDPs segmented                                                                                 [90-100]% by value / [90-100]% by
                                     swallowing SPAIN  V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC
by the delivery mechanism used, i.e.                                                                                          volume
CDMO services for FDPs segmented                       A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN -->         [90-100]% by value / [90-100]% by
                                     swallowing SWEDEN
by the delivery mechanism used, i.e.                   TOCOFERSOLAN                                                           volume
CDMO services for FDPs segmented                       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC   [90-100]% by value / [90-100]% by
                                     swallowing SWEDEN
by the delivery mechanism used, i.e.                   PRODUCTS --> BETAINE                                                   volume
CDMO services for FDPs segmented                       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [70-80]% by value / [70-80]% by
                                     swallowing SWEDEN
by the delivery mechanism used, i.e.                   PRODUCTS --> CARGLUMIC ACID                                            volume
CDMO services for FDPs segmented                       A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC     [10-20]% by value / [70-80]% by
                                     swallowing SWEDEN
by the delivery mechanism used, i.e.                   PRODUCTS --> MERCAPTAMINE                                              volume
CDMO services for FDPs segmented                       B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH              [90-100]% by value / [90-100]% by
                                     swallowing SWEDEN
by the delivery mechanism used, i.e.                   HAEMATOLOGIC AGENTS --> HEMIN                                          volume
CDMO services for FDPs segmented                       01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->   [80-90]% by value / [80-90]% by
                                     inhalation FRANCE
by the delivery mechanism used, i.e.                   SODIUM                                                                 volume
 ---pagebreak--- CDMO services for FDPs segmented                                 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->     [90-100]% by value / [90-100]% by
                                     inhalation         ITALY
by the delivery mechanism used, i.e.                             ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER                             volume
                                                                                                                                 [60-70]% by value / [60-70]% by
CDMO services for FDPs segmented                                 R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF -->
                                     inhalation         ITALY                                                                   volume (CVC share [70-80]% by
by the delivery mechanism used, i.e.                             BUDESONIDE
                                                                                                                                   value / [70-80]% by volume)
                                                                                                                                 [60-70]% by value / [50-60]% by
CDMO services for FDPs segmented
                                     inhalation         ITALY    R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE    volume (CVC share [60-70]% by
by the delivery mechanism used, i.e.
                                                                                                                                   value / [60-70]% by volume)
CDMO services for FDPs segmented     absorption through          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                [90-100]% by value / [90-100]% by
                                                        BULGARIA
by the delivery mechanism used, i.e. the skin                    ANTIFUNGALS --> FENTICONAZOLE                                                volume
CDMO services for FDPs segmented     absorption through CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES -->  [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC CHARCOAL!IRON METAL                                                          volume
CDMO services for FDPs segmented     absorption through CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->          [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented     absorption through CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->             [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC LIDOCAINE!TRIBENOSIDE                                                        volume
CDMO services for FDPs segmented     absorption through CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS        [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC ACULEATUS!SODIUM                                                             volume
CDMO services for FDPs segmented     absorption through CZECH    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O       [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC CORTIC --> LIDOCAINE!TRIBENOSIDE                                             volume
CDMO services for FDPs segmented     absorption through CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                [90-100]% by value / [90-100]% by
by the delivery mechanism used, i.e. the skin           REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                                volume
 ---pagebreak---                                                                 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CDMO services for FDPs segmented     absorption through                                                                        [90-100]% by value / [90-100]% by
                                                        FRANCE  COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
by the delivery mechanism used, i.e. the skin                                                                                               volume
                                                                BILOBA!PYRIDOXINE
CDMO services for FDPs segmented     absorption through         09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->    [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                       volume
CDMO services for FDPs segmented     absorption through         09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->    [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                             volume
CDMO services for FDPs segmented     absorption through         10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO      [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   BILOBA!HEPTAMINOL!TROXERUTIN                                                volume
CDMO services for FDPs segmented     absorption through         83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->            [50-60]% by value / [50-60]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   COMPOSITION UNKNOWN                                                         volume
CDMO services for FDPs segmented     absorption through         A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->      [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                       volume
CDMO services for FDPs segmented     absorption through         A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->      [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                             volume
CDMO services for FDPs segmented     absorption through         C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE                 [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                     volume
CDMO services for FDPs segmented     absorption through         L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->           [90-100]% by value / [90-100]% by
                                                        FRANCE
by the delivery mechanism used, i.e. the skin                   CHLORMETHINE                                                                volume
CDMO services for FDPs segmented     absorption through         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-   [60-70]% by value / [50-60]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   PROPANOL                                                                    volume
 ---pagebreak--- CDMO services for FDPs segmented     absorption through         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-        [40-50]% by value / [40-50]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   PROPANOL                                                                     volume
CDMO services for FDPs segmented     absorption through                                                                        [90-100]% by value / [90-100]% by
                                                        GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC
by the delivery mechanism used, i.e. the skin                                                                                                volume
CDMO services for FDPs segmented     absorption through                                                                          [50-60]% by value / [20-30]% by
                                                        GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC
by the delivery mechanism used, i.e. the skin                                                                                                volume
CDMO services for FDPs segmented     absorption through         06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   SALICYLIC ACID                                                               volume
CDMO services for FDPs segmented     absorption through         12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS -->       [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   LIDOCAINE!PRILOCAINE                                                         volume
CDMO services for FDPs segmented     absorption through         18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS -->         [70-80]% by value / [20-30]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   MENTHA ARVENSIS                                                              volume
CDMO services for FDPs segmented     absorption through         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING             [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC                                      volume
CDMO services for FDPs segmented     absorption through         D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING               [70-80]% by value / [60-70]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   AGENTS --> ZINC                                                              volume
CDMO services for FDPs segmented     absorption through         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE         [30-40]% by value / [0-5]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   PRD --> OXYBUTYNIN                                                           volume
CDMO services for FDPs segmented     absorption through         G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL       [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   PRODS --> LIDOCAINE!PRILOCAINE                                               volume
 ---pagebreak--- CDMO services for FDPs segmented     absorption through         L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->       [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   CHLORMETHINE                                                             volume
CDMO services for FDPs segmented     absorption through         M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &     [50-60]% by value / [50-60]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   ANALG --> 2-PROPANOL                                                     volume
CDMO services for FDPs segmented     absorption through         V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL             [90-100]% by value / [90-100]% by
                                                        GERMANY
by the delivery mechanism used, i.e. the skin                   PREPARATIONS --> MENTHA ARVENSIS                                         volume
CDMO services for FDPs segmented     absorption through         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                                                        GREECE
by the delivery mechanism used, i.e. the skin                   FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented     absorption through         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                                                        GREECE
by the delivery mechanism used, i.e. the skin                   FENTICONAZOLE                                                            volume
CDMO services for FDPs segmented     absorption through         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                        GREECE
by the delivery mechanism used, i.e. the skin                   ANTIFUNG --> FENTICONAZOLE                                               volume
CDMO services for FDPs segmented     absorption through         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                                                        GREECE
by the delivery mechanism used, i.e. the skin                   ANTIFUNGALS --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented     absorption through         G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE    [30-40]% by value / [5-10]% by
                                                        IRELAND
by the delivery mechanism used, i.e. the skin                   PRD --> OXYBUTYNIN                                                       volume
CDMO services for FDPs segmented     absorption through         02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                   BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS                   volume
                                                                02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented     absorption through                                                                    [90-100]% by value / [90-100]% by
                                                        ITALY   BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by the delivery mechanism used, i.e. the skin                                                                                            volume
                                                                COMMUNIS
 ---pagebreak--- CDMO services for FDPs segmented     absorption through       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE        [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 BARBADENSIS!BENZETHONIUM CHLORIDE                                         volume
CDMO services for FDPs segmented     absorption through       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE        [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 BARBADENSIS!ENOXOLONE!HYALURONIC ACID                                     volume
                                                              02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented     absorption through                                                                    [90-100]% by value / [90-100]% by
                                                        ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
by the delivery mechanism used, i.e. the skin                                                                                           volume
                                                              COMMUNIS
CDMO services for FDPs segmented     absorption through       02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 DICLOFENAC                                                                volume
CDMO services for FDPs segmented     absorption through       02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS -->    [40-50]% by value / [40-50]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 NAPROXEN                                                                  volume
CDMO services for FDPs segmented     absorption through       06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER                               volume
CDMO services for FDPs segmented     absorption through       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->    [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 FENTICONAZOLE                                                             volume
CDMO services for FDPs segmented     absorption through       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->     [80-90]% by value / [80-90]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 FENTICONAZOLE                                                             volume
CDMO services for FDPs segmented     absorption through       06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->       [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 FENTICONAZOLE                                                             volume
CDMO services for FDPs segmented     absorption through       12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                     [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                 OINTMENTS/CREAMS --> FENTICONAZOLE                                        volume
 ---pagebreak--- CDMO services for FDPs segmented     absorption through        12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->   [50-60]% by value / [60-70]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented     absorption through        12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->   [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented     absorption through        D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented     absorption through        G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [60-70]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  ANTIFUNGALS --> FENTICONAZOLE                                           volume
CDMO services for FDPs segmented     absorption through        G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  PRODS --> LIDOCAINE!PRILOCAINE                                          volume
CDMO services for FDPs segmented     absorption through        L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS -->       [90-100]% by value / [90-100]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  CHLORMETHINE                                                            volume
CDMO services for FDPs segmented     absorption through        M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &     [50-60]% by value / [40-50]% by
                                                        ITALY
by the delivery mechanism used, i.e. the skin                  ANALG --> NAPROXEN                                                      volume
CDMO services for FDPs segmented     absorption through        10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                                                        LATVIA
by the delivery mechanism used, i.e. the skin                  LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented     absorption through        10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                                                        LATVIA
by the delivery mechanism used, i.e. the skin                  LIDOCAINE!TRIBENOSIDE                                                   volume
CDMO services for FDPs segmented     absorption through        C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                                                        LATVIA
by the delivery mechanism used, i.e. the skin                  CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
 ---pagebreak--- CDMO services for FDPs segmented     absorption through           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                        LITHUANIA
by the delivery mechanism used, i.e. the skin                     LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented     absorption through           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                                        LITHUANIA
by the delivery mechanism used, i.e. the skin                     LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented     absorption through           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                        LITHUANIA
by the delivery mechanism used, i.e. the skin                     CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CDMO services for FDPs segmented     absorption through           G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                                                        LITHUANIA
by the delivery mechanism used, i.e. the skin                     ANTIFUNGALS --> FENTICONAZOLE                                            volume
CDMO services for FDPs segmented     absorption through           10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->          [50-60]% by value / [60-70]% by
                                                        POLAND
by the delivery mechanism used, i.e. the skin                     LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented     absorption through           10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                                                        POLAND
by the delivery mechanism used, i.e. the skin                     LIDOCAINE!TRIBENOSIDE                                                    volume
CDMO services for FDPs segmented     absorption through           C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O       [70-80]% by value / [60-70]% by
                                                        POLAND
by the delivery mechanism used, i.e. the skin                     CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
                                                                  02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE
CDMO services for FDPs segmented     absorption through                                                                       [90-100]% by value / [90-100]% by
                                                        PORTUGAL  BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the delivery mechanism used, i.e. the skin                                                                                              volume
                                                                  ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                                  02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented     absorption through                                                                       [90-100]% by value / [90-100]% by
                                                        PORTUGAL  BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the delivery mechanism used, i.e. the skin                                                                                              volume
                                                                  ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                                                  02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CDMO services for FDPs segmented     absorption through           BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS       [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the delivery mechanism used, i.e. the skin                     SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC                    volume
                                                                  ACID!XANTHAN GUM!XYLITOL
 ---pagebreak---                                                                  02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CDMO services for FDPs segmented     absorption through                                                                      [90-100]% by value / [90-100]% by
                                                        PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
by the delivery mechanism used, i.e. the skin                                                                                            volume
                                                                 ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
CDMO services for FDPs segmented     absorption through          06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) -->  [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the delivery mechanism used, i.e. the skin                    COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA                volume
CDMO services for FDPs segmented     absorption through          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the delivery mechanism used, i.e. the skin                    LIDOCAINE + TRIBENOSIDE                                                 volume
CDMO services for FDPs segmented     absorption through          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                        PORTUGAL
by the delivery mechanism used, i.e. the skin                    CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented     absorption through          06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->  [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    FENTICONAZOLE                                                           volume
CDMO services for FDPs segmented     absorption through          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    LIDOCAINE + TRIBENOSIDE                                                 volume
CDMO services for FDPs segmented     absorption through          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    + TRIBENOSIDE                                                           volume
CDMO services for FDPs segmented     absorption through          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CDMO services for FDPs segmented     absorption through          D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT        [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    ANTIFUNG --> FENTICONAZOLE                                              volume
CDMO services for FDPs segmented     absorption through          G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                                                        ROMANIA
by the delivery mechanism used, i.e. the skin                    ANTIFUNGALS --> FENTICONAZOLE                                           volume
 ---pagebreak--- CDMO services for FDPs segmented     absorption through             02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                                                           SLOVAKIA
by the delivery mechanism used, i.e. the skin                       CHARCOAL + IRON METAL                                                     volume
CDMO services for FDPs segmented     absorption through             10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [90-100]% by value / [90-100]% by
                                                           SLOVAKIA
by the delivery mechanism used, i.e. the skin                       LIDOCAINE!TRIBENOSIDE                                                     volume
CDMO services for FDPs segmented     absorption through             10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->            [90-100]% by value / [90-100]% by
                                                           SLOVAKIA
by the delivery mechanism used, i.e. the skin                       LIDOCAINE!TRIBENOSIDE                                                     volume
CDMO services for FDPs segmented     absorption through             10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS       [90-100]% by value / [90-100]% by
                                                           SLOVAKIA
by the delivery mechanism used, i.e. the skin                       ACULEATUS!SODIUM                                                          volume
CDMO services for FDPs segmented     absorption through             C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O      [90-100]% by value / [90-100]% by
                                                           SLOVAKIA
by the delivery mechanism used, i.e. the skin                       CORTIC --> LIDOCAINE!TRIBENOSIDE                                          volume
CDMO services for FDPs segmented     absorption through             86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-            [40-50]% by value / [10-20]% by
                                                           SPAIN
by the delivery mechanism used, i.e. the skin                       AERO+SPRAY --> COMPOSITION UNKNOWN                                        volume
CDMO services for FDPs segmented     absorption through             86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-          [90-100]% by value / [90-100]% by
                                                           SPAIN
by the delivery mechanism used, i.e. the skin                       AERO+SPRAY --> DIMETICONE!JOJOBA OIL                                      volume
CDMO services for FDPs segmented     absorption through             G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL     [90-100]% by value / [90-100]% by
                                                           SPAIN
by the delivery mechanism used, i.e. the skin                       PRODS --> LIDOCAINE!PRILOCAINE                                            volume
CDMO services for FDPs segmented                                    C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER             [90-100]% by value / [90-100]% by
                                     intravenous injection AUSTRIA
by the delivery mechanism used, i.e.                                CARDIOVASCULAR PRD --> IBUPROFEN                                          volume
CDMO services for FDPs segmented                                    C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER             [90-100]% by value / [90-100]% by
                                     intravenous injection FRANCE
by the delivery mechanism used, i.e.                                CARDIOVASCULAR PRD --> IBUPROFEN                                          volume
 ---pagebreak--- CDMO services for FDPs segmented                                    C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER          [90-100]% by value / [90-100]% by
                                     intravenous injection GERMANY
by the delivery mechanism used, i.e.                                CARDIOVASCULAR PRD --> IBUPROFEN                                       volume
CMO services (excluding CDO                                         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH              [90-100]% by value / [90-100]% by
                                     -                     AUSTRIA
services)                                                           HAEMATOLOGIC AGENTS --> HEMIN                                          volume
CMO services (excluding CDO                                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                     -                     BELGIUM
services)                                                           AGENTS,PLAIN --> METOPROLOL                                            volume
CMO services (excluding CDO                                         C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR [90-100]% by value / [90-100]% by
                                     -                     BELGIUM
services)                                                           COMB --> FELODIPINE!METOPROLOL                                         volume
CMO services (excluding CDO                                         S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM         [90-100]% by value / [90-100]% by
                                     -                     BELGIUM
services)                                                           TOPICAL --> MERCAPTAMINE                                               volume
CMO services (excluding CDO                                         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING             [60-70]% by value / [50-60]% by
                                     -                     BULGARIA
services)                                                           AGENTS,PLAIN --> METOPROLOL                                            volume
CMO services (excluding CDO                                         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG            [90-100]% by value / [90-100]% by
                                     -                     BULGARIA
services)                                                           ANTIFUNGALS --> FENTICONAZOLE                                          volume
CMO services (excluding CDO                                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [60-70]% by value / [60-70]% by
                                     -
services)                                                  REPUBLIC ACETYLSALICYLIC ACID                                                   volume
CMO services (excluding CDO                                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [70-80]% by value / [80-90]% by
                                     -
services)                                                  REPUBLIC ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                              volume
CMO services (excluding CDO                                CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                                     -
services)                                                  REPUBLIC CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                    volume
 ---pagebreak--- CMO services (excluding CDO   CZECH    02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ACETYLSALICYLIC ACID                                                     volume
CMO services (excluding CDO   CZECH    02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC CHARCOAL!IRON METAL                                                      volume
                                       03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CMO services (excluding CDO   CZECH    CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONIN       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC E!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VIT              volume
                                       AMIN E
                                       03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CMO services (excluding CDO   CZECH                                                                 [90-100]% by value / [90-100]% by
                            -          CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
services)                     REPUBLIC                                                                          volume
                                       PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                       03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CMO services (excluding CDO   CZECH                                                                 [90-100]% by value / [90-100]% by
                            -          CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
services)                     REPUBLIC                                                                          volume
                                       PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
CMO services (excluding CDO   CZECH    07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ASCORBIC ACID!XANTOFYL!ZEAXANTHIN                                        volume
CMO services (excluding CDO   CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                  volume
CMO services (excluding CDO   CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                   volume
                                       07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CMO services (excluding CDO   CZECH                                                                 [90-100]% by value / [90-100]% by
                            -          ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
services)                     REPUBLIC                                                                          volume
                                       E!XANTOFYL!ZEAXANTHIN
CMO services (excluding CDO   CZECH    07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                 volume
 ---pagebreak--- CMO services (excluding CDO   CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC LIDOCAINE!TRIBENOSIDE                                                     volume
CMO services (excluding CDO   CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->            [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC LIDOCAINE!TRIBENOSIDE                                                     volume
CMO services (excluding CDO   CZECH    10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS       [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ACULEATUS!SODIUM                                                          volume
                                       88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES
CMO services (excluding CDO   CZECH                                                                 [90-100]% by value / [90-100]% by
                            -          NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS
services)                     REPUBLIC                                                                           volume
                                       (DULCIS)!VITAMIN E!ZINC
CMO services (excluding CDO   CZECH    88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES         [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC              volume
CMO services (excluding CDO   CZECH    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O      [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC CORTIC --> LIDOCAINE!TRIBENOSIDE                                          volume
CMO services (excluding CDO   CZECH    C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                [70-80]% by value / [60-70]% by
                            -
services)                     REPUBLIC AGENTS,PLAIN --> METOPROLOL                                               volume
CMO services (excluding CDO   CZECH    G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG               [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ANTIFUNGALS --> FENTICONAZOLE                                             volume
CMO services (excluding CDO   CZECH    G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC PRD --> PROPIVERINE                                                       volume
CMO services (excluding CDO   CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC              [60-70]% by value / [60-70]% by
                            -
services)                     REPUBLIC ANALGESICS --> ACETYLSALICYLIC ACID                                       volume
 ---pagebreak--- CMO services (excluding CDO   CZECH    N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC           [90-100]% by value / [90-100]% by
                            -
services)                     REPUBLIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                       volume
CMO services (excluding CDO            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [60-70]% by value / [50-60]% by
                            - ESTONIA
services)                              AGENTS,PLAIN --> METOPROLOL                                              volume
CMO services (excluding CDO            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [10-20]% by
                            - FINLAND
services)                              AGENTS,PLAIN --> METOPROLOL                                              volume
CMO services (excluding CDO            C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR   [90-100]% by value / [90-100]% by
                            - FINLAND
services)                              COMB --> FELODIPINE!METOPROLOL                                           volume
CMO services (excluding CDO            01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT -->         [20-30]% by value / [30-40]% by
                            - FRANCE
services)                              ACETYLCYSTEINE                                                           volume
CMO services (excluding CDO            01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS -->              [30-40]% by value / [40-50]% by
                            - FRANCE
services)                              ACETYLCYSTEINE                                                           volume
                                       01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS -->
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - FRANCE   CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM
services)                                                                                                       volume
                                       USITATISSIMUM!PROPOLIS
CMO services (excluding CDO            01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->     [80-90]% by value / [80-90]% by
                            - FRANCE
services)                              SODIUM                                                                   volume
CMO services (excluding CDO            02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE [90-100]% by value / [90-100]% by
                            - FRANCE
services)                              BARBADENSIS!HYALURONIC ACID                                              volume
CMO services (excluding CDO            02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE  [90-100]% by value / [90-100]% by
                            - FRANCE
services)                              BARBADENSIS!HYALURONIC ACID                                              volume
 ---pagebreak---                                      02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC
CMO services (excluding CDO                                                                      [90-100]% by value / [90-100]% by
                            - FRANCE ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA
services)                                                                                                     volume
                                     GLABRA!HYALURONIC ACID!MENTHOL
CMO services (excluding CDO          02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE       [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            BARBADENSIS!HYALURONIC ACID                                              volume
                                     05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS -->
CMO services (excluding CDO                                                                      [90-100]% by value / [90-100]% by
                            - FRANCE COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO
services)                                                                                                     volume
                                     BILOBA!PYRIDOXINE
CMO services (excluding CDO          09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
CMO services (excluding CDO          09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                          volume
                                     10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS
CMO services (excluding CDO                                                                      [90-100]% by value / [90-100]% by
                            - FRANCE HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN
services)                                                                                                     volume
                                     E!VITIS VINIFERA
CMO services (excluding CDO          10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO   [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            BILOBA!HEPTAMINOL!TROXERUTIN                                             volume
CMO services (excluding CDO          83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS -->         [50-60]% by value / [50-60]% by
                            - FRANCE
services)                            COMPOSITION UNKNOWN                                                      volume
CMO services (excluding CDO          87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED          [50-60]% by value / [70-80]% by
                            - FRANCE
services)                            GUM&G --> COMPOSITION UNKNOWN                                            volume
CMO services (excluding CDO          A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->   [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL                                    volume
 ---pagebreak--- CMO services (excluding CDO          A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT -->  [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE                         volume
CMO services (excluding CDO          A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W       [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            ELECTRO --> MACROGOL(S)                                                 volume
CMO services (excluding CDO          A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR -->  [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            MACROGOL(S)!POTASSIUM!SODIUM                                            volume
CMO services (excluding CDO          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CMO services (excluding CDO          C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE             [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN                 volume
CMO services (excluding CDO          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [40-50]% by value / [20-30]% by
                            - FRANCE
services)                            AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO          C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            COMB --> FELODIPINE!METOPROLOL                                          volume
CMO services (excluding CDO          G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL -->   [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            METRONIDAZOLE!NEOMYCIN!NYSTATIN                                         volume
CMO services (excluding CDO          G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            PRD --> FLAVOXATE                                                       volume
CMO services (excluding CDO          H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &     [90-100]% by value / [90-100]% by
                            - FRANCE
services)                            SIMILAR --> OSILODROSTAT                                                volume
 ---pagebreak--- CMO services (excluding CDO           J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR        [10-20]% by value / [80-90]% by
                            - FRANCE
services)                             TYPE --> ERYTHROMYCIN                                                       volume
CMO services (excluding CDO                                                                            [30-40]% by value / [30-40]% by
                            - FRANCE  R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE
services)                                                                                                         volume
CMO services (excluding CDO           R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC       [90-100]% by value / [90-100]% by
                            - FRANCE
services)                             ACID!BENZOIC ACID!BROMINE!CODEINE                                           volume
CMO services (excluding CDO           R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC       [90-100]% by value / [90-100]% by
                            - FRANCE
services)                             ACID!BROMOFORM!CODEINE                                                      volume
CMO services (excluding CDO           R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB -->                [90-100]% by value / [90-100]% by
                            - FRANCE
services)                             CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL                                      volume
CMO services (excluding CDO           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM              [90-100]% by value / [90-100]% by
                            - FRANCE
services)                             TOPICAL --> MERCAPTAMINE                                                    volume
CMO services (excluding CDO           S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->   [90-100]% by value / [90-100]% by
                            - FRANCE
services)                             RIFAMYCIN                                                                   volume
CMO services (excluding CDO           02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-   [60-70]% by value / [50-60]% by
                            - GERMANY
services)                             PROPANOL                                                                    volume
CMO services (excluding CDO           02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-        [40-50]% by value / [40-50]% by
                            - GERMANY
services)                             PROPANOL                                                                    volume
CMO services (excluding CDO           03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO     [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             OVATA                                                                       volume
 ---pagebreak--- CMO services (excluding CDO           03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->    [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS                          volume
                                      03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CMO services (excluding CDO                                                                          [90-100]% by value / [90-100]% by
                            - GERMANY LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR
services)                                                                                                         volume
                                      JUGURTI POLYSACCHARIDE
CMO services (excluding CDO           03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->    [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             LACTOBACILLUS HELVETICUS                                                    volume
CMO services (excluding CDO           04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             CALCIUM!MAGNESIUM!POTASSIUM                                                 volume
CMO services (excluding CDO                                                                          [90-100]% by value / [90-100]% by
                            - GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC
services)                                                                                                         volume
CMO services (excluding CDO                                                                            [50-60]% by value / [20-30]% by
                            - GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC
services)                                                                                                         volume
CMO services (excluding CDO           06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             SALICYLIC ACID                                                              volume
CMO services (excluding CDO           12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS -->       [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             LIDOCAINE!PRILOCAINE                                                        volume
CMO services (excluding CDO           18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS -->         [70-80]% by value / [20-30]% by
                            - GERMANY
services)                             MENTHA ARVENSIS                                                             volume
                                      A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CMO services (excluding CDO                                                                          [90-100]% by value / [90-100]% by
                            - GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
services)                                                                                                         volume
                                      HELVETICUS
 ---pagebreak---                                       A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
CMO services (excluding CDO                                                                            [90-100]% by value / [90-100]% by
                            - GERMANY ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS
services)                                                                                                            volume
                                      HELVETICUS VAR JUGURTI POLYSACCHARIDE
CMO services (excluding CDO           A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-           [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             ORGANISM --> LACTOBACILLUS HELVETICUS                                          volume
CMO services (excluding CDO           C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR          [60-70]% by value / [50-60]% by
                            - GERMANY
services)                             COMB --> FELODIPINE!METOPROLOL                                                 volume
CMO services (excluding CDO           D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING               [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC                                        volume
CMO services (excluding CDO           D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING                 [70-80]% by value / [60-70]% by
                            - GERMANY
services)                             AGENTS --> ZINC                                                                volume
CMO services (excluding CDO           G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE           [30-40]% by value / [0-5]% by
                            - GERMANY
services)                             PRD --> OXYBUTYNIN                                                             volume
CMO services (excluding CDO           G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL         [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             PRODS --> LIDOCAINE!PRILOCAINE                                                 volume
CMO services (excluding CDO           H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --      [40-50]% by value / [10-20]% by
                            - GERMANY
services)                             > DEXAMETHASONE                                                                volume
CMO services (excluding CDO           H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES &           [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             SIMILAR --> OSILODROSTAT                                                       volume
CMO services (excluding CDO           K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             HEMIN                                                                          volume
 ---pagebreak--- CMO services (excluding CDO           M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL                       volume
CMO services (excluding CDO           M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             PLN --> PHENYLBUTAZONE                                                  volume
CMO services (excluding CDO           M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &     [50-60]% by value / [50-60]% by
                            - GERMANY
services)                             ANALG --> 2-PROPANOL                                                    volume
CMO services (excluding CDO           M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE                 [70-80]% by value / [60-70]% by
                            - GERMANY
services)                             RELAXANTS,CENTRAL --> METHOCARBAMOL                                     volume
CMO services (excluding CDO           N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->      [60-70]% by value / [60-70]% by
                            - GERMANY
services)                             CARIPRAZINE                                                             volume
CMO services (excluding CDO           S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             TOPICAL --> MERCAPTAMINE                                                volume
CMO services (excluding CDO           V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL             [90-100]% by value / [90-100]% by
                            - GERMANY
services)                             PREPARATIONS --> MENTHA ARVENSIS                                        volume
CMO services (excluding CDO           06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                            - GREECE
services)                             FENTICONAZOLE                                                           volume
CMO services (excluding CDO           06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                            - GREECE
services)                             FENTICONAZOLE                                                           volume
CMO services (excluding CDO           C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                            - GREECE
services)                             COMB --> FELODIPINE!METOPROLOL                                          volume
 ---pagebreak--- CMO services (excluding CDO           D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT       [90-100]% by value / [90-100]% by
                            - GREECE
services)                             ANTIFUNG --> FENTICONAZOLE                                               volume
CMO services (excluding CDO           G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                            - GREECE
services)                             ANTIFUNGALS --> FENTICONAZOLE                                            volume
CMO services (excluding CDO           B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - HUNGARY
services)                             HAEMATOLOGIC AGENTS --> HEMIN                                            volume
CMO services (excluding CDO           C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [50-60]% by value / [30-40]% by
                            - HUNGARY
services)                             AGENTS,PLAIN --> METOPROLOL                                              volume
CMO services (excluding CDO           C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                            - HUNGARY
services)                             COMB --> FELODIPINE!METOPROLOL                                           volume
CMO services (excluding CDO           G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                            - HUNGARY
services)                             ANTIFUNGALS --> FENTICONAZOLE                                            volume
CMO services (excluding CDO           G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            - IRELAND
services)                             PRD --> FLAVOXATE                                                        volume
CMO services (excluding CDO           G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE    [30-40]% by value / [5-10]% by
                            - IRELAND
services)                             PRD --> OXYBUTYNIN                                                       volume
CMO services (excluding CDO           01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS -->  [90-100]% by value / [90-100]% by
                            - ITALY
services)                             ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER                         volume
CMO services (excluding CDO           02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE [90-100]% by value / [90-100]% by
                            - ITALY
services)                             BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS                   volume
 ---pagebreak---                                     02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
services)                                                                                                       volume
                                    COMMUNIS
CMO services (excluding CDO         02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE          [90-100]% by value / [90-100]% by
                            - ITALY
services)                           BARBADENSIS!BENZETHONIUM CHLORIDE                                           volume
CMO services (excluding CDO         02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE          [90-100]% by value / [90-100]% by
                            - ITALY
services)                           BARBADENSIS!ENOXOLONE!HYALURONIC ACID                                       volume
                                    02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - ITALY BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS
services)                                                                                                       volume
                                    COMMUNIS
CMO services (excluding CDO         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                            - ITALY
services)                           -> FLURBIPROFEN                                                             volume
CMO services (excluding CDO         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) -->   [90-100]% by value / [90-100]% by
                            - ITALY
services)                           DICLOFENAC                                                                  volume
CMO services (excluding CDO         02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS -->      [40-50]% by value / [40-50]% by
                            - ITALY
services)                           NAPROXEN                                                                    volume
                                    02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - ITALY ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL
services)                                                                                                       volume
                                    SULFONE!GLUCOSAMINE
                                    02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS -->
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - ITALY ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL
services)                                                                                                       volume
                                    SULFONE!GLUCOSAMINE
CMO services (excluding CDO         03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS -->         [90-100]% by value / [90-100]% by
                            - ITALY
services)                           TILACTASE                                                                   volume
 ---pagebreak--- CMO services (excluding CDO         03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS -->          [90-100]% by value / [90-100]% by
                            - ITALY
services)                           DIMETICONE!LOPERAMIDE                                                    volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - ITALY
services)                           BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [70-80]% by value / [70-80]% by
                            - ITALY
services)                           COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->         [80-90]% by value / [80-90]% by
                            - ITALY
services)                           LACTOBACILLUS REUTERI                                                    volume
                                    03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CMO services (excluding CDO                                                                     [90-100]% by value / [90-100]% by
                            - ITALY ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS
services)                                                                                                    volume
                                    ACIDOPHILUS
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                            - ITALY
services)                           BACILLUS COAGULANS!PYRIDOXINE!THIAMINE                                   volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [50-60]% by value / [50-60]% by
                            - ITALY
services)                           COLECALCIFEROL!LACTOBACILLUS REUTERI                                     volume
                                    03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->
CMO services (excluding CDO                                                                     [90-100]% by value / [90-100]% by
                            - ITALY HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN
services)                                                                                                    volume
                                    TRIGLYCERIDES (UNSPECIFIED)
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->   [60-70]% by value / [60-70]% by
                            - ITALY
services)                           LACTOBACILLUS REUTERI                                                    volume
CMO services (excluding CDO         03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC    [90-100]% by value / [90-100]% by
                            - ITALY
services)                           MEDICINES                                                                volume
 ---pagebreak--- CMO services (excluding CDO         04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS -->      [50-60]% by value / [70-80]% by
                            - ITALY
services)                           DIMETHYL SULFONE                                                       volume
CMO services (excluding CDO         04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS -->      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           DIMETHYL SULFONE                                                       volume
                                    04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO
CMO services (excluding CDO                                                                   [90-100]% by value / [90-100]% by
                            - ITALY OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN
services)                                                                                                  volume
                                    E
CMO services (excluding CDO         04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO   [90-100]% by value / [90-100]% by
                            - ITALY
services)                           OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E                           volume
CMO services (excluding CDO         04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [50-60]% by value / [50-60]% by
                            - ITALY
services)                           ARGININE                                                               volume
CMO services (excluding CDO         04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->    [90-100]% by value / [90-100]% by
                            - ITALY
services)                           ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE                           volume
CMO services (excluding CDO         04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS -->      [50-60]% by value / [60-70]% by
                            - ITALY
services)                           LYSINE                                                                 volume
CMO services (excluding CDO         04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS -->      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           INOSITOL                                                               volume
CMO services (excluding CDO         06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS -->    [90-100]% by value / [90-100]% by
                            - ITALY
services)                           HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER                            volume
CMO services (excluding CDO         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> [90-100]% by value / [90-100]% by
                            - ITALY
services)                           FENTICONAZOLE                                                          volume
 ---pagebreak--- CMO services (excluding CDO         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS -->    [80-90]% by value / [80-90]% by
                            - ITALY
services)                           FENTICONAZOLE                                                            volume
CMO services (excluding CDO         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC -->      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           FENTICONAZOLE                                                            volume
CMO services (excluding CDO         07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS -->                [70-80]% by value / [60-70]% by
                            - ITALY
services)                           NAPHAZOLINE!THONZYLAMINE                                                 volume
CMO services (excluding CDO         07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           HYALURONIC ACID!MALVA SYLVESTRIS                                         volume
CMO services (excluding CDO         07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS -->      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           HYALURONIC ACID!SODIUM!TROMETAMOL                                        volume
                                    07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS -->
CMO services (excluding CDO                                                                     [90-100]% by value / [90-100]% by
                            - ITALY EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA
services)                                                                                                    volume
                                    CHAMOMILLA!PHOSPHORIC ACID!SODIUM
                                    09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->
CMO services (excluding CDO                                                                     [90-100]% by value / [90-100]% by
                            - ITALY CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA
services)                                                                                                    volume
                                    PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL
CMO services (excluding CDO         09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES -->   [60-70]% by value / [80-90]% by
                            - ITALY
services)                           COMPOSITION UNKNOWN                                                      volume
CMO services (excluding CDO         10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->        [90-100]% by value / [90-100]% by
                            - ITALY
services)                           FLUOCINOLONE ACETONIDE!KETOCAINE                                         volume
CMO services (excluding CDO         10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->           [90-100]% by value / [90-100]% by
                            - ITALY
services)                           FLUOCINOLONE ACETONIDE!KETOCAINE                                         volume
 ---pagebreak--- CMO services (excluding CDO         11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS -->                 [90-100]% by value / [90-100]% by
                            - ITALY
services)                           PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE                      volume
                                    11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC
CMO services (excluding CDO         ACID!MATRICARIA                                            [90-100]% by value / [90-100]% by
                            - ITALY
services)                           CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI               volume
                                    BER OFFICINALE
                                    11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC
CMO services (excluding CDO         ACID!MATRICARIA                                            [90-100]% by value / [90-100]% by
                            - ITALY
services)                           CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGI               volume
                                    BER OFFICINALE
CMO services (excluding CDO         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                            - ITALY
services)                           OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
CMO services (excluding CDO         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES -->   [50-60]% by value / [60-70]% by
                            - ITALY
services)                           FENTICONAZOLE                                                           volume
CMO services (excluding CDO         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS -->   [90-100]% by value / [90-100]% by
                            - ITALY
services)                           FENTICONAZOLE                                                           volume
CMO services (excluding CDO         12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                            - ITALY
services)                           DIOSCOREA VILLOSA                                                       volume
CMO services (excluding CDO         18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS -->       [20-30]% by value / [30-40]% by
                            - ITALY
services)                           BORAGO OFFICINALIS                                                      volume
                                    87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH
CMO services (excluding CDO                                                                    [90-100]% by value / [90-100]% by
                            - ITALY --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA
services)                                                                                                   volume
                                    PIPERITA!XYLITOL
CMO services (excluding CDO         A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->         [60-70]% by value / [60-70]% by
                            - ITALY
services)                           DOMPERIDONE                                                             volume
 ---pagebreak--- CMO services (excluding CDO         A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST         [20-30]% by value / [30-40]% by
                            - ITALY
services)                           CORTICOSTER PROD --> BUDESONIDE                                             volume
CMO services (excluding CDO         A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM       [90-100]% by value / [90-100]% by
                            - ITALY
services)                           BOWEL DIS PRD OTH --> CROMOGLICIC ACID                                      volume
CMO services (excluding CDO         A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS -->       [90-100]% by value / [90-100]% by
                            - ITALY
services)                           DIMETICONE!LOPERAMIDE                                                       volume
CMO services (excluding CDO         A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES -- [90-100]% by value / [90-100]% by
                            - ITALY
services)                           > TILACTASE                                                                 volume
CMO services (excluding CDO         B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH                   [90-100]% by value / [90-100]% by
                            - ITALY
services)                           HAEMATOLOGIC AGENTS --> HEMIN                                               volume
CMO services (excluding CDO         C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA         [70-80]% by value / [70-80]% by
                            - ITALY
services)                           RED) --> LOVASTATIN                                                         volume
CMO services (excluding CDO         C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC         [90-100]% by value / [90-100]% by
                            - ITALY
services)                           PREPS --> ALPROSTADIL ALFADEX                                               volume
CMO services (excluding CDO         C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB           [40-50]% by value / [50-60]% by
                            - ITALY
services)                           ACTIV --> CINNARIZINE                                                       volume
                                    C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - ITALY HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE
services)                                                                                                       volume
                                    ACETONIDE!KETOCAINE
CMO services (excluding CDO         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                  [30-40]% by value / [20-30]% by
                            - ITALY
services)                           AGENTS,PLAIN --> BISOPROLOL                                                 volume
 ---pagebreak--- CMO services (excluding CDO         C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                 [30-40]% by value / [20-30]% by
                            - ITALY
services)                           AGENTS,PLAIN --> METOPROLOL                                                  volume
CMO services (excluding CDO         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT          [90-100]% by value / [90-100]% by
                            - ITALY
services)                           ANTIFUNG --> FENTICONAZOLE                                                   volume
CMO services (excluding CDO         G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG                 [60-70]% by value / [90-100]% by
                            - ITALY
services)                           ANTIFUNGALS --> FENTICONAZOLE                                                volume
CMO services (excluding CDO         G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           PRODS --> LIDOCAINE!PRILOCAINE                                               volume
CMO services (excluding CDO         J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --    [90-100]% by value / [90-100]% by
                            - ITALY
services)                           > CEFTIBUTEN                                                                 volume
CMO services (excluding CDO         J1D CEPHALOSPORINS & COMBS --> J1D2                           [90-100]% by value / [90-100]% by
                            - ITALY
services)                           CEPHALOSPORINS,PARENT. --> CEFODIZIME                                        volume
CMO services (excluding CDO         M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &      [90-100]% by value / [90-100]% by
                            - ITALY
services)                           ANALG --> FLURBIPROFEN                                                       volume
CMO services (excluding CDO         M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &        [50-60]% by value / [40-50]% by
                            - ITALY
services)                           ANALG --> NAPROXEN                                                           volume
CMO services (excluding CDO         N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->       [90-100]% by value / [90-100]% by
                            - ITALY
services)                           CARIPRAZINE                                                                  volume
                                                                                                    [60-70]% by value / [60-70]% by
CMO services (excluding CDO         R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF -->
                            - ITALY                                                                 volume (CVC share [70-80]% by
services)                           BUDESONIDE
                                                                                                      value / [70-80]% by volume)
 ---pagebreak---                                                                                                        [60-70]% by value / [50-60]% by
CMO services (excluding CDO
                            - ITALY  R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE      volume (CVC share [60-70]% by
services)
                                                                                                         value / [60-70]% by volume)
CMO services (excluding CDO          R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES               [30-40]% by value / [30-40]% by
                            - ITALY
services)                            SYSTEMIC --> RUPATADINE                                                        volume
CMO services (excluding CDO          S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-                     [70-80]% by value / [60-70]% by
                            - ITALY
services)                            ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE                                  volume
CMO services (excluding CDO          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM               [90-100]% by value / [90-100]% by
                            - ITALY
services)                            TOPICAL --> MERCAPTAMINE                                                       volume
CMO services (excluding CDO          S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR -->    [90-100]% by value / [90-100]% by
                            - ITALY
services)                            CIPROFLOXACIN                                                                  volume
CMO services (excluding CDO          S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR -- [90-100]% by value / [90-100]% by
                            - ITALY
services)                            > CIPROFLOXACIN!FLUOCINOLONE ACETONIDE                                         volume
CMO services (excluding CDO          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->            [90-100]% by value / [90-100]% by
                            - LATVIA
services)                            LIDOCAINE!TRIBENOSIDE                                                          volume
CMO services (excluding CDO          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->               [90-100]% by value / [90-100]% by
                            - LATVIA
services)                            LIDOCAINE!TRIBENOSIDE                                                          volume
CMO services (excluding CDO          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O         [90-100]% by value / [90-100]% by
                            - LATVIA
services)                            CORTIC --> LIDOCAINE!TRIBENOSIDE                                               volume
CMO services (excluding CDO          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING                   [40-50]% by value / [20-30]% by
                            - LATVIA
services)                            AGENTS,PLAIN --> METOPROLOL                                                    volume
 ---pagebreak--- CMO services (excluding CDO               10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                            - LITHUANIA
services)                                 LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO               10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                            - LITHUANIA
services)                                 LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO               C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                            - LITHUANIA
services)                                 CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CMO services (excluding CDO               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [70-80]% by value / [70-80]% by
                            - LITHUANIA
services)                                 AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG             [90-100]% by value / [90-100]% by
                            - LITHUANIA
services)                                 ANTIFUNGALS --> FENTICONAZOLE                                           volume
CMO services (excluding CDO               C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING            [90-100]% by value / [90-100]% by
                            - LUXEMBOURG
services)                                 AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO               B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - NETHERLANDS
services)                                 HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CMO services (excluding CDO               G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            - NETHERLANDS
services)                                 PRD --> FLAVOXATE                                                       volume
CMO services (excluding CDO               N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->      [80-90]% by value / [80-90]% by
                            - NETHERLANDS
services)                                 CARIPRAZINE                                                             volume
CMO services (excluding CDO               S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                            - NETHERLANDS
services)                                 TOPICAL --> MERCAPTAMINE                                                volume
 ---pagebreak--- CMO services (excluding CDO          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - NORWAY
services)                            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CMO services (excluding CDO          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [30-40]% by value / [10-20]% by
                            - NORWAY
services)                            AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                            - NORWAY
services)                            TOPICAL --> MERCAPTAMINE                                                volume
CMO services (excluding CDO          01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                            - POLAND
services)                            ACID!LACTOFERRIN                                                        volume
CMO services (excluding CDO          01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC     [90-100]% by value / [90-100]% by
                            - POLAND
services)                            ACID!LACTOFERRIN!MENTHOL                                                volume
CMO services (excluding CDO          10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->         [50-60]% by value / [60-70]% by
                            - POLAND
services)                            LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO          10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                            - POLAND
services)                            LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO          12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O                   [90-100]% by value / [90-100]% by
                            - POLAND
services)                            OINTMENTS/CREAMS --> FENTICONAZOLE                                      volume
CMO services (excluding CDO          12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> [90-100]% by value / [90-100]% by
                            - POLAND
services)                            FENTICONAZOLE                                                           volume
CMO services (excluding CDO          C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O      [70-80]% by value / [60-70]% by
                            - POLAND
services)                            CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
 ---pagebreak--- CMO services (excluding CDO            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING               [30-40]% by value / [20-30]% by
                            - POLAND
services)                              AGENTS,PLAIN --> METOPROLOL                                              volume
CMO services (excluding CDO            G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                            - POLAND
services)                              ANTIFUNGALS --> FENTICONAZOLE                                            volume
CMO services (excluding CDO            01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS -->        [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              TIBEZONIUM                                                               volume
CMO services (excluding CDO            01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM      [70-80]% by value / [80-90]% by
                            - PORTUGAL
services)                              OFFICINALE                                                               volume
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM
services)                                                                                                       volume
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM
services)                                                                                                       volume
                                       02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
services)                                                                                                       volume
                                       ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                       02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
services)                                                                                                       volume
                                       ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
                                       02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE
CMO services (excluding CDO            BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS       [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC                    volume
                                       ACID!XANTHAN GUM!XYLITOL
                                       02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE
CMO services (excluding CDO                                                                        [90-100]% by value / [90-100]% by
                            - PORTUGAL BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC
services)                                                                                                       volume
                                       ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE
 ---pagebreak--- CMO services (excluding CDO            02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES - [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              -> FLURBIPROFEN                                                             volume
CMO services (excluding CDO            03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC              [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              ACID!DODECYL SULFOACETIC ACID                                               volume
CMO services (excluding CDO            03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->          [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LACTOBACILLUS LACTIS                                                        volume
CMO services (excluding CDO            03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->          [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LACTOBACILLUS REUTERI                                                       volume
CMO services (excluding CDO            03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LACTOBACILLUS LACTIS                                                        volume
CMO services (excluding CDO            03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) -->    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LACTOBACILLUS REUTERI                                                       volume
CMO services (excluding CDO            05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC                 [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              ACID!CAFFEINE!GLUCURONAMIDE                                                 volume
CMO services (excluding CDO            06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) -->     [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA                    volume
CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->           [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LIDOCAINE + TRIBENOSIDE                                                     volume
CMO services (excluding CDO            A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN -->          [30-40]% by value / [10-20]% by
                            - PORTUGAL
services)                              COLECALCIFEROL                                                              volume
 ---pagebreak--- CMO services (excluding CDO            A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS -->       [50-60]% by value / [50-60]% by
                            - PORTUGAL
services)                              SUCRALFATE                                                              volume
CMO services (excluding CDO            A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT        [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE                     volume
CMO services (excluding CDO            A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS -->    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              CITRIC ACID!DODECYL SULFOACETIC ACID                                    volume
CMO services (excluding CDO            C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CMO services (excluding CDO            C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL                              volume
CMO services (excluding CDO            G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              PRD --> FLAVOXATE                                                       volume
CMO services (excluding CDO            G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [50-60]% by value / [50-60]% by
                            - PORTUGAL
services)                              OTH --> ALPROSTADIL                                                     volume
CMO services (excluding CDO            M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S  [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              PLN --> DEXIBUPROFEN                                                    volume
CMO services (excluding CDO            M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS &   [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              ANALG --> FLURBIPROFEN                                                  volume
CMO services (excluding CDO            M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT              [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              PREPARATIONS --> COLCHICINE                                             volume
 ---pagebreak--- CMO services (excluding CDO            N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              CARIPRAZINE                                                             volume
CMO services (excluding CDO                                                                       [90-100]% by value / [90-100]% by
                            - PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM
services)                                                                                                      volume
CMO services (excluding CDO            R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              SISYMBRIUM OFFICINALE                                                   volume
CMO services (excluding CDO            R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS -->   [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              TIBEZONIUM                                                              volume
CMO services (excluding CDO            S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM          [90-100]% by value / [90-100]% by
                            - PORTUGAL
services)                              TOPICAL --> MERCAPTAMINE                                                volume
CMO services (excluding CDO            03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              FRUCTOOLIGSACCHARIDES!MALTODEXTRIN                                      volume
CMO services (excluding CDO            03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->             [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              INULIN!MALTODEXTRIN                                                     volume
CMO services (excluding CDO            04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT -->          [30-40]% by value / [20-30]% by
                            - ROMANIA
services)                              CALCIUM!COLECALCIFEROL                                                  volume
CMO services (excluding CDO            06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              FENTICONAZOLE                                                           volume
CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              LIDOCAINE + TRIBENOSIDE                                                 volume
 ---pagebreak--- CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              + TRIBENOSIDE                                                            volume
CMO services (excluding CDO            C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O     [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              CORTIC --> LIDOCAINE!TRIBENOSIDE                                         volume
CMO services (excluding CDO            C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE               [80-90]% by value / [90-100]% by
                            - ROMANIA
services)                              THERAPY,SYSTEM. --> DIOSMIN                                              volume
CMO services (excluding CDO            D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT        [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              ANTIFUNG --> FENTICONAZOLE                                               volume
CMO services (excluding CDO            G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL -->    [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              METRONIDAZOLE!NEOMYCIN!NYSTATIN                                          volume
CMO services (excluding CDO            G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG              [90-100]% by value / [90-100]% by
                            - ROMANIA
services)                              ANTIFUNGALS --> FENTICONAZOLE                                            volume
CMO services (excluding CDO            02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->         [80-90]% by value / [80-90]% by
                            - SLOVAKIA
services)                              ACETYLSALICYLIC ACID                                                     volume
CMO services (excluding CDO            02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL                                volume
CMO services (excluding CDO            02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              CAFFEINE!PARACETAMOL!PROPYPHENAZONE                                      volume
CMO services (excluding CDO            02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->    [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ACETYLSALICYLIC ACID                                                     volume
 ---pagebreak--- CMO services (excluding CDO            02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT -->     [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ACETYLSALICYLIC ACID!ASCORBIC ACID                                        volume
CMO services (excluding CDO            02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              CHARCOAL + IRON METAL                                                     volume
                                       03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CMO services (excluding CDO                                                                         [90-100]% by value / [90-100]% by
                            - SLOVAKIA CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!
services)                                                                                                        volume
                                       PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E
                                       03B1 LIVER REMEDIES --> 03B1C CAPS/TABS -->
CMO services (excluding CDO                                                                         [90-100]% by value / [90-100]% by
                            - SLOVAKIA CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC
services)                                                                                                        volume
                                       ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E
CMO services (excluding CDO                                                                           [70-80]% by value / [80-90]% by
                            - SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN
services)                                                                                                        volume
                                       07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CMO services (excluding CDO                                                                         [90-100]% by value / [90-100]% by
                            - SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN
services)                                                                                                        volume
                                       E!XANTOFYL!ZEAXANTHIN
                                       07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CMO services (excluding CDO                                                                         [90-100]% by value / [90-100]% by
                            - SLOVAKIA ASCORBIC ACID!COLECALCIFEROL!FOLIC
services)                                                                                                        volume
                                       ACID!TAURINE!XANTOFYL!ZINC
CMO services (excluding CDO            07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL                 volume
CMO services (excluding CDO            07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN                    volume
                                       07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->
CMO services (excluding CDO                                                                         [90-100]% by value / [90-100]% by
                            - SLOVAKIA ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN
services)                                                                                                        volume
                                       E!XANTOFYL!ZEAXANTHIN
 ---pagebreak--- CMO services (excluding CDO            07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS -->     [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC                                volume
CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS -->       [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES -->          [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              LIDOCAINE!TRIBENOSIDE                                                   volume
CMO services (excluding CDO            10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS     [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ACULEATUS!SODIUM                                                        volume
CMO services (excluding CDO            C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O    [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              CORTIC --> LIDOCAINE!TRIBENOSIDE                                        volume
CMO services (excluding CDO            C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [60-70]% by value / [30-40]% by
                            - SLOVAKIA
services)                              AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO            G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              PRD --> PROPIVERINE                                                     volume
CMO services (excluding CDO            N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC            [80-90]% by value / [80-90]% by
                            - SLOVAKIA
services)                              ANALGESICS --> ACETYLSALICYLIC ACID                                     volume
CMO services (excluding CDO            N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC          [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE                      volume
CMO services (excluding CDO            S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> [90-100]% by value / [90-100]% by
                            - SLOVAKIA
services)                              HYALURONIC ACID!MALVA SYLVESTRIS                                        volume
 ---pagebreak--- CMO services (excluding CDO         03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS -->                [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CMO services (excluding CDO         03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                  [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CMO services (excluding CDO         03C1 FIBRE LAXATIVES --> 03C1P POWDERS -->                  [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE                   volume
CMO services (excluding CDO                                                                        [70-80]% by value / [0-5]% by
                            - SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE
services)                                                                                                    volume
CMO services (excluding CDO         03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS -->              [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           FRUCTOOLIGSACCHARIDES + MALTODEXTRIN                                     volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           LACTOBACILLUS LACTIS                                                     volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS -->       [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           LACTOBACILLUS REUTERI                                                    volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           LACTOBACILLUS REUTERI                                                    volume
CMO services (excluding CDO         03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS -->     [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           LACTOBACILLUS REUTERI                                                    volume
CMO services (excluding CDO         08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS       [90-100]% by value / [90-100]% by
                            - SPAIN
services)                           SALIVARIUS                                                               volume
 ---pagebreak--- CMO services (excluding CDO          86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-          [40-50]% by value / [10-20]% by
                            - SPAIN
services)                            AERO+SPRAY --> COMPOSITION UNKNOWN                                      volume
CMO services (excluding CDO          86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-        [90-100]% by value / [90-100]% by
                            - SPAIN
services)                            AERO+SPRAY --> DIMETICONE!JOJOBA OIL                                    volume
CMO services (excluding CDO          A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS -->         [70-80]% by value / [70-80]% by
                            - SPAIN
services)                            CINITAPRIDE                                                             volume
CMO services (excluding CDO          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - SPAIN
services)                            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
CMO services (excluding CDO          C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING              [80-90]% by value / [80-90]% by
                            - SPAIN
services)                            AGENTS,PLAIN --> METOPROLOL                                             volume
CMO services (excluding CDO          C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR  [90-100]% by value / [90-100]% by
                            - SPAIN
services)                            COMB --> FELODIPINE!METOPROLOL                                          volume
CMO services (excluding CDO          G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD   [40-50]% by value / [50-60]% by
                            - SPAIN
services)                            OTH --> ALPROSTADIL                                                     volume
CMO services (excluding CDO          G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL   [90-100]% by value / [90-100]% by
                            - SPAIN
services)                            PRODS --> LIDOCAINE!PRILOCAINE                                          volume
CMO services (excluding CDO          N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS -->    [90-100]% by value / [90-100]% by
                            - SPAIN
services)                            CARIPRAZINE                                                             volume
CMO services (excluding CDO          B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH               [90-100]% by value / [90-100]% by
                            - SWEDEN
services)                            HAEMATOLOGIC AGENTS --> HEMIN                                           volume
 ---pagebreak--- CMO services (excluding CDO          S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM [90-100]% by value / [90-100]% by
                            - SWEDEN
services)                            TOPICAL --> MERCAPTAMINE                                      volume
 ---pagebreak---                                                                                                                                                                                                                                                                              Case M.10247 - CVC/Cooper
                                                                                                               Appendix 7.2
                                                                                          (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                                                                                 Upstream Market (Target)                                                                                                                         Downstream FDP Market (Theramex)
    Upstream Hypothetical Market Segment       Upstream Hypothetical Market Sub-Segment
                                                                                                            Geographic Market                               Share (2020, EEA)                 Geographic Market            Product Market (ATC3/CHC3)                        Share (2020)
                    (CDMO)                                        (CDMO)
                                                                                                                                                                                             BULGARIA           A11C VIT A & D INC. COMBS                        [30-40]% by value / [30-40]% by volume
                                                                                                                                                                                             ITALY              04F1   CALCIUM SUPPLEMENTS                       [30-40]% by value / [30-40]% by volume
                                             solid and powder pharmaceuticals                                                                                                                ROMANIA            A11C VIT A & D INC. COMBS                        [40-50]% by value / [40-50]% by volume
                                                                                                                                                                                             SLOVAKIA           A11C VIT A & D INC. COMBS                        [50-60]% by value / [50-60]% by volume
CDMO services for FDPs segmented by its
                                                                                                                                                                                             SPAIN              04F1   CALCIUM SUPPLEMENTS                       [80-90]% by value / [80-90]% by volume
pharmaceutical form, i.e.
                                                                                                                                                                                                                G2F TOPICAL SEX HORMONES                         [30-40]% by value / [20-30]% by volume
                                                                                                                                                                                             FRANCE
                                             liquid and semi-solid pharmaceuticals                                                                                                                              G3C OESTROG EX G3A,G3E,G3F                       [20-30]% by value / [50-60]% by volume
                                                                                                                                                                                             SPAIN              G2F TOPICAL SEX HORMONES                         [30-40]% by value / [50-60]% by volume
                                             sterile liquid pharmaceuticals                                                                                                                  LITHUANIA          G3G GONADOTROPHINS                               [50-60]% by value / [50-60]% by volume
CDMO services for FDPs segmented by the
                                             sterile environment                                                                                                                             LITHUANIA          G3G GONADOTROPHINS                               [50-60]% by value / [50-60]% by volume
conditions of manufacture i e
                                                                                                                                                                                             BULGARIA           A11C VIT A & D INC. COMBS                        [30-40]% by value / [30-40]% by volume
                                                                                                                                                                                                                G2F TOPICAL SEX HORMONES                         [30-40]% by value / [20-30]% by volume
                                                                                                                                                                                             FRANCE
                                                                                                                                                                                                                G3C OESTROG EX G3A,G3E,G3F                       [20-30]% by value / [50-60]% by volume
                                                                                                                                                                                             ITALY              04F1   CALCIUM SUPPLEMENTS                       [30-40]% by value / [30-40]% by volume
CDMO services for FDPs segmented by the type chemically-synthesized APIs                                    At least EEA-wide                                    <10%                        POLAND             G3F OESTROGEN + PROGESTOGEN                      [30-40]% by value / [30-40]% by volume
of API used, i.e.                                                                                                                                                                            ROMANIA            A11C VIT A & D INC. COMBS                        [40-50]% by value / [40-50]% by volume
                                                                                                                                                                                             SLOVAKIA           A11C VIT A & D INC. COMBS                        [50-60]% by value / [50-60]% by volume
                                                                                                                                                                                                                04F1   CALCIUM SUPPLEMENTS                       [80-90]% by value / [80-90]% by volume
                                                                                                                                                                                             SPAIN
                                                                                                                                                                                                                G2F TOPICAL SEX HORMONES                         [30-40]% by value / [50-60]% by volume
                                             biopharmaceutical APIs                                                                                                                          LITHUANIA          G3G GONADOTROPHINS                               [50-60]% by value / [50-60]% by volume
                                                                                                                                                                                             BULGARIA           A11C VIT A & D INC. COMBS                        [30-40]% by value / [30-40]% by volume
                                                                                                                                                                                             ITALY              04F1   CALCIUM SUPPLEMENTS                       [30-40]% by value / [30-40]% by volume
                                             swallowing                                                                                                                                      ROMANIA            A11C VIT A & D INC. COMBS                        [40-50]% by value / [40-50]% by volume
                                                                                                                                                                                             SLOVAKIA           A11C VIT A & D INC. COMBS                        [50-60]% by value / [50-60]% by volume
CDMO services for FDPs segmented by the
                                                                                                                                                                                             SPAIN              04F1   CALCIUM SUPPLEMENTS                       [80-90]% by value / [80-90]% by volume
delivery mechanism used, i.e.
                                                                                                                                                                                                                G2F TOPICAL SEX HORMONES                         [30-40]% by value / [20-30]% by volume
                                                                                                                                                                                             FRANCE
                                                                                                                                                                                                                G3C OESTROG EX G3A,G3E,G3F                       [20-30]% by value / [50-60]% by volume
                                             absorption through the skin
                                                                                                                                                                                             POLAND             G3F OESTROGEN + PROGESTOGEN                      [30-40]% by value / [30-40]% by volume
                                                                                                                                                                                             SPAIN              G2F TOPICAL SEX HORMONES                         [30-40]% by value / [50-60]% by volume
 ---pagebreak---                                                                                                                                                                                                                                                                          Case M.10247 - CVC/Cooper
                                                                                                            Appendix 7.2
                                                                                       (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                                                                              Upstream Market (Target)                                                                                                                        Downstream FDP Market (Theramex)
    Upstream Hypothetical Market Segment      Upstream Hypothetical Market Sub-Segment
                                                                                                         Geographic Market                               Share (2020, EEA)                 Geographic Market           Product Market (ATC4/CHC4)                        Share (2020)
                   (CDMO)                                        (CDMO)
                                                                                                                                                                                          BELGIUM            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FINLAND            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                                             04F1E EFFERVESCENT                             [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FRANCE             G3A1 MONOPHAS PREP<50MCG OEST                   [20-30]% by value / [30-40]% by volume
                                                                                                                                                                                                             G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          GERMANY            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
CDMO services for FDPs segmented by its
                                             solid and powder pharmaceuticals
pharmaceutical form, i.e.
                                                                                                                                                                                          ITALY              G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          LITHUANIA          G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          LUXEMBOURG         G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          PORTUGAL           G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          SPAIN              G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          SWEDEN             G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          BELGIUM            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FINLAND            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                                             04F1E EFFERVESCENT                             [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FRANCE             G3A1 MONOPHAS PREP<50MCG OEST                   [20-30]% by value / [30-40]% by volume
                                                                                                                                                                                                             G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          GERMANY            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
CDMO services for FDPs segmented by the type
                                             chemically-synthesized APIs                                 At least EEA-wide                                    <10%
of API used, i.e.
                                                                                                                                                                                          ITALY              G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          LITHUANIA          G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          LUXEMBOURG         G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          PORTUGAL           G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          SPAIN              G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          SWEDEN             G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          BELGIUM            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FINLAND            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                                             04F1E EFFERVESCENT                             [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          FRANCE             G3A1 MONOPHAS PREP<50MCG OEST                   [20-30]% by value / [30-40]% by volume
                                                                                                                                                                                                             G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                          GERMANY            G3A2 MONOPHAS PREP>=50MCG OES                  [90-100]% by value / [90-100]% by volume
CDMO services for FDPs segmented by the
                                             swallowing
 ---pagebreak---                               swallowing
delivery mechanism used, i.e.
                                         ITALY      G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
                                         LITHUANIA  G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
                                         LUXEMBOURG G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
                                         PORTUGAL   G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
                                         SPAIN      G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
                                         SWEDEN     G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                                                                                                                                                                                                                                                                                   Case M.10247 - CVC/Cooper
                                                                                                                     Appendix 7.2
                                                                                                                (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
                                                                  Upstream Market (Target)                                                                                                                                                Downstream FDP Market (Theramex)
                                                                        Upstream Hypothetical Market Sub Segmen                                                 Geographic
           Upstream Hypothetical Market Segment (CDMO)                                                            Geographic Market       Share (2020, EEA)                                                                          Product Market (Molecule)                                      Share (2020)
                                                                                           (CDMO)                                                                 Market
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [60-70]% by value / [60-70]% by volume
                                                                                                                                                             BELGIUM
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [50-60]% by value / [40-50]% by volume
                                                                                                                                                             FINLAND           G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID                                [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID                                                         [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE                        [90-100]% by value / [90-100]% by volume
                                                                                                                                                             FRANCE            G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE                           [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL       [40-50]% by value / [30-40]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN                           [80-90]% by value / [80-90]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [20-30]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                             GERMANY           M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID  [10-20]% by value / [90-100]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID                [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                       solid and powder pharmaceuticals
                                                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
                                                                                                                                                             ITALY
                                                                                                                                                                               G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE         [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                                                                                                                        [40-50]% by value / [20-30]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID
                                                                                                                                                                                                                                                                                      (CVC share [40-50]% by value / [20-30]%
                                                                                                                                                             LITHUANIA         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
CDMO services for FDPs segmented by its pharmaceutical form, i.e.                                                                                            LUXEMBOURG
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                        [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID                              [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL                                     [40-50]% by value / [40-50]% by volume
                                                                                                                                                             NETHERLANDS
                                                                                                                                                                               A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID                                                 [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                             POLAND            G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL                           [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE                 [90-100]% by value / [90-100]% by volume
                                                                                                                                                             PORTUGAL
                                                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [10-20]% by volume
                                                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                             SPAIN
                                                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [70-80]% by value / [70-80]% by volume
                                                                                                                                                             SWEDEN            G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE                        [90-100]% by value / [90-100]% by volume
                                                                                                                                                             FRANCE
                                                                                                                                                                               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE                           [90-100]% by value / [90-100]% by volume
                                                                                                                                                                               G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                       liquid and semi-solid pharmaceuticals
                                                                                                                                                                               G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL                                 [20-30]% by value / [50-60]% by volume
 ---pagebreak---                                                                                                                                    ITALY       G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   LATVIA      G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   PORTUGAL    G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   SPAIN       G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   GERMANY     55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN                                       [0-5]% by value / [40-50]% by volume
                                                                        sterile liquid pharmaceuticals
                                                                                                                                   HUNGARY     G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA                                          [40-50]% by value / [20-30]% by volume
                                                                                                                                   GERMANY     55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN                                       [0-5]% by value / [40-50]% by volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e. sterile environment
                                                                                                                                   HUNGARY     G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA                                          [40-50]% by value / [20-30]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [60-70]% by value / [60-70]% by volume
                                                                                                                                   BELGIUM
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [50-60]% by value / [40-50]% by volume
                                                                                                                                   FINLAND     G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                               04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID                                [90-100]% by value / [90-100]% by volume
                                                                                                                                               06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                               12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                                                               A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID                                                         [90-100]% by value / [90-100]% by volume
                                                                                                                                               D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE                        [90-100]% by value / [90-100]% by volume
                                                                                                                                               G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE                           [90-100]% by value / [90-100]% by volume
                                                                                                                                               G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   FRANCE
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL       [40-50]% by value / [30-40]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL                                 [20-30]% by value / [50-60]% by volume
                                                                                                                                               G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL              [90-100]% by value / [90-100]% by volume
                                                                                                                                               M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN                           [80-90]% by value / [80-90]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [20-30]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                   GERMANY     M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID  [10-20]% by value / [90-100]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID                [90-100]% by value / [90-100]% by volume
                                                                                                       At least EEA-wide <[10-20]%
                                                                                                                                               G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                        chemically-synthesized APIs
                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
CDMO services for FDPs segmented by the type of API used, i.e.                                                                     ITALY
                                                                                                                                               G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL              [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE         [90-100]% by value / [90-100]% by volume
                                                                                                                                                                                                                                                        [40-50]% by value / [20-30]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID
                                                                                                                                                                                                                                                      (CVC share [40-50]% by value / [20-30]%
                                                                                                                                   LATVIA      G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                   LITHUANIA   G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
                                                                                                                                   LUXEMBOURG
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                                                               M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                        [90-100]% by value / [90-100]% by volume
                                                                                                                                               04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID                              [90-100]% by value / [90-100]% by volume
                                                                                                                                               A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL                                     [40-50]% by value / [40-50]% by volume
                                                                                                                                   NETHERLANDS
                                                                                                                                               A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID                                                 [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                                                   POLAND      G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                                                               G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                                                                               G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL                           [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                                                                              PORTUGAL    G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE                 [90-100]% by value / [90-100]% by volume
                                                                                                         G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [10-20]% by volume
                                                                                                         G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                                [90-100]% by value / [90-100]% by volume
                                                                                             SPAIN       G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [70-80]% by value / [70-80]% by volume
                                                                                             SWEDEN      G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                             GERMANY     55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN                                       [0-5]% by value / [40-50]% by volume
                                                                      biopharmaceutical APIs
                                                                                             HUNGARY     G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA                                          [40-50]% by value / [20-30]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [60-70]% by value / [60-70]% by volume
                                                                                             BELGIUM
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [50-60]% by value / [40-50]% by volume
                                                                                             FINLAND     G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID                                [90-100]% by value / [90-100]% by volume
                                                                                                         A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID                                                         [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL       [40-50]% by value / [30-40]% by volume
                                                                                             FRANCE      G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN                           [80-90]% by value / [80-90]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [20-30]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                             GERMANY     M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID  [10-20]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID                [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
                                                                                             ITALY
                                                                                                         G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE         [90-100]% by value / [90-100]% by volume
                                                                      swallowing
                                                                                                                                                                                                                  [40-50]% by value / [20-30]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID
                                                                                                                                                                                                                (CVC share [40-50]% by value / [20-30]%
                                                                                             LITHUANIA   G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                     [80-90]% by value / [80-90]% by volume
                                                                                             LUXEMBOURG
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                        [90-100]% by value / [90-100]% by volume
CDMO services for FDPs segmented by the delivery mechanism used, i.e.
                                                                                                         04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID                              [90-100]% by value / [90-100]% by volume
                                                                                                         A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL                                     [40-50]% by value / [40-50]% by volume
                                                                                             NETHERLANDS
                                                                                                         A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID                                                 [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                             POLAND      G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL                           [90-100]% by value / [90-100]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE                 [90-100]% by value / [90-100]% by volume
                                                                                             PORTUGAL
                                                                                                         G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE                   [90-100]% by value / [90-100]% by volume
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [30-40]% by value / [10-20]% by volume
                                                                                                         G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                             SPAIN
                                                                                                         M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID                          [70-80]% by value / [70-80]% by volume
                                                                                             SWEDEN      G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE       [90-100]% by value / [90-100]% by volume
                                                                                                         06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                         12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE                               [90-100]% by value / [90-100]% by volume
                                                                                                         D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE                        [90-100]% by value / [90-100]% by volume
                                                                                             FRANCE      G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE                           [90-100]% by value / [90-100]% by volume
 ---pagebreak---                                      G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                   [90-100]% by value / [90-100]% by volume
                                     G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL                   [20-30]% by value / [50-60]% by volume
absorption through the skin
                                     G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volume
                                     G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                   [90-100]% by value / [90-100]% by volume
                            ITALY
                                     G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volume
                            LATVIA   G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                   [90-100]% by value / [90-100]% by volume
                            PORTUGAL G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                   [90-100]% by value / [90-100]% by volume
                            SPAIN    G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE                   [90-100]% by value / [90-100]% by volume
 ---pagebreak---